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Abstract
Bipolar disorder (BP) and schizophrenia are severe neuropsychiatric conditions that 
are among the leading causes of morbidity and chronic disability world-wide. Both 
conditions are characterised by a substantial genetic heterogeneity, which has 
complicated the search for susceptibility loci. One strategy to tackle this difficulty 
lies in the study of population isolates that are characterised by a reduced genetic 
heterogeneity. In this thesis, I have therefore conducted genetic studies of BP and 
schizophrenia in the well-characterised South American population isolate of 
Antioquia, Colombia.
Our group has recently reported the results of a linkage scan of six Antioquian 
families segregating severe BP. Here, I performed a follow-up study of a candidate 
region on chromosome 5q33. I sequenced the CLINT 1 gene, a functional candidate 
that has also been implicated in schizophrenia, in affecteds from four BP pedigrees 
from the original linkage study and identified three single base pair variants, all of 
which had been previously described. A transmission distortion test of one of these 
variants, rs 11955293, in a sample of 176 unrelated BP patients from Antioquia and 
their parents found no evidence of association with BP. Although these results do not 
rule out a minor effect of the CLINT 1 gene on susceptibility to the disorder in 
Antioquia, other loci are likely to be of greater significance. This includes other 
genes on chromosome 5q33, but also other candidate regions in the genome.
To further explore the latter possibility, I conducted a whole-genome linkage scan in 
an additional nine pedigrees with severe BP from Antioquia and analysed the 
obtained genotype data jointly with that of the initial linkage scan. Using parametric 
and non-parametric linkage approaches, I explored three different diagnostic models: 
a narrow model including only BP type I (BPI) as affected; a model including BPI 
and II and major unipolar depression; and a third model including only individuals 
who had experienced psychosis as affected. This second linkage scan found evidence 
for a number of candidate regions, including chromosome 13q33 for BPI, 
chromosomes l p l 3-31 and 1 q25-31 for mood disorders, chromosome 12ct-ql4 for 
mood disorders, and chromosomes 2q24-31 and 16pl 2 for psychosis. Encouragingly, 
many of these loci had previously been pinpointed as BP susceptibility loci in other 
populations; on the other hand, we also identified a novel locus on chromosome 12q.
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While the use of population isolates can help decrease the genetic heterogeneity of a 
complex disease, complementary strategies can be used to reduce this heterogeneity 
even further. In studying the NOS JAP gene, a functional candidate on chromosome 
lq23 that is involved in glutamatergic neurotransmission, in a sample of 102 
unrelated Antioquian schizophrenia patients and their parents, I have therefore used 
both categorical and dimensional approaches to the disease phenotype. In the 
categorical approach, I conducted an analysis for association between the NOS1AP 
gene and DSM-IV schizophrenia by TDT. For the dimensional approach, two clinical 
scales measuring positive and negative symptoms, SANS and SAPS, were applied to 
all patients and dimensional scores were obtained from these scales by factors 
analysis. I then performed quantitative TDT analysis of the dimensional scores. My 
analyses found association to both DSM-IV schizophrenia and a clinical dimension 
capturing negative symptoms, in line with a role of NOS1AP in glutamatergic 
neurotransmission. The results of these analyses also underline the usefulness of a 
dimensional approach in psychiatric genetics.
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C h a p t e r  O n e
In t r o d u c t io n
1. Introduction
This thesis aims at making a contribution to the genetics of two major 
neuropsychiatric disorders, bipolar disorder, also known as manic depression, and 
schizophrenia. In this introduction, I shall put the present work into the context of 
current efforts to understand the aetiology of psychiatric disease. First, I shall 
introduce the rationale of focussing on the genetics of psychiatric disease (chapter 
1.1). In chapters 1.2 and 1.3, I will introduce different aspects of the methodology 
used in this thesis and elsewhere to localise and identify loci involved in the genetic 
susceptibility to disease. Chapters 1.4 and 1.5 shall give an introduction to the 
phenotypes studied here -  bipolar disorder and schizophrenia - ,  and to their 
epidemiology and genetics. In chapter 1.6, I will present the ongoing psychiatric 
genetics project in the populations of Antioquia and Costa Rica, in the context of 
which this thesis has to be viewed. Finally, the aims of this thesis will be presented in 
detail in chapter 1.7.
1.1. Why Study Psychiatric Genetics?
Neuropsychiatric disorders are among the leading causes of morbidity and chronic 
disability world-wide, with unipolar depression as well as the two major psychoses, 
bipolar disorder and schizophrenia, ranking among the top ten causes of years lost to 
disability in both the developing and the developed world1. Severe psychiatric 
conditions do not only have devastating consequences for the patients’ mental, social
9  r  sr
and economic well-being ' and even their general health , they also represent a 
major cost to health systems and national economies alike. It has been estimated that 
the annual cost of bipolar disorder to society, including treatment as well as indirect 
costs due to factors such as unemployment and absenteeism, amounts to about £2 
billion in the UK7. The figure for schizophrenia is even higher, with an estimated 
annual cost of £2.6 billion for England alone8, and the yearly costs of major unipolar 
depression for adults in England are leading the list at a staggering £9 billion9. It is 
evident that there is a great need to reduce the burden of mental illness on both 
affected individuals and society as a whole.
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1.1.1. Limitations of current diagnostic and treatment strategies
The successful and cost-efficient treatment of psychiatric illness (its cure not 
currently being conceivable) relies crucially on a meaningful and reliable diagnosis, 
as well as on an adequate choice of pharmacotherapy. In practice, however, both the 
correct diagnosis of psychiatric illness and the choice of treatment can represent a 
challenge. Because there are no indicators at a molecular, physiological or 
behavioural level that are at the same time necessary and sufficient for the diagnosis 
of any mental disorder (i.e., there are no biological or behavioural markers for mental 
disease), psychiatric diagnoses rely solely on constellations of clinical signs and 
symptoms as well as on the course of disease10. This is reflected by the diagnostic 
procedures specified in the main clinical manuals of psychiatry, the Diagnostic and 
Statistical Manual of Mental Disorders, published by the American Psychiatric 
Association (currently in its 4th edition: DSM-IV)11 and the International 
Classification of Diseases, published by the World Health Organization (currently in 
its 10 edition: ICD-10) . The classification system on which these manuals are 
based does most likely not represent true disease entities. Indeed, there is substantial 
clinical heterogeneity within the current diagnostic categories for many mental 
disorders. An extreme example is schizophrenia, where two patients with the same
1 9diagnosis might not share a single symptom . This supports the idea that the current 
diagnostic categories include distinct diseases with different, but possibly related, 
pathophysiologies, resulting in a similar clinical phenotype. Conversely, disorders 
which have traditionally been regarded as distinct entities, namely the two main 
functional psychoses, bipolar disorder and schizophrenia14, might share at least part 
of their aetiopathology15,16. As these examples show, there is still considerable 
uncertainty in psychiatric nosology, and although the diagnoses based on the current 
classification of mental disease are reliable and practical in many ways, they might 
not be valid from an aetiological point of view17.
A valid and meaningful diagnosis should be based on the aetiology of the disease and 
will ideally inform the choice of treatment, with the ultimate goal to spare patients 
the tedious procedure of trial and error in order to find the right medication, as it is 
currently the case in psychiatric practice. This trial and error procedure is not only 
emotionally upsetting for patients and delays the onset of efficient treatment; it can 
even have an adverse impact on the treatment outcome, since the success of
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pharmacological treatment may depend on an early intervention at the onset of the 
disease. This is thought to be due to neurotoxic effects of psychotic and depressive 
episodes, leading to structural changes in the brain and rendering subsequent 
treatment more difficult18'20. A quick start of the right course of pharmacotherapy is 
therefore essential, and a meaningful diagnosis is crucial to achieve this.
An additional factor influencing and often complicating diagnosis and treatment is
91comorbidity with other psychiatric disorders . Mood disorders, for example,
9 9  99frequently co-occur with anxiety disorders ’ . There is also substantial comorbidity 
between bipolar disorder and panic disorder24 and, in children, attention-deficit 
hyperactivity disorder25, while substance abuse disorder is very common in patients
9A 9 8with schizophrenia and mood disorders among others ' . There are several possible 
mechanisms leading to psychiatric comorbidity: (1) one disorder could act as a risk 
factor for the development of another (e.g., cannabis abuse increases the risk of 
developing psychosis29); (2) the two disorders might share common risk factors (e.g., 
it has been suggested that schizophrenia and diabetes might share common genetic 
predisposition ); and (3) the two co-occurring disorders might in fact be different 
facets of the same disease. It is possible that all three mechanisms are truly relevant 
to psychiatric comorbidity. The distinction between them ultimately comes down to 
the distinction between true comorbidity, i.e., the true co-occurrence of two distinct 
disorders in the same patient, and the co-occurrence of symptoms in a single 
disorder. Since the aetiology of a disorder whose phenotype, for example, comprises 
both depressive and anxious symptoms might be different to the aetiology of both 
depression and anxiety disorder, this distinction might entail important consequences
91for the treatment and the prediction of course and outcome of mental illness .
As we have seen, there are several limitations to the current, descriptive classi­
fication system of psychiatric illness concerning the aetiological relationship between 
diseases, including comorbidity. Resolving these issues would lead to a better and 
more complete understanding of the epidemiology of psychiatric illness, including 
risk factors, course of disease, treatment outcome and patterns of true comorbidity, as 
well as to an aetiologically valid diagnostic system. To achieve a shift from a 
descriptive to a true taxonomic classification of disease (i.e., a classification system 
based on true disease entities), better insights into the pathophysiology of mental 
illness are indispensable.
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While substantial advances have been made in the elucidation of disease mechanisms 
in other areas of medicine, research into the biological causes of mental illness has 
been much less successful, and our understanding of its aetiopathology remains 
poor31. This is due to the aetiological complexity of psychiatric disease, resulting 
from genetic heterogeneity, variable expressivity, pleiotropy and gene-environmental 
interaction among others10,32, and reflecting the complexity of brain function. 
However, while we still have a long way to go in order to achieve a thorough 
understanding of mental illness that can be translated into better diagnosis and, 
ultimately, into better and more individualised treatment options, we have certainly 
started to move into the right direction. The past decades have seen important 
progress in the understanding of the neurobiology underlying many neuropsychiatric
'K'X T7conditions, including Alzheimer’s disease, schizophrenia, and bipolar disorder ' , 
and the field of psychiatric genetics has significantly contributed to these advances.
1.1.2. The relevance of genetics to psychiatry
From the early days of genetic research in psychiatry on, family, twin, and adoption 
studies have demonstrated the importance of genetic liability to mental illness ’ . 
With the advent of the first generation of psychotropic drugs, specific pathways 
involved in the aetiology of psychiatric disease, such as monoaminergic 
neurotransmission, could be pinpointed for the first time40,41. One of the major roles 
of genetic research since then has consisted in confirming the importance of these 
biochemical pathways for the pathophysiology of mental illness42, the main 
methodological approach consisting in candidate gene association studies. In recent 
years, advances in high-throughput genotyping techniques and statistical analysis 
have made whole-genome association studies a reality43-45, a development that raises 
the distinct possibility of inversing this relationship and uncovering new pathways 
involved in psychiatric disease through the identification of novel susceptibility loci. 
Since long before the era of genome-wide association, linkage analysis studies have 
pursued the same goal, although their success in psychiatric disease has been limited 
by the complex nature of mental illness46,47. The feasibility of whole-genome 
association approaches has been shown for other complex traits, such as obesity, 
where the discovery of a previously unknown susceptibility locus, the FTO gene, has
AO
opened up the possibility of detecting a whole new pathway . At the same time, the
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establishment of large-scale national and international collaborations allows the 
collection of samples that are large enough to detect susceptibility loci with small to 
moderate effects, such as they are expected for most psychiatric diseases49. This 
approach has been successful in other diseases including type l 50 and type 2 
diabetes51,52 and breast cancer53.
Through the uncovering of susceptibility loci and novel pathways leading to mental 
illness, progress in psychiatric genetics has the potential to catalyse advances in 
many areas of psychiatry. Some of the most important areas will be discussed in the 
following.
1.1.1.1. Identification of disease markers
As an essential step towards valid and meaningful diagnoses, as well as towards 
early detection and prevention of illness, genetics may contribute to the development 
of biological markers of disease. Because psychiatric diseases are thought to be 
caused by an accumulation of common genetic variants, each of which might only 
confer a small increase in disease risk, it seems unlikely that the test of a single 
genetic variant will be specific and at the same time sensitive enough to serve as a 
disease marker on its own10,54. However, the elucidation of disease mechanisms with 
the help of genetics should facilitate the identification of physiological markers with 
a higher predictive value than the genetic polymorphisms associated with disease 
alone. These might include neuroendocrinological factors and proteins involved in 
signal transduction, among others. Additionally, genetic polymorphisms could be 
incorporated in a panel of markers that together have a higher and more specific 
predictive value than any marker on its own10. A recent study on type 2 diabetes, for 
example, has shown that the combined information from three known risk loci allows 
the identification of population subgroups at risk for the disease55. Through 
simulation studies, Janssens et al. (2006) have recently shown that genetic profiling 
by typing a panel of up to 400 risk-associated polymorphisms can have high 
specificity and sensitivity in predicting the risk of developing common disease56. 
This is particularly true for rare diseases with a prevalence of around 1 % and a high 
heritability, such as schizophrenia and bipolar disorder.
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The development of biological markers of disease will be essential for the diagnostic 
process, as well as for the early identification of individuals at risk for psychiatric 
illness, thereby moving towards the ultimate goal of disease prevention. One setting 
in which early identification of individuals at risk might happen, is genetic 
counselling.
I.I.I.2. Genetic counselling and predictive testing
Genetic counselling is the process of educating patients and/or their relatives about 
principles of human genetics applicable to inherited disease, such as patterns of 
inheritance and the risk of disease attached to predisposing genes, thereby enabling 
them to make informed and autonomous decisions in all areas of their lives57. 
Importantly, this process should always be non-directive so that the decision making 
remains entirely with the consultand. Most counselling situations explore two basic 
scenarios: (1) in the case of affected individuals and their spouses, most questions 
evolve around the risk of disease in offspring, and (2) in the case of unaffected 
relatives of patients suffering from the disease, both the risk of disease in the 
offspring and the personal risk of developing the disease later in life are of
1 0  r o
concern ’ . Most genetic counselling occurs in the context of rare Mendelian 
disorders where risk estimation is relatively straightforward and is either based on 
the results of a genetic test or on the mode of inheritance. In psychiatry, where 
inheritance patterns are much more complex, genetic counselling is still a nascent 
field, but there is growing awareness of a need for such services59. This need might 
become more urgent as patients’ awareness of genetic predisposition to mental 
illness is raised through the mass media.
Because there are no predictive tests for the vast majority of psychiatric diseases, and 
because of the complex inheritance of mental illness, recurrence risk estimates can 
only be given based on empirical epidemiological data. Currently, the main goals of 
genetic counselling in psychiatry are therefore to educate the patient about genetic 
factors in psychiatric disease, to provide empirical recurrence risks and to help the 
consultand cope with practical and psychological issues arising from this process59,60. 
While the first and the last point represent very important aspects of the genetic
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counselling process, it is on risk prediction that advances in psychiatric genetics are 
most likely to have a direct impact.
Empirical recurrence risks are available for all major psychiatric conditions38. For 
example, the recurrence risk in the first-degree relative of a bipolar patient lies 
between 4 and 18%, while for the same relative, the risk of developing unipolar 
major depression can be as high as 25%59. These estimates can vary according to the 
number of affected relatives and their relationship to the consultand38. Naturally, 
empirical risk figures are not available for every possible family constellation, and it 
is therefore difficult to give consultands an estimate of their personal disease 
liability. The development of disease markers, as discussed in chapter 1.1.1.1, holds 
the -  albeit still distant -  promise of a more accurate disease prediction. This would 
enable mental health professionals to monitor specific individuals at high risk and 
intervene at the earliest stage of the disease, thereby significantly increasing the 
chance of effective treatment and management of the disease. Early recognition of 
individuals at risk for mental illness paired with innovative treatment approaches (see 
chapter 1.1.1.3), both fuelled by advances in psychiatric genetics, could constitute an 
important step on the way to disease prevention.
An aspect of special interest in the context of genetic counselling is the possibility of 
defining the interaction between genetic and environmental factors in a way that 
could enable counsellors in the future to give consultands personalised advice about 
which environmental risk factors best to avoid in order to keep their disease risk at 
bay. Given our current fragmentary level of knowledge, this scenario might seem 
even further away than risk prediction based on genetics alone, but its potential for 
disease prevention would make it well worth striving for. In recent years, evidence 
for the modifying effect of specific genotypes on the susceptibility to environmental 
risk factors for mental illness has accumulated (Ref 61; see also chapter 1.1.1.4), and 
this knowledge could be used to inform life-style choices in individuals at risk for 
psychiatric disease.
While predictive testing in psychiatry has the potential to be of great benefit for 
psychiatric patients and their relatives, some important ethical considerations need to 
be made. Although these issues can only be touched upon in this thesis, it should be 
emphasised that it is crucial for every researcher in psychiatric genetics to realise and 
reflect on the profound impact the possibility of predictive testing might have on the
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lives of those suffering from or at risk for mental illness. The availability of a genetic 
test for psychiatric disease introduces the possibility of prenatal or preimplantation 
testing for children of couples with a family history of mental illness. Although it 
might be justifiable to screen for the most severe conditions such as treatment 
resistant schizophrenia, it is not clear where the limit lies between disease prevention 
and screening for offspring with a certain behaviour, desirable to the parents or 
society as a whole. Only recently, a genetic test that helps predict physical endurance
fi'yhas become available , and while this test (which only analyses a single genetic 
polymorphism) might still be a long way from allowing precise predictions of 
physical performance, the possibility of tailoring one’s offspring according to 
specific, non health-related ideals is conceivable. The prospect of this kind of 
physical performance-based selection seems sinister; a behaviour-based selection 
might seem even more so.
Furthermore, predictive testing in psychiatry can have a profound impact on the 
availability of medical insurance to individuals at risk, as well as on employment 
chances. These are just very few aspects of the stigmatisation resulting from being 
labelled as “at risk” for psychiatric disease, and a legal and ethical framework is 
needed before predictive testing in psychiatry can be put into practice.
1.1.1.3. Drug development and individualised pharmacological treatment
The first drug for the treatment of a psychiatric condition to become available was 
iproniazid, an antidepressant belonging to the class of monoamine oxidase inhibitors 
(MAOIs). Its discovery in the early 1950s was serendipitous -  it had originally been 
developed for the treatment of tuberculosis but was then found to produce euphoria 
and enhanced activity in some patients - ,  and so were the discoveries of the first 
antipsychotic, chlorpromazine, the first tricyclic antidepressant (TCA), imipramine, 
and the mood stabiliser lithium . Because they had not been specifically designed 
for the use in psychiatric disease, it was not surprising that this first generation of 
psychotropic drugs showed a broad spectrum of side effects, including 
cardiovascular and anticholinergic complications (TCAs), potentially life-threatening 
hypertensive crises through interaction with tyramine contained in food (MAOIs)64, 
and debilitating extra-pyramidal side effects and tardive dyskinesia (first generation
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antipsychotics)65. The side effects of lithium, an alkali metal about whose mechanism
* 'X1of action very little is known , include lack of coordination, cognitive effects, 
weight gain, hypothyroidism, and, in the case of lithium intoxication, renal failure 
and cardiac problems66. The most important innovation in psychiatric pharmacology 
in the last fifty years has therefore been the development of substances with fewer of 
these unwanted and often harmful effects, such as selective reuptake inhibitor 
antidepressants (SRIs) and atypical antipsychotics41.
However, these second-generation psychotropic drugs are generally no more 
efficacious than older compounds41,64,67. Only 60-70% of patients with major 
depression respond to antidepressant treatment41, and a recent review of published as 
well as unpublished clinical trials submitted to the U.S. American Food and Drug 
Administration (FDA) concluded that new generation antidepressants only 
performed significantly better than placebo in severe, but not moderate or mild
/TO
depression . An additional drawback of currently available antidepressants is the 
delay in the onset of therapeutic response, although, at least for selective serotonin 
reuptake inhibitors (SSRIs), this view has recently been challenged69.
In schizophrenia, between 25 and 60% of all cases are classified as treatment 
resistant or partial responders. The only compound that has consistently been proven 
to be more efficacious than first-generation, or conventional, antipsychotics in the 
treatment of positive, negative and cognitive symptoms (see chapter 1.5.1), is 
clozapine. It is also characterised by the absence of extra-pyramidal side effects and 
tardive dyskinesia; however, it can cause other severe and debilitating side effects 
including weight gain, seizures, diabetes, and agranulocytosis, and is therefore never 
the first choice for treating schizophrenia65.
Because of the severe limitations of currently available treatment options, there is a 
great need for the development of new psychotropic drugs with novel mechanisms of 
pharmacological action. Research in genetics and genomics holds great potential for 
this process. As discussed above, through the identification of susceptibility loci for 
mental illness, advances in psychiatric genetics can lead to the uncovering of novel 
pathways involved in the aetiology of disease (e.g., for depression, outside the 
monoaminergic pathway, which is currently targeted by all known classes of 
antidepressants41). Such novel pathways could then be targeted by new, and possibly 
more efficacious, therapeutic agents31. Importantly, this includes the possibility of
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finding drugs that do not only treat the symptoms of psychiatric disease, but fix the 
underlying defect (current relapse rates upon treatment discontinuation indicate that 
the medications available at present do not achieve this)41,70. Genomic approaches 
could also contribute to the identification of novel targets for existing drugs, which 
could then pave the way to the development of new compounds aiming at the same 
pathways41. Furthermore, an improved understanding of the aetiology of psychiatric 
disease spawned by advances in genetics should help determine specific subgroups 
within the current diagnostic categories which will then allow the development of 
more specific drugs for each of these subgroups, with the ultimate goal of 
individualised treatment options41.
A truly individualised treatment should take into account not only the patient’s 
belonging to a specific subgroup within a diagnostic category (or, ideally, his 
aetiologically valid diagnosis once a true classification of disease has been 
established), but also his personal genetic makeup which might influence the efficacy 
of psychotropic drug action, as well as the patient’s propensity to side effects71. The 
targets of pharmacogenetic studies include the site of drug action, as well as drug-
I'y
metabolising enzymes . A class belonging to the latter type, the cytochrome P450 
(CYP) enzymes, has been studied extensively in the context of psychotropic drug 
metabolism. Many of its members have been shown to be involved in the metabolism 
of antidepressants and antipsychotics, and associations between specific alleles of the 
CYP-coding genes and adverse response to drug treatment have been reported
79(reviewed by Kerwin and Arranz 2004) . As a taste of the potential use of 
pharmacogenetics for individualised drug response prediction, the FDA has recently 
approved the AmpliChip CYP450 Test (developed by Roche), which screens 
polymorphisms in the CYP2D6 and CYP2C19 genes. CYP2D6 plays a role in the 
metabolism of many antidepressants and antipsychotics, while CYP2C19 is 
important for the metabolism of some antidepressants, such as amytriptiline, 
citalopram and imipramine, among others72,73. The AmpliChip CYP450 Test is 
designed to identify ultrarapid and poor metabolisers to help choose a treatment for 
individual patients, and concrete suggestions for antidepressant and antipsychotic
79treatment according to metaboliser status have been made .
Finally, genetic research could help overcome an important limitation to current drug 
development strategies: the lack of adequate animal models reflecting the aetiology
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of mental illness to test newly developed compounds on70,74. The development of 
such animal models is severely hampered by the paucity of our knowledge about the 
neurobiology and the genetics of psychiatric disease. Currently, it is therefore 
common practice to conduct tests in healthy animals, mostly rodents, in which 
symptoms resembling mental illness are induced externally, either through 
behavioural or pharmacological stimuli, or through neurosurgery. The forced swim
-7c H f\ HH  7fttest , the tail suspension test and the learned helplessness test ’ all induce 
hypoactive behaviour similar to that seen in depressive patients and are therefore 
used as behavioural models of depression in the screening of antidepressants. In 
pharmacological models, drugs such as amphetamines and hallucinogens are used to 
produce specific effects similar to characteristic symptoms of mental disease (e.g. 
hallucinations as the hallmark of psychosis), and drug withdrawal can cause 
depressive or anxious symptoms. An example of the neurological approach is 
olfactory bulbectomy in rats, which causes a constellation of symptoms resembling 
major depression and has a high predictive value for the effectiveness of
HA. HQ  ft 1antidepressants ’ ' . However, there is considerable uncertainty about the validity 
of such models of psychiatric symptoms from an aetiological point of view. Often 
their validation is based on the model’s susceptibility to currently available
7Q ftnpsychotropic drugs targeted at the modelled condition ’ . While this allows for a 
good prediction of the efficaciousness of compounds targeted at the same pathways 
as currently used drugs, it might not be a good strategy to screen drugs targeted at 
different pathways. This might be more successful if true aetiological models of the 
disease could be developed, and knowledge about the genetics of psychiatric disease 
is indispensable to achieve this.
In this context, a further crucial advantage of genetic models in psychiatry is the 
possibility to distinguish between substances that only target the symptoms of mental 
illness and those that address the underlying defect of the brain. This is based on the 
assumption that, while drugs that only cope with the symptoms can be tested in 
healthy animals with induced mental illness-like behaviour, drugs that target the 
underlying defect will only show an effect in aetiological animal models of disease70.
In summary, progress in psychiatric genetics will have an important impact on the 
field of drug development and individualised treatment, and will therefore constitute
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an essential step towards the management and, in the long term, perhaps even the 
cure of mental illness.
1.1.1.4. Impact on psychiatric research
By helping to cast light onto the “black box” of psychiatric aetiopathology, advances 
in genetics will be of great benefit for further research in the field of psychiatry. The 
identification of susceptibility loci and the biochemical pathways that link them 
should spark a new generation of neurobiological studies which should allow a much
89improved understanding of the mechanisms of disease . Together, progress in 
genetics and neurobiology should then enable psychiatrists to move towards 
establishing a nosology of psychiatric illness that reflects true disease entities. This 
will not only be of great clinical benefit, it will also allow a more precise phenotype 
definition for future research into the neurology, epidemiology and genetics of 
psychiatric illness, thereby further catalysing our understanding of psychiatric 
aetiopathology.
Specifically, the identification of genetic risk factors will allow researchers to 
explore gene-gene and gene-environmental interactions, an approach that is 
increasingly being put into practice. Gene-gene interactions have been studied a 
number of psychiatric phenotypes, such as attention deficit hyperactivity disorder 
(ADHD), suicidal behaviour, anorexia nervosa, and autism, among others83'87. So far, 
the field of gene-gene interactions in psychiatry is still a nascent one. However, as 
the number of susceptibility loci identified in mental disease and our knowledge 
about the pathways they are involved in grows, the number of true gene-gene 
interactions being identified will increase as well. This will not least be due to the 
fact that more detailed knowledge about the aetiopathology of disease will enable 
researchers to formulate meaningful hypotheses which will inform research strategies 
better than it is possible at present.
Research into gene-environmental interactions has shown some interesting results in 
recent years. These include evidence that a functional polymorphism in the serotonin 
transporter acts as a modifier on life stress as a risk factor for depression88, and that 
genetic variation in the MAO A gene influences mental health outcomes in children 
exposed to maltreatment89,90. Again, a lot of work remains to be done before the
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effects of nature and nurture can be disentangled and incorporated into a 
comprehensive model of the aetiology of mental illness, but as with gene-gene 
interactions, this is likely to become increasingly feasible the more we learn about 
genetic susceptibility factors. It is also noteworthy that gene-environmental 
interactions can be studied in animal models once susceptibility loci have been 
established61.
In summary, advances in psychiatric genetics will help shed light on disease 
aetiopathology, thereby enabling progress in many fields of psychiatry. 
Improvements in the diagnostic process through the establishment of disease markers 
and a meaningful nosology of mental illness, as well as advances in drug discovery 
will be of immediate clinical benefit to patients. Genetic counselling in psychiatry, 
on the other hand, is still in its infancy, but will improve with increasing knowledge 
about the aetiopathology of psychiatric diseases. Progress in psychiatric genetics will 
also reflect back on research in other areas of psychiatry, such as neuropsychiatry 
and psychiatric epidemiology, as well as on further research in genetics, and will 
therefore catalyse advances in all areas of psychiatry. The ultimate goal of this 
process is disease prevention.
1.1.3. The example of Alzheimer's Disease
An example of how advances in genetics can help decipher the underlying causes of 
a complex disease is provided by Alzheimer’s Disease (AD), a severe 
neurodegenerative disease and the leading cause of dementia9192. Although the brain 
lesions characteristic for AD had been known for several decades, it was the 
localisation and identification of the first AD locus, the gene encoding the Amyloid 
Precursor Protein (APP), in the late 1980s/early 1990s93’96 that led to the formulation
0 7of a hypothesis explaining the aetiopathology of AD , the amyloid cascade 
hypothesis. This hypothesis has been further corroborated by the subsequent 
identification of additional loci for AD, PSEN19S, PSEN299'100, and ApoE]0\  which
1 07are all thought to act together in one pathway .
Although familial forms of AD constitute a minority of all cases91, the APP, PSEN1 
and PSEN2 genes were all identified through linkage analysis in extended pedigrees, 
thereby demonstrating the potential of the study of Mendelian forms of complex
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diseases. While it is uncertain whether this approach can easily be transferred to 
other neuropsychiatric diseases -  simply because true Mendelian forms of these 
disorders might not exist it shows that the identification of loci that have a direct 
impact on a small subset of affecteds only might represent an essential step towards 
the understanding of the molecular mechanisms of disease.
The identification of ApoE as an important risk factor for the common, late-onset, 
sporadic form of the disease, on the other hand, is a success story of association 
mapping approaches and provides hope for similar findings in other complex 
diseases. Additionally, the fact that ApoE has also been shown to act as a modifier of 
the age of onset in familial disease103,104 is an example of the possibilities to study 
gene-gene (as in this case), but also gene-environmental interactions, which will then 
further enhance our understanding of the aetiopathological process.
The advances in AD also show how an improved understanding of disease aetiology 
can be translated into real therapeutic benefit for the patients. The formulation and 
subsequent corroboration of the amyloid hypothesis have made it possible for drug 
development strategies to move from targeting symptoms to targeting the underlying 
pathway of AD aetiology105,106. Although none of the approaches have yet led to the 
approval of an innovative, disease-modulating drug for AD, many compounds have 
entered clinical trials, and there is considerable hope that drugs targeting the 
aetiology of the disease will be available within the next five to ten years106. This 
development would be a very encouraging one for the vision of a disease-modifying 
therapy in other neuropsychiatric disorders.
Although there are clear differences between the elucidation of the aetiology of AD 
and that of other neuropsychiatric diseases -  such as the fact that biomarkers for AD 
had been known for a long time before the first locus was identified, whereas the 
same is not true for other phenotypes - ,  the recent advances in AD can serve as an 
inspiring example of successes in neuropsychiatric genetics.
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1.2. Strategies for Gene Discovery
1.2.1. Monogenic vs. complex diseases
An important distinction for the purposes of genetic mapping is that between 
monogenic and complex diseases. As their name implies, monogenic diseases are 
caused by a mutation at a single locus, and their inheritance often follows simple 
Mendelian patterns. A mutation at the disease locus is necessary and in many cases 
sufficient to cause the phenotype. The probability of developing the disease given a 
certain genotype is referred to as the penetrance. At full penetrance, this probability 
equals 1 for homozygotes and heterozygotes in dominant disorders, and in 
homozygotes for recessive disorders. Several factors can render the inheritance 
patterns of monogenic diseases more complex, such as parental genomic imprinting, 
variable expressivity, and reduced penetrance, suggesting the interaction with 
additional, possibly genetic, factors. However, there is always one specific gene with 
a major effect. Monogenic diseases are often severe and debilitating from young age, 
and affected individuals may not reproduce. Therefore, even recessive disorders tend 
to be rare in the population. Examples of monogenic disorders include Huntington’s 
Disease and familial Alzheimer’s Disease, both autosomal dominant conditions, and 
cystic fibrosis, an autosomal recessive disease.
The relationship between genotype and phenotype is much more complicated in 
common diseases with a genetic component, such as diabetes, asthma, cardiovascular 
disease and psychiatric disorders. They are characterised by very complex, polygenic 
patterns of inheritance, where a combination of genetic variants at different loci
1 07influences the phenotype . None of these variants seem to be sufficient, and most of 
them are probably not necessary to cause the disease. In contrast to monogenic 
disorders, mutations and polymorphisms implicated in the aetiology of complex 
diseases should therefore be thought of as risk or susceptibility factors, rather than 
causative variants. Additionally, the risk for complex diseases is influenced by 
environmental factors, and by the interaction of genes and environment. Complex 
diseases might be thought of as representing the extreme of a distribution of normal 
variation in the population, although this concept seems more intuitive for some 
phenotypes, such as cardiovascular disease, than for others, such as schizophrenia 
and bipolar disorder, where it is not clear of which normal variation they might
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represent an extreme; however, the underlying concept is the same. Under this 
model, every individual has a certain liability for a complex disease. This liability is 
a function of the exposure to a variety of genetic and non-genetic risk factors. If the 
disease liability is higher than a certain threshold, the individual will become affected 
(see Figure 1.1 for illustration).




Here, it is assumed that the underlying distribution of the disease liability in the population is 
normal, as it is typical for polygenic traits. Individuals become affected when their liability 
exceeds a certain threshold.
This thesis is a contribution to the genetic mapping of two complex neuropsychiatric 
diseases, bipolar disorder and schizophrenia. The discussion of mapping strategies in 
this chapter will therefore focus on complex disease, although the first method 
discussed, linkage analysis (chapter 1.2.3), is of great relevance for the discovery of 
genes in monogenic disorders.
1.2.2. Genetic Mapping -  a Conceptual Overview
In order to provide the conceptual context for the different gene mapping strategies 
presented in this chapter, this section will give an overview of the process of gene 
mapping and its different stages. Further details will be given in the subsequent 
sections.
Genetic mapping is the process of localising and identifying genetic variants that 
contribute to a phenotypic trait. In most cases, the trait of interest is a disease, and in
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the following, I will refer to disease mapping. However, the same strategies can be 
applied to normal human variation. Genetic mapping involves three main stages -  (1) 
establishing evidence for a genetic contribution to a disease (in practice, this is not 
part of the mapping procedure, but it represents an essential condition for mapping 
projects to go ahead), (2) gene localisation, and (3) gene identification. A schematic 
summary of the gene mapping procedure is shown in Figure 1.2.
Figure 1.2: Stages of gene discovery. 
Stage 1 - genetic contribution to disease?_____________
Family, twin and adoption studies




Stage 3 - gene identification ^
Candidate gene analysis
See text for details of the gene mapping process.
Stage 1 -  establishing evidence fo r  the genetic contribution to a disease
Before embarking on a mapping project, there has to be convincing evidence for a
->0 1 AO
genetic contribution to the phenotype ’ . A first indication is familial accumulation
of the disease; however, this might be due to a shared environment. Genetic factors 
can be disentangled from environmental ones through twin and adoption studies. 
These study designs shall not be explained in detail here; briefly, in twin studies, trait 
concordance is compared in monozygotic twins, who share genes and environment, 
and dizygotic twins, who also share their environment, but only 50% of their genes. 
In adoption studies, disease recurrence is compared between adoptive and biological 
families of affected adoptees, or between adopted-away offspring of affected and 
unaffected biological parents. The idea behind these approaches is that, in these 
settings, trait concordance patterns will vary with the relative importance of genetic
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as opposed to environmental risk factors. The relative contribution of genetic factors 
to phenotypic variability is expressed as the heritability (h2)m .
h2 = — = ----- - -----  (1)
V G + B + E
Here, V denotes the total phenotypic variance, G is the genetic variance of the 
phenotype, B the within-family variance of the phenotype, and E  represents the 
random environmental variance of the phenotype. It is important to note that 
heritability estimates are specific for the population in which they have been 
obtained; in a population with a very uniform exposure to environmental risk factors, 
the heritability estimate will be higher than in a population with large environmental 
variance although the genetic component might be the same109.
Stage 2 -  localisation o f  the disease gene
Once it has been established that the phenotype has a genetic component, the next 
step is a genome-wide screen for causal variants using genetic markers such as 
microsatellites and/or single nucleotide polymorphisms (SNPs). Traditionally, this 
used to be a linkage screen with highly polymorphic markers, usually microsatellites, 
an approach that proved very successful for monogenic Mendelian disorders, but less 
so for complex diseases, as will be discussed later in this chapter. Whole-genome 
association using SNPs has only recently become feasible but has already provided 
promising results for common diseases with complex inheritance49. Whole-genome 
analyses, be they based on linkage or association methods, are free of a prior 
hypothesis and are carried out to pinpoint candidate regions that might be involved in 
the aetiology of a disease.
The next step consists in fine-mapping the candidate regions identified in whole- 
genome scans, particularly linkage scans. This is normally done by adding additional 
markers in the region of interest to obtain a higher resolution image of that region. 
The genotyping of additional individuals or families in this step can also be useful. 
Sometimes, not all available samples can be included in the initial scan because of 
limits to the budget or the availability of DNA for specific samples; adding these 
samples to the study at the fine-mapping stage can help decide whether a linkage 
peak represents a genuine signal.
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Stage 3 -  identification o f  the disease gene
Finally, if there is good evidence for a specific candidate region, the last stage of the 
mapping project consists in screening genes located within that region. Those genes 
with a known biological function that fit best into the emerging picture of the 
aetiopathology underlying a disease should be considered first; they are often 
referred to as candidate genes. In the ideal case, candidate gene screening efforts will 
identify a clear sequence variant, such as a single-base change, an insertion or 
deletion, which will then have to be shown to co-segregate with the disease (in 
Mendelian disorders) or to be associated with the phenotype (in the case of complex 
diseases) before it can be considered as a candidate for the disease mutation, or, in 
complex disease, the susceptibility variant. In complex disease, a replication of the 
results obtained for a specific candidate region or gene in an independent sample is 
crucial. The ultimate proof that a variant is relevant to the aetiology of a disease, 
especially in diseases with complex inheritance, cannot be provided by studies at the 
DNA level. Instead, functional studies have to be carried out in order to establish a 
causal link between genetic and phenotypic variation.
Although genetic mapping is straightforward in theory, its practical implementation 
is often less simple. The genetic mapping of complex diseases in particular is riddled 
by difficulties, and successes in this field are still scarce, especially in the genetic 
dissection of psychiatric disorders110. However, if used correctly, the toolbox of 
genetic mapping described in detail in the remainder of this chapter should continue 
to yield important results in the discovery of genetic variation leading to disease.
1.2.3. Linkage Analysis
The main gene mapping strategy in family studies is linkage analysis' 11. Linkage 
analysis tests for co-segregation within a family between a disease phenotype and 
genetic marker loci, such as microsatellites or SNPs. The principle of linkage 
analysis is illustrated in Figure 1.3.
Under the null hypothesis of no linkage -  i.e., independent assortment - ,  the 
recombination fraction 0 between a marker and the phenotype is expected to 
correspond to 0.5. This means that the inheritance of the phenotype is independent of 
that of a given marker allele. A recombination fraction of < 0.5, on the other hand,
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means that the inheritance of the phenotype and of given marker allele are not 
independent events; there is genetic linkage between the marker and the locus 
causing the phenotype. It is noteworthy that the observed phenotype serves as a 
proxy for the underlying genotype at the susceptibility locus, which cannot be 
observed; the simpler the relationship between genotype and phenotype, the easier it 
is to infer the underlying genotype based on the phenotype. The complexity of this 
relationship in common, complex diseases is one of the reasons why the genetic 
mapping of these diseases is difficult.
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Filled symbols indicate diseased individuals, blank ones unaffected individuals. The co- 
segregating haplotype is marked by a red box. Founders are phase-unknown, all other 
genotypes are phased. Note the recombination between marker B and the disease phenotype in 
the third generation. Based on this pedigree, it seems likely that the gene causing the disease is 
located on the same chromosome as the two markers, probably closer to marker A than marker 
B: everybody who has allele 1 at marker A, also has the disease.
The kind of linkage analysis described so far relies on the specification of a genetic 
model, which describes mode of inheritance, allele frequencies at trait and marker 
loci, penetrances (i.e., the probability of developing the disease given a certain 
genotype at the susceptibility locus), as well as the sex-specific recombination rates 
between the marker loci and the mutation rate at the marker loci (although the latter
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119is often assumed to be zero) . It is therefore referred to as parametric linkage 
analysis.
The statistic generally employed to measure statistical significance in parametric
1 i ^
linkage analysis is the LOD score . It is equal to the logarithm of the likelihood 
ratio of the data under linkage (0 < 0.5) compared to the data under free 
recombination (0 = 0.5).
, likelihooddata\0  <0.5)LOD -  log10-----------------  1------- (2)
likelihood^data \ 6 = 0.5)
For a fully informative pedigree,
f)R(\ — ff\NR
LOD = logl0 °  ^  , (3)
where R is the number of recombinant meioses, NR the number of non-recombinant 
meioses, and TV the total number of meioses.
A LOD score of 3.0 means that the likelihood of the observed pedigree data 
(including information on pedigree structure, phenotypes and marker genotypes) is 
1000 times higher under linkage than under independent assortment. In genome-wide 
studies (in fact, in any study that is not hypothesis-driven, even if only few markers 
are tested), the prior probability of linkage at any one marker locus is low. Given this 
low prior probability, Lander & Kruglyak (1995) have shown that a LOD score of 
3.3 needs to be attained in order to declare genome-wide significance of linkage, 
corresponding to an adjusted p-value of 0.05114. In practice, many studies use a
119threshold of LOD = 3.0 to declare genome-wide significance . A LOD score < -2.0 
is considered to provide evidence against linkage113.
The LOD score is a function of several parameters: the pedigree data, the genetic 
model specified and the recombination fraction, 0. By maximising the LOD score 
over the different parameters, it is therefore possible to get an estimate of these
119parameters . This is one of the advantages of the LOD score method compared to 
other mapping methods. By determining the maximum LOD for a range of 
recombination fractions, for example, we can get a good estimate of the true 0 
between marker and disease locus. In addition to measuring statistical significance, 
the LOD score therefore also allows us to estimate how far the disease locus is from 
the marker.
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The simple LOD score statistic assumes that the disease locus is the same in all 
families; however, in the analysis of complex diseases, this is an unlikely situation. 
This locus heterogeneity between families can be accounted for by incorporating an 
additional variable in the likelihood model. This variable is termed a (for 
“admixture”) and corresponds to the proportion of families that are linked to a 
potential disease locus. The calculation of this “heterogeneity LOD score” (HLOD)
119provides a simultaneous test for linkage and heterogeneity :
A further extension of the LOD score method is the possibility to analyse co­
segregation of the disease phenotype with a map of markers. This allows to 
overcome limitations imposed by missing genotype data and uninformative markers,
where <po represents a specific genetic model and x  is the location of the disease locus 
on a specified marker map. The null hypothesis, no linkage, is defined by assuming 
that the disease locus is not located on the marker map (x = oo).
The LOD score method is a powerful tool for the genetic mapping of monogenic 
Mendelian disorders; however, in the context of complex diseases it is only of 
limited use. As explained above, parametric linkage analysis relies on the 
specification of a genetic model, which can be done with reasonable confidence for 
Mendelian disorders. For complex traits, the underlying genetic model is far more 
difficult to estimate. Since model mis-specification can produce misleading results in
119parametric analysis , the use of mapping strategies that are less dependent on model 
specification has become commonplace in the analysis of complex traits. Affected- 
only approaches measure the amount of allele sharing between affecteds within a 
pedigree115. These methods are based on the principle that, at a marker locus close to 
a disease-causing gene, affected individuals should have identical alleles more often 
than expected by chance. In this context, it should be distinguished between identity 
by state (IBS) and identity by descent (IBD). While IBS can occur in unrelated
HLOD = log10likelihood^data\ 6 < 0.5,a  > 0) 
likelihooc{data\ 0  = 0.5, a  — 0)
119and helps localise the disease locus on the marker map . The multipoint LOD score 
is defined as




individuals and simply refers to the fact that genotyping methods will produce the 
same result in both cases, IBD means that the shared allele is inherited from a 
common ancestor. By definition, this can only occur in related individuals. Allele 
sharing methods are generally aimed at investigating IBD in affecteds (since the 
disease locus is also assumed to be IBD); however, some methods use IBS status as a 
surrogate for IBD, and the distribution of IBS sharing probabilities between two 
affecteds approaches the IBD distribution for polymorphic markers, such as 
microsatellites115.
Because they do not depend on the specification of a genetic model of disease 
inheritance, allele sharing methods are frequently referred to as non-parametric 
linkage approaches. However, this term can be misleading since these methods are 
not parameter-free in the statistical sense; they may still depend on the specification 
of certain parameters, e.g. marker allele frequencies and recombination fractions 
between marker loci.
A popular statistic measuring the significance of evidence in non-parametric linkage 
approaches is the NPL score116. It is calculated by first determining the amount of 
allele sharing, either between pairs of affecteds (NPLPAirs), or between all affecteds 
(NPLall), and then evaluating whether there is significant evidence against 
independence of marker and disease loci. The NPLPAirs scoring statistic is defined 
as:
(6)
where Sy is the number of alleles shared IBD by two individuals i and j .  It can be 0, 1 
or 2115. The significance of this statistic is evaluated by either normalising it and 
comparing it to a normal distribution, or by generating an empirical p-value by 
simulation.
The NPLALl scoring statistic is defined as:
s* u . = 2 - £ (7)
where a denotes the number of affecteds in the pedigree; h is the collection of alleles 
generated by taking one allele from each affected individual -  there are 2a possible 
collections - ;  2 /is  the total number of founder alleles in the pedigree; and bj(h) is the
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total number of copies of founder allele j  in collection hus. Again, the significance of 
this statistic can be determined by a normal transformation or through simulation. 
Both the N PL rairs and the NPLall statistics depend on the inheritance pattern of 
marker alleles. For most pedigrees, this inheritance cannot be determined 
unambiguously; the statistics are then calculated and weighted across inheritance 
patterns. Genome-wide significance is reached for p-values that occur with a 
probability of 0.05 in a whole-genome scan, or in other words, that occur by chance 
once in every 20 genome scans114. For a microsatellite scan with 382 independent 
markers, this is equal to a p-value of 0.05/382 = 1.3 x 10'4, or a NPL score of 3.88.
While non-parametric approaches are popular in the analysis of complex diseases, 
some authors have suggested that LOD score-based methods can be more powerful, 
especially when the LOD score is maximised over several inheritance models, 
thereby circumnavigating the difficulties caused by model mis-specification. This
117 171seems to hold even when accounting for multiple testing ‘ . However, the
reasoning of these authors is mainly based on simulations where complex diseases 
are modelled as two-locus traits, and it is not certain whether these conclusions can 
be extended to true polygenic inheritance, such as it is expected to underlie complex 
human disease.
1.2.4. Linkage Disequilibrium and Association Mapping
1.2.4.1. Linkage disequilibrium as a tool for gene mapping
Linkage disequilibrium mapping is based on allelic association and is a powerful tool 
for the genetic dissection of complex disease. Allelic association between two loci is 
observed when a combination of alleles at these loci is more frequent in the 
population than expected if the loci were independent. Therefore, alleles at two loci 
are associated when
fAB ± /a x f B, (8)
where/} is the frequency of allele A at locus \ , / b is the frequency of allele B at locus 
2, and / ab is the frequency of the joint occurrence of alleles A and B in a haploid 
genome (in most cases, and in all cases relevant to linkage disequilibrium mapping, 
this means the frequency of a haplotype carrying both alleles A and B). Allelic
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association can occur in linked as well as unlinked loci; it should not be confused 
with linkage which refers to a recombination fraction 0 < 0.5 between two loci (see 
chapter 1.2.3). Allelic association usually arises through the occurrence of a mutation 
on a particular haplotypic background (see Figure 1.4), the ancestral haplotype. 
Because each mutational event only occurs once, and because the same mutation is 
unlikely to occur more than once on different haplotypic backgrounds, this event 
creates allelic association between the new mutant allele and SNP alleles on the 
ancestral haplotype.
Recombination between the mutation-carrying haplotype and other haplotypes 
present in the population gradually leads to the decay of allelic association (see 
Figure 1.4). This decay is a function of the time that has passed since the original 
mutational event, and the distance between loci (and the mutation rate; however, 
mutation rates are so low they are unlikely to contribute significantly to the decay of 
LD122). Because of this pattern of decline, allelic association naturally occurs more 
commonly between alleles at linked than at unlinked loci. Allelic association 
maintained by linkage is referred to as linkage disequilibrium (LD)123.
Figure 1.4: Linkage Disequilibrium.
Mutation
Historical Recombination
Linkage Disequilibrium arises through the occurrence of a mutational event on an ancestral 
haplotype (represented by the red horizontal bar). The boxed letters represent alleles at biallelic 
SNP loci; the star, the mutation, in this case a single base substitution. Historical recombination 
events gradually lead to the decline of linkage disequilibrium, until in a contemporary 
population -  represented by the four haplotypes, or chromosomes, at the bottom of the figure -  
complete association can only be observed between the mutation and allele A at the adjacent 
SNP. Varying degrees of association can be observed with alleles at the other loci.
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Allelic association and LD can be exploited to map loci predisposing for common, 
complex diseases47,124,125. The principle of association mapping is that, while there is 
no straightforward relationship between genotype and phenotype in these diseases, 
genetic risk variants will occur more frequently in individuals with the disease than 
in ones without it. By collecting a large enough sample of affected (cases) and 
unaffected individuals (controls), it is possible to test whether a specific variant is 
more common in either of the groups and therefore increases or decreases the 
susceptibility to complex disease (see Figure 1.5). From the design of association 
studies, it results that, as opposed to linkage analysis, where a locus can be mapped 
using different families sharing the same disease locus, but not necessarily the same 
mutant allele, mapping strategies based on association rely on affected individuals 
sharing the same susceptibility allele.
Figure 1.5: The principle of association analysis.
Controls
Among both affecteds and unaffecteds, there are individuals exposed to a specific genetic risk 
factor, i.e., individuals possessing a specific susceptibility allele (shown in yellow). Because there 
is no straightforward relationship between genotype and phenotype, not all individuals carrying 
the risk-conferring allele will become affected, and not all affecteds will carry the risk allele. 
However, a significantly larger proportion of cases as opposed to controls will carry the risk 
allele. Picture courtesy of Andres Ruiz-Linares.
Association analysis is relatively straightforward if the risk-conferring allele is 
genotyped and analysed directly. Flowever, because of the very nature of gene 
mapping studies, it cannot be known whether the variants chosen for study include 
the risk allele. Additionally, although a vast amount of SNPs have been reported 
across the human genome (the current build of the NCBI’s dbSNP database (no. 128) 
contains approximately 12 million SNPs; http://www.ncbi.nlm.nih.gov/SNP/;
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accessed on 08/04/2008), the risk variant might not be among them, especially if it is 
rare, or not a SNP. This problem can be circumvented by typing densely spaced 
genetic markers across a region of interest. If there is a risk allele in that region and if 
the marker density is high enough, one of the typed markers will be in LD with the 
risk allele. This LD between marker and risk alleles will allow the detection of 
association between the marker allele and the disease. Because the marker allele is 
not the disease causing variant, this is an example of indirect association. In Figure
1.4, allele A of the SNP to the right of the disease mutation is in complete LD with 
the mutant allele; allele A will therefore be found more commonly in affecteds than 
in unaffecteds although it is not the risk-conferring variant. When association 
between a genetic variant and a disease phenotype is found, it remains unclear 
whether this variant is the risk-conferring allele until further studies (preferably of a 
functional nature) have been undertaken; however, the risk-conferring variant will be 
located very close-by.
LD mapping can be carried out in different contexts, either as a fine-mapping 
strategy after an initial whole-genome linkage scan, as a tool for candidate gene 
analysis, or, thanks to recent advances in genotyping technologies and statistical 
analysis tools, in a genome-wide approach. From a conceptual point of view, the first 
two strategies are hypothesis-based, while the last is free of a prior hypothesis (other 
than that the disease has a genetic component).
I.2.4.2. Measures of linkage disequilibrium
Several statistics have been proposed to measure the amount of LD between markers. 
One of the earliest statistics, and also the simplest, has been suggested in the 1960s126 
and can easily be derived from equation 8 (see chapter 1.2.4.1).
D = /ab - / a x / b (9)
If two markers are completely independent of each other, D is expected to be 0. 
Flowever, because D  depends on the allele frequencies at both markers, its values for 
different pairs of markers are hard to compare, and it does not provide a very useful 
measure of LD. Therefore, several other measures have been introduced127. A 
popular measure is D  ’, which describes the observed D in relation to the maximum 
possible modulus of D given the allele frequencies at both loci.
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D '= ------- =-^-------- for D > 0 (10a)
mi n ( J J hJ J B)
D '= --------------------   for D < 0 (10b)
ma
D ’ can vary between 0 (no association) and 1 (complete linkage disequilibrium). A 
D ’ value of 1 means that there is no evidence of recombination between the two loci 
in the analysed sample. Because recombination between two bi-allelic loci always 
results in the creation of all four possible haplotypes (i.e., A-B, A-b, a-B, and a-b), a 
D ’ of 1 occurs when not all of these possible haplotypes are present in the sample.
The formula of the correlation coefficient r2 shows a key property of this statistic: it 
is equal to 1 if, and only if, the two alleles that are in LD also have the exact same 
allele frequencies; i.e., if only two out of the four possible haplotypes occur in the 
population.
Like D \ r2 ranges between 0 and 1; however, these two statistics, which are the most 
commonly used in the literature, measure slightly different properties of the data: 
because D ’ always equals 1 for a pair of loci unless there has been at least one 
recombination between them, the pattern of D ’ in a certain region can be interpreted 
as an indicator of recombination in that region, whereas r2 focuses on measuring the 
correlation between the alleles at two loci. Pairs of loci including a rare allele tend to 
have a D  ’ value of 1 because, due to the rarity of that allele, not all four haplotypes 
will tend to occur. They are, however, unlikely to have an r2 value of 1, because the 
second locus is unlikely to have an equally rare allele.
If D ’ = 1 for a pair of loci, this is referred to as complete LD; if r2 is = 1, this is
1 99known as perfect LD .
I.2.4.3. Patterns of linkage disequilibrium in the human genome
Since Risch and Merikangas predicted the future of complex disease mapping to lie 
in association-based rather than linkage-based strategies in 199647, there has been 
considerable interest in the extent and patterns of LD in the human genome. As
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discussed before, untyped susceptibility alleles for complex diseases can be mapped 
through their LD with typed marker alleles. The greater the extent of LD in the 
genome, the lower the number of markers that need to be typed across a candidate 
region in order to capture the susceptibility variant, thereby reducing the cost of 
association studies. On the other hand, in fine-mapping studies greater stretches of 
LD result in a lower average resolution. In either case, the extent of LD levels in the 
human genome has important implications for genetic association studies.
Results from early studies of LD patterns varied a lot, with some studies providing 
evidence for high LD over hundreds of kilobases (kb), while others detected very 
little LD over distances as short as 10 kb. The latter results were corroborated by 
simulation studies, which predicted that levels of LD high enough to be used for
1 Ofi 1 OQmapping purposes would occur over distances no greater than 5-10 kb ’ . These
discrepancies triggered a systematic attempt to empirically study LD in unrelated
1TOindividuals across a range of independent genomic regions . That study found high 
levels of LD at distances of up to 60 kb in North Americans of European ancestry, 
but a much shorter range of LD of < 5kb in the Yoruban population from Nigeria, 
thereby suggesting that the extent of LD in the genome might be population-specific. 
Like the findings from some of the earlier studies, the observation of long stretches 
of LD in European Americans found by Reich and colleagues (2001) were in marked 
contrast to the results obtained in simulations. Pritchard and Przeworski (2001) 
discussed several possible reasons for these discrepancies, including the fact that 
local variation in recombination frequency had not been taken into account in the 
simulations129. This point proved to be of great relevance when it was found that 
indeed, recombination rates vary greatly throughout the genome, and that the 
majority of recombination events are concentrated in very restricted areas along the 
genome, the so-called recombination hotspots. Direct evidence for the existence of 
such hotspots came from single-molecule analysis of the HLA locus in male sperm
i ' l l
cells . At the same time, it became evident that the human genome is organised in 
distinct haplotype blocks of limited diversity, i.e., with few distinct haplotypes 
accounting for the majority of observed chromosomes, but with high levels of
1 T9recombination between adjacent blocks . These findings are complementary and 
provide a simple and plausible explanation for the widely varying estimates of LD 
extent obtained from previous studies: long stretches with relatively low levels of
48
recombination and therefore high levels of LD, the haplotype blocks, are interspersed 
by short sequences with high recombinational activity, the hotspots, which account 
for the vast majority of cross-overs in the human genome (as much as 80% of 
recombination occurs in only 10-20% of the sequence)133. These hotspots are 
responsible for “re-shuffling” adjacent haplotypes and cause the abrupt, but not 
complete134, decay of LD. Further investigation of LD patterns in the human genome 
showed the importance of hotspots in both female and male meiosis, the general 
similarity of LD patterns between different ethnic groups, although with significantly 
lower levels of LD in populations of African ancestry, and the genome-wide 
correlation of high LD levels and haplotype blocks133,135.
The haplotype block structure of the genome has important consequences for genetic 
association mapping. Because of high levels of LD within blocks, combinations of 
single-marker analyses can be substituted by haplotype analysis, where each 
haplotype can be treated as a distinct allele at a multi-locus marker. In addition to 
reducing the complexity of analysis, this might reflect the underlying population
i ^
structure better than any single-marker analysis . It has been suggested to use a 
subset of SNPs in each haplotype block that are in strong LD with the remaining
SNPs to capture the complete variation of that block. Such SNPs, which can be typed
1 ^in representation of the whole haplotype, are called haplotype tag SNPs (htSNPs) , 
or tagging SNPs.
The completion of the first haplotype map of the human genome, the HapMap 
(http://www.hapmap.org). represented a major landmark on the way to understanding
1 ^ 4  1 7 7  I T Spatterns of LD in the human genome ’ ’ . The aim of its first phase was to
characterise the haplotype block structure of the entire genome by typing at least one 
common SNP [minor allele frequency (MAF) > 0.05] every ~5 kb in four different 
populations: the Yoruba from Ibadan, Nigeria (YRI), North Americans of European 
ancestry from Utah (CEU), Han Chinese from Beijing (CHB), and Japanese from 
Tokyo (JPT). Phase I of the HapMap project provided genotype and allele frequency 
information for these populations on -1.3 million SNPs. The second phase of the 
project, completed in 2005, added information for the same populations on a further 
3.1 million SNPs to this unique resource, increasing its resolution to ~1 SNP per kb, 
and the HapMap data is now thought to capture all common genetic variation with an 
average maximum r2 between 0.8 (for Africans) and 0.95 (for non-African
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populations). Although the project data has shown many similarities between LD 
patterns in different human populations, there are also important differences, e.g. in 
allele frequencies and fine-scale LD variation, due to differences in genetic 
population histories. A third phase of the project, which at the time of writing is 
ongoing, therefore aims at characterising an additional seven populations (Luhya and 
Maasai in Kenya, Italians from Tuscany, African Americans, and Gujarati Indians, 
Chinese and Mexicans from the U.S.A.). The extension of the HapMap to include a 
wider range of human populations will further promote the understanding of LD 
patterns in humans and facilitate the marker choice for association studies in 
populations not included in the current HapMap. Because of their high coverage of 
the human genome, enabling researchers to choose tagging SNPs capturing most of 
the variation in any of the available populations, the data from the HapMap project 
represent an invaluable and very powerful resource for the design of genetic 
association studies. It is also an important tool in the analysis of association data, 
where it is often useful to see how far LD extends from a site where association with 
a disease phenotype is detected, facilitating a more detailed interpretation of 
association signals in the context of the surrounding genes.
After LD is created by the occurrence of a new mutation on a particular ancestral 
haplotype, the single most important factor leading to a decrease in LD, and thereby 
shaping LD patterns in the human genome, is recombination, which, as discussed 
above, is governed by the occurrence of hotspots. Additional forces contributing to 
the creation of specific LD patterns are related to the genetic history of a population 
and include genetic drift, population growth, admixture, migration, population 
structure, and selection122. Some of these factors, such as drift, population growth 
and admixture, are of particular interest for the work presented in this thesis because 
of the choice of population in which this work has been carried out. This will be 
discussed in more detail in chapter 1.3.
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I.2.4.4. The "common disease, common variant" and "common disease, 
rare variant" hypotheses
In complex disease, the effect size of each susceptibility variant is likely to be small, 
an estimate that has been supported by the recent results obtained in complex disease 
association studies (e.g., reference 49). However, disease variants might be present at 
high frequencies within the general population, and it has been pointed out that in 
spite of their small to modest effect sizes, their population-attributable risk (i.e., the 
proportion of people affected by the disease due to a specific variant) might be high 
because of their common occurrence47. This hypothesis is often dubbed the 
“common disease, common variant” (CD/CV) hypothesis139’141. A much-cited 
example of a common allele predisposing for a common disease is the ApoE e4 
allele in Alzheimer’s Disease139,142 (see chapter 1.1.3). A simulation-based approach 
has been used to explore the competing hypothesis, namely whether complex disease 
could instead be ascribed to the occurrence of combinations of rare variants (the 
“common disease, rare variant” hypothesis; CD/RV)143. The results of these 
simulations show that the allelic heterogeneity at putative disease loci depends on 
several parameters, such as the mutation rate at that locus and the selective pressure 
on the mutant allele. The results from that study do not contradict the CD/CV 
hypothesis for loci with a low mutation rate, for which a specific variant represents a 
major fraction of the disease-causing alleles at that locus; however, loci with a higher 
mutation rate are shown to be likely to exhibit a more complex spectrum of disease 
alleles, thereby leading to substantial allelic heterogeneity. Although to a lesser 
extent than for the CD/CV hypothesis, there is also some empirical support for the 
CD/RV hypothesis144,145, and it is well possible that both common and rare alleles 
play a role in the aetiology of complex disease.
Whether a susceptibility variant is common or rare has important implications for the 
genetic analysis of complex disease. Because of the nature of association mapping, 
much larger sample sizes will be needed to detect the effect of rare variants, and 
allelic heterogeneity can therefore cause a significant loss of power in association 
studies143. The development of more advanced statistical methods for the analysis of 
association data might overcome this problem, but the methods currently available 
perform better at uncovering the effects of common alleles than rare ones.
51
Importantly, this might be one of the reasons why there seem to be more examples of 
common variants influencing complex disease as opposed to rare ones.
1.2.4.5. Candidate Gene Studies
Before the recent advent of genome-wide association studies, the most common use 
of LD-based strategies was for the fine mapping of candidate regions after an initial 
linkage scan, and for the association analysis of candidate genes in complex diseases, 
applications that remain highly relevant. Candidate genes are chosen for study 
because of their location within a candidate region identified in a genome-wide 
linkage scan, based on findings from previous studies, or based on prior hypotheses 
about their potential function for the aetiology of a disease. They are studied in a 
straightforward way by typing genetic variants, mostly SNPs, across the gene and 
testing these variants for association with the disease under study. Although 
candidate gene studies are very popular and have helped establish genetic risk factors 
for complex disease, such as DTNBP1 in schizophrenia146, they are often criticised 
for generating false-positive results147,148. This might be due to the relatively low 
thresholds of statistical significance and the small or medium-sized samples often 
used in these studies, which have been shown to contribute to false-positive results 
and the overestimation of the effect size, especially in the first report of a candidate 
gene association, where publication bias is a common issue (i.e., studies with 
positive results have a better chance of being published in a scientific journal)149,150. 
However, these are not inherent limitations of the candidate gene approach; they can 
be overcome by careful study design and strict and consistent standards for data 
analysis. Nevertheless, as with any association study, replication is crucial to lend 
credibility to the results of candidate gene studies151.
1.2.4.6. Population stratification and family-based association
Association studies can be done in different settings, the simplest one consisting in a 
case-control approach where genotype, haplotype or allele frequencies (at a 
candidate locus, or genome-wide) are compared between a sample of unrelated cases 
and a sample of unrelated controls. However, a common issue with case-control
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studies is the occurrence of undetected population structure within the sample. This 
is also referred to as population stratification; it describes a situation where samples 
within the same study are -  unknowingly -  ascertained from different genetic 
backgrounds, such as different ethnic or religious groups.
Figure 1.6: Spurious association due to population stratification in case-control studies.
From Marchini et al. (2004)152. See text for explanations.
Figure 1.6 shows how such sampling problems can lead to false positive association 
results. Assume cases and controls are sampled from a population that comprises two 
distinct underlying sub-populations. Assume furthermore that (1) these two sub­
populations differ in their allele (and therefore, assuming Hardy-Weinberg, 
genotype) frequency distribution at the marker locus of interest, and that (2) the 
disease prevalence also varies between the two sub-populations, so that they will 
make up different proportions of case and control groups. In this case, frequencies 
between the combined case and control samples will vary, although there is no 
association between the locus tested and the disease153.
One strategy to overcome this problem is the use of family-based approaches. In the 
simplest case, association analysis is carried out in a sample of trios consisting of 
affected individuals and their parents. Consider the trio shown in Figure 1.7.
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Figure 1.7: Principle of trio-based association.
a/b b/d
b/b
See text for explanations.
In this example, the affected daughter has received a copy of allele b from each 
parent, while alleles a and c, also present in the parents, have not been transmitted. In 
a large sample of trios, it will be possible to detect if some alleles are transmitted to 
the affected offspring more often than expected. If there is such preferential 
transmission of one allele over the other(s), this provides evidence for association 
between that allele and the disease. This is the principle of the trio design in 
association studies. At first, this approach might seem somehow counterintuitive 
because it seems to imply that the disease status of the child determines allele 
transmission from the parents, when the causal link should be the other way round. 
However, this is merely an artefact of the ascertainment strategy, which is based on 
the affected offspring. Importantly, family-based association analysis is robust to 
population stratification because every transmitted allele is matched to an 
untransmitted allele from the same individual. Even if the study sample contains 
individuals of different genetic backgrounds, “case” and “control” chromosomes will 
therefore always be perfectly matched.
One of the most well-known tests implementing this approach is the Transmission 
Disequilibrium Test (TDT)154, which counts the occurrences of paired observations 
of transmission of alleles of one type and non-transmission of alleles of another type 
and compares them to the expected values. An extended version of the original TDT, 
which allows for missing data and makes it possible to analyse association with 
haplotypes is implemented in the program TRANSMIT 155 156.
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1.3. Population isolates and the Paisa Community of Antioquia, 
Colombia
1.3.1. Population Isolates
The great difficulty in the genetic mapping of complex diseases lies in their 
heterogeneity at both locus and allelic levels. One of the possible strategies to help 
reduce this genetic heterogeneity and thereby increase the chances of mapping 
susceptibility loci for complex diseases consists in the use of population isolates.
In genetics, a population is considered to be isolated if it has not had any substantial
admixture with neighbouring populations for a number of generations. This might be
due to geographical, socio-political, or religious barriers157. Additionally, isolated
populations often go back to a limited number of founding individuals, whose gene
pool represented a sub-sample of that of their parental population, therefore leading
to a reduced genetic heterogeneity in the newly founded population. This
phenomenon is known as the founder effect. In the newly established population,
genetic drift -  the loss or fixation of alleles through random stochastic processes -
will further decrease genetic heterogeneity, especially if the population is small,
resulting in a noticeably less variable gene pool than that of outbred populations. A
variety of studies have successfully exploited this reduced heterogeneity to map
1genes for Mendelian disorders , and as a consequence, a substantial interest has 
arisen in the use of population isolates for the mapping of complex diseases159. As 
outlined below, the advantages of isolates apply to both linkage-based and 
association-based methods.
The success of family-based linkage analysis strongly depends on the use of 
extended pedigrees with multiple affected individuals, or alternatively on the 
combined analysis of several families segregating the same disease locus (see chapter 
1.2.3). Due to the genetic complexity of diseases like schizophrenia and bipolar 
disorder, it is highly unlikely to obtain a suitable, genetically homogeneous 
collection of pedigrees from an outbred population. This problem might be dealt with 
through the use of pedigrees from population isolates. The use of sub-isolates in 
particular can offer advantages for family-based studies160. Sub-isolates are local, 
often small, populations with restricted gene flow to and from other parts of the
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isolate, such as the population of a village in an inaccessible mountainous region. 
Because of their restricted size, founder effect and genetic drift are stronger here than 
for the isolate as a whole, and there is often increased inbreeding due to a limited 
choice of mates. Coupled with a founder effect and genetic drift, inbreeding can lead 
to the accumulation of particular susceptibility variants in a sub-isolate, and a 
collection of disease-loaded pedigrees from such a population is likely to be 
genetically more homogeneous than a collection of pedigrees from an outbred 
population, thereby increasing the chances of gene localisation through pedigree 
analysis.
Similarly, population isolates offer advantages for LD mapping. A key prerequisite 
for association mapping is that affecteds share the same predisposing variants, that is, 
not only the same loci but more specifically the same allelic variants at those loci. 
Hence, the reduced heterogeneity found in population isolate can be crucial to the 
success of an LD study160. Additionally, it has long been suspected and recently been 
shown that isolated populations have increased levels of LD, especially if they have 
been founded recently (< 20 generations ago) and by a limited number of 
individuals161. Longer stretches of LD make it possible to use a reduced number of 
markers in mapping studies160, as well as to use the detection of shared (IBD) 
haplotype signatures in affecteds as an additional strategy in disease mapping162.
Generally, it has been argued that different populations might be suitable for 
different purposes160. While younger isolates, such as the Colombian province of 
Antioquia (see below) and the Central Valley of Costa Rica (CVCR) 163, with their 
high levels of background LD, are thought to be useful for the initial mapping of a 
candidate region using genome-wide LD approaches, they might prove less useful to 
narrow down candidate regions. This is because their longer LD blocks offer limited 
resolution for fine-mapping studies. In this case, the use of older isolates (< 200 
generations), also with an increased genetic homogeneity compared to outbred 
populations, but with less background LD than younger isolates, might be of greater 
advantage. Examples of such populations include Finland, which has become well- 
known because of its unique disease heritage -  another common characteristic of 
isolated populations and where many Mendelian disease genes have successfully 
been mapped158; Iceland, Sardinia and Japan160.
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Other factors influencing the choice of population for mapping studies are the 
number of founders -  with smaller founder populations leading to an increased 
genetic homogeneity -  and the current size of the population160. The latter can be of 
considerable importance for disease mapping because, if the population is too small, 
it might not be possible to collect a sufficiently large sample in order to carry out an 
association study. Linkage-based studies, on the other hand, are less affected by a 
small population size, as long as there are large disease-loaded pedigrees available 
for study.
An additional advantage of population isolates in the context of complex disease 
mapping is their higher environmental homogeneity compared to outbred 
populations157. Members of a population isolate are often exposed to a more uniform 
environment, including dietary, socio-economical and cultural factors, than members 
of an outbred population. Environmental factors influence the risk for complex 
disease and can act as confounders in genetic studies; greater uniformity in the 
exposure to environmental risk factors can therefore help disentangle environment 
and genetics in complex disease. This increased cultural homogeneity might apply 
particularly to sub-isolates.
Complex disease mapping has already yielded promising results in isolated 
populations. Family-based successes include the localisation of susceptibility loci for 
high-density lipoprotein cholesterol levels, a trait related to cardiovascular disease164, 
and asthma165 in Finland, for non-syndromic hearing loss in Bedouins166, and for 
type 2 diabetes167,168 and stroke169,170 in Iceland. The two Icelandic studies used a 
two-step approach where linkage analysis was followed by population-based 
association analysis, showing that isolates can offer advantages for both strategies.
Population isolates have also shown their potential for research in psychiatric 
genetics. The NRG1 gene, encoding neuregulin, a neuronal signalling protein, and 
the DAO A gene, encoding a protein involved in glutamatergic neurotransmission, 
both associated with schizophrenia and BP, were first identified in Iceland and 
French Canada, respectively171,172. A series of studies conducted in the CVCR has 
identified susceptibility loci for bipolar disorder on chromosomes 5q, 8p and 18p and
1 7^ 1 '7Qq, using a combination of pedigree- and population-based approaches ' . The
studies in the CVCR are of particular interest for this thesis because of its close
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genetic and demographic relatedness to the population of Antioquia, Colombia, 
studied here180.
1.3.2. The Paisa Community of Antioquia, Colombia
The province of Antioquia is located in the Northwest of Colombia (see Figure 1.9) 
and lies embedded between the Central and Western ranges of the Andean
*L iL
Mountains. Its population has been founded in the 16 /17 century through
] Q 1 t O'}
admixture of mostly native women and European men of Spanish ancestry ’ .
Historical and genetic evidence indicates that the admixture process was mostly 
completed by the mid-17th century, and that subsequent population growth from 
initially a few thousand individuals to the current size of ~4 million (see Figure 1.8) 
was fuelled almost entirely from within the population, with no substantial 
immigration taking place due to the rugged mountainous territory isolating the 
inhabitants of Antioquia from other local populations181,182. During this period of 
relative isolation, a strong sense of local identity developed in the region, reflected in 
the term paisa , derived from the Spanish word for compatriot, and used in Colombia 
to describe the inhabitants of Antioquia.
Figure 1.8: Population growth in the Province of Antioquia, Colombia, from 1780 to the 1990s.
Modified from Alvarez (1996)183
The original area of settlement of the paisa community is not entirely equivalent to 
the political limits of today’s province of Antioquia, shown in Figure 1.9. Instead, 
paisa settlement was concentrated in the coffee-growing regions of today’s
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Antioquia and also extended to what is nowadays the province of Caldas (also shown 
in Figure 1.9), whose inhabitants are also part of the paisa community. In the 
following, the term “Antioquia” will be used as a synonym of the paisa community.
Figure 1.9: Map of Colombia and the Province of Antioquia 
The province of Antioquia lies in the Northwest of Colombia. It consists of nine regions; the 
province’s capital, Medellin, lies in the “Area Metropolitana” Region, the Metropolitan Area. 
The outlines of the province of Caldas, south of Antioquia and part of the region of original 
paisa settlement, are also shown on the map of Colombia. The map of Antioquia is taken from 
http://www.antioquia.gov.co/generalidades/mapas.htm; accessed on 20/05/2006.
Having been founded only ~20 generations ago, Antioquia is a young population 
isolate and is therefore expected to have increased LD in comparison with older 
isolates and outbred populations. Because of differences in allele frequencies 
between the parental populations -  Spanish and Native Americans - , the admixture 
process is an additional source of LD in Antioquia. Increased levels of LD in this 
population have indeed recently been shown161. As discussed in chapter 1.3.1, this 
increased LD, together with the limited number of founder individuals and the initial 
small population size, giving rise to founder effect and genetic drift and therefore to a 
decrease in genetic heterogeneity, makes Antioquia a suitable population for the 
genetic mapping of complex diseases. Additional advantages of Antioquia in both
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complex and Mendelian disease mapping include the relatively common occurrence 
of large sibships and tight family bonds that make it feasible to localise members of 
large extended pedigrees.
Within the paisa community, the region of Oriente (see Figure 1.9) has been 
established as a sub-isolate showing reduced mtDNA, Y-chromosomal and
i g2
autosomal diversity than Antioquia as a whole . The use of multigenerational 
pedigrees segregating severe bipolar disorder from this region, as well as from a 
village in Caldas, Aranzazu, whose founders had immigrated from the Oriente region 
(A. Ruiz-Linares, personal communication), therefore represents a promising 
approach to the identification of locally enriched susceptibility loci. This has been 
implemented in a genome-wide microsatellite scan of bipolar families described in 
chapter 4.
The population of the Central Valley of Costa Rica (CVCR) is demographically 
related to Antioquia: it originates from related ancestral populations, has been 
founded around the same time as Antioquia and has also shown a high demographic 
expansion based almost only on internal growth. Autosomal, Y-chromosomal and 
mtDNA analyses have confirmed this close relatedness180, giving rise to the 
possibility that susceptibility loci for complex diseases might be shared between the 
two populations. The joint analysis of pedigree data from both isolates has identified 
a candidate susceptibility region on chromosome 5q31-34184. This promising result 
from the analysis of two closely related population isolates has been followed up 
within the frame of this thesis (see chapter 3).
1.4. Bipolar Disorder
1.4.1. Clinical Presentation and Classification
Bipolar disorder (BP) is a complex psychiatric condition characterised by severe 
mood disturbances manifesting as alternating episodes of depression and mania185. 
Depressive episodes in BP show great similarity to recurrent unipolar disorder; they 
are characterised by low mood and energy levels, loss of interest in activities 
otherwise enjoyed, decreased self-esteem, changes in sleep patterns (sleeping to 
much or too little), changes in appetite leading to weight loss or gain, decreased
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psychomotor activity and difficulties to concentrate. These changes lead to a marked 
impairment of everyday functioning. Suicidal ideation is common, and 10-20% of 
bipolar patients take their own life185. Psychotic symptoms, such as hallucinations, 
paranoia, and delusions, may be present in depression, but are more characteristic of 
manic episodes. Mania is in many respects the opposite of depression. Its main 
symptom is extremely elevated mood, accompanied by inflated self-esteem, often 
leading to risk-taking behaviour, decreased need of sleep and increased energy 
levels, high activity levels and high levels of psychomotor activity. Patients may 
experience racing or crowded thoughts, and their ability to concentrate is decreased.
1 8ADuring severe mania, everyday functioning is also markedly impaired . While 
depressive episodes are characteristic of BP, it is the occurrence of at least one 
episode of mania that serves as a necessary diagnostic criterion for BP.
A commonly made distinction is that between Bipolar Disorder Type I (BP I), which 
includes at least one episode of full-blown mania, and Bipolar Disorder Type II (BP 
II), for which a milder form of mania, referred to as “hypomania”, is typical. 
Hypomania shares many features with mania but is less severe and by definition 
never requires hospitalisation. Many patients describe an increase of goal-directed
1 fiAactivities and creativity during hypomanic episodes , and artists and writers are 
over-represented among BP patients187. In contrast to severe mania, functioning in 
hypomania might be increased compared to the euthymic state (i.e., the state of 
normal mood in between affective episodes), and patients’ mood is often 
characterised by irritability rather than the elatedness typical of mania. Mixed 
episodes, where symptoms of depression and mania co-occur, can occur in both BPI 
and BPII185.
While the differences in the severity of manic episodes, along with further 
epidemiological evidence, seem to support BPI and II as different subtypes, it is still 
unknown whether these subtypes are a reflection of true aetiological 
differences186,188. A concept that has gained popularity in recent years views bipolar 
disorders as a spectrum, or continuum, of conditions with gradual rather than
1 QQ
categorical differences between subtypes . This spectrum concept can be applied to 
different dimensions. One dimension incorporates the different types of mood 
disorders and extends from BPI over BPII to unipolar depression, while another 
spectrum-based approach can be used to capture the severity of the disease190. A
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severe subtype of BP in this dimension is that of rapid cycling, which is defined as 
the occurrence of four or more episodes of either polarity within one year is 
generally reported to occur in 10-20% of patients with bipolar disorder, especially 
BPII185’191, while a less severe subtype is cyclothymia, in which hypomania alternates 
with depressive symptoms that do not meet the criteria for a major depressive
1 09episode . A possible continuum between mood disorders and schizophrenia has
1 09also been suggested . For none of these possible spectra, it has been established 
with certainty whether a dimensional or a categorical approach is a more accurate 
reflection of the underlying aetiology. This underlines the nosological and 
aetiological uncertainties discussed in chapter 1.1.1.
1.4.2. Epidemiology
The lifetime prevalence of bipolar disorder in the general population is often cited as 
—1-1.6% [e.g., Mtiller-Oerlinghausen (2002)] ; however, these estimates are based
on a restricted definition of the disorder, taking into account only the most severe 
forms of the disease194 and might therefore be interpreted as estimates of the 
prevalence of BPI only. This is in agreement with a more recent review of the 
prevalence of bipolar disorders across European countries, which found estimates
1 O')between 0.2 and 1.8% for BPI lifetime prevalence . The prevalence of BPII is less 
well studied. In the past, the administration of structured (and therefore possibly too 
rigid) diagnostic interviews by lay interviewers is thought to have led to common 
misdiagnosis of the disorder as unipolar depression, thereby leading to relatively low 
lifetime prevalence estimates of -0.5%  for BPII. Recent studies focusing on 
symptoms particularly characteristic for hypomania have resulted in much higher 
lifetime prevalence estimates of up to -5%  in community samples, while 50% of 
depressed outpatients are thought to be suffering from BPII186,194. The prevalence of 
bipolar spectrum disorders (including BPI, BPII and cyclothymia) has been estimated 
at up to 13.5%, although it is likely to be closer to 5%186.
The prevalence of BPI is the same in both genders, while findings on BPII are more 
divergent. Some authors report a higher rate of BPII in females than males [e.g.,
1 8ABenazzi (2007)] , whereas other epidemiological reviews find no differences
1 09between the two genders [e.g., Pini et al. (2005)] . While the comparison of
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epidemiological studies is hampered by their use of different diagnostic instruments 
and the inclusion of different phenotypes, no evidence for a variation in prevalence 
across populations could be found in the literature [e.g., Pini et al. (2005)192 and 
Wittchen & Jacobi (2005)195 for Europe].
The age at onset of BPI varies, and it has been suggested that there are several peak 
ages of onset -  17, 27 and 46 years -  for an early, intermediate and late age of onset 
group, respectively196. Other authors do not make this distinction and cite the average
i qj 1 Qn
age of onset between 20 and 30 years ’ . While the average age at onset of BPII
does not differ from that of BPI, there has been evidence for a possible gender-effect, 
with early-onset females more likely to suffer from BPII, and early-onset males more 
likely to be affected with BPI197.
Bipolar disorder is often accompanied by other psychiatric conditions, such as 
alcohol and substance abuse. A study of nearly 400 bipolar patients from North 
Carolina, U.S.A., has found lifetime drug abuse rates as high as 60%26, and 
conversely, significantly elevated rates of mood disorders, including bipolar disorder, 
have been reported in a cross-European study of drug and alcohol abusers . High 
rates of comorbidity also exist between BP and anxiety disorders22, BP and eating 
disorders198 and BP and attention-deficit hyperactivity disorder, especially in 
children25.
Relatively little research has been conducted on the role of environmental risk factors 
in BP, although some evidence points towards the importance of stressful life events 
in precipitating the disease199’200. The biggest risk factor for BP, however, is of a 
genetic nature.
1.4.3. Genetics of Bipolar Disorder
There is a wealth of studies showing that BP runs in families, and numerous twin and 
adoption studies have provided evidence that this familial aggregation is caused by
901 90?shared genes rather than a shared environment ’ . Heritability estimates for BP are
very high (80-90%)203, and the greatest risk factor for developing BP remains a 
strong family history of the disease (^s, the ratio of the recurrence risk in siblings of 
bipolar probands to the one of the general population, is 5-10) . I n  spite of the 
strong evidence pointing towards the importance of a genetic predisposition to BP,
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no locus with a major effect on disease risk has been identified to date. This is almost 
certainly due to the complex nature of the disease (see chapter 1.2.1), where every 
predisposing variant is thought to have only a small effect on disease risk. In spite of 
these difficulties, there are now a range of interesting findings that have been 
confirmed through replication or in meta-analyses. Some of these findings have 
arisen from linkage-based studies, others from candidate gene analyses.
Several meta-analyses have been carried out on genome-wide linkage scans of BP. 
The first meta-analysis in the literature included eleven linkage scans and found 
genome-wide evidence for linkage on chromosomes 13q and 22q204, while a 
subsequent analysis, based on 18 genome-wide scans and using a different 
methodology, identified suggestive evidence for linkage on chromosomes 9p, lOq 
and 14q205. The most recent meta-analysis for BP is based on eleven studies; the 
main regions identified here are chromosomes 6q and 8q, both of which reached
00 f\genome-wide significance for linkage . All three meta-analyses were based on a 
range of populations; however, the most recent one excluded studies from special 
populations (e.g., isolates).
While a review of candidate gene studies published as recently as 2006 still 
concluded that no locus had been consistently implicated in the genetics of BP203, 
this picture seems to be rapidly changing. The most recent review of the genetics of
BP has identified a number of genes that have repeatedly and consistently been found
001to be associated with the disease . These include genes that are of importance in the 
metabolism of the neurotransmitter serotonin, such as the serotonin transporter gene 
5HTT on chromosome 1 7 q ll.l-q l2  and the gene encoding the neuronal tryptophan 
hydroxylase {TPH2\ chromosome 12q21.1), an enzyme involved in serotonin 
synthesis. Another pathway that might be implicated in the aetiology of BP is that of 
dopaminergic neurotransmission, with evidence for association between the disease 
and the DRD4 gene on chromosome 1 l p l 5.5, encoding the dopamine receptor D4, 
and the dopamine transporter gene SLC6A3 on chromosome 5pl5.3. Promising 
results have also been obtained for the D-amino acid oxidase activator 
DAOA(G72)/G30 locus on chromosome 13q34, which encodes a protein involved in 
glutamatergic neurotransmission, and the gene encoding the brain-derived 
neurotrophic factor (BDNF) located on chromosome l lp l3 207. Our group has 
performed a transmission distortion analysis of the BDNF gene in a sample of 224
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BPI patients from the paisa community and their parents and has found an 
association of a BDNF functional variant, and of a two-marker haplotype comprising 
this variant and a nearby microsatellite, to BP208 (our article is attached to this thesis 
in appendix 8.3). Further genes that have repeatedly shown association with BP 
include the dystrobrevin binding protein 1 (or dysbindin) locus (DTNBP1) on 
chromosome 6p22.3, the neuregulin 1 gene (NRG1) on chromosome 8p22-pll, and 
the DISCI (disrupted in schizophrenia) locus on chromosome lq42.1. These last 
three genes have also been implicated in schizophrenia, a finding that lends support 
to a theory of common susceptibility to BP and schizophrenia16,146,193. Other 
promising candidate genes comprise the gene for the monoamine oxidase A (MAOA) 
on chromosome Xp 11.23 and the gene encoding the catechol-o-methyltransferase 
(COMT) on chromosome 22ql 1.2, yet another gene which has also been shown to be 
associated with schizophrenia.
In spite of these very promising results, there is still a great deal to be learnt about 
the genetics of BP. Only those genes for which the evidence of association is 
currently strongest have been included here; this list of candidate genes is not 
exhaustive, and in the future, other genes might well receive further confirmation as 
candidates. Furthermore, the findings that are mentioned in this chapter need to be 
further replicated and confirmed, possibly in different populations, and additional 
loci remain to be discovered, so that an ever more detailed picture of the pathways of 
disease can be achieved.
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1.5. Schizophrenia
1.5.1. Clinical Presentation and Classification
Schizophrenia is a severe and debilitating psychiatric condition, which often leads to 
life-long disability. Its symptoms can be grouped into three main complexes: positive 
symptoms, negative symptoms, and cognitive impairment209,210. Different groups of 
symptoms can dominate over others in different patients, making schizophrenia an 
extremely clinically heterogeneous disease and giving rise to the notion that it might 
represent a group of related conditions rather than one disease entity211.
Positive, or psychotic, symptoms include delusions, hallucinations and bizarre 
behaviour. Delusions are irrational but firmly held beliefs that are not rooted in the 
patient’s culture, such as delusions of control, where patients believe that their 
behaviour is controlled by, e.g., aliens, and paranoid delusions, where patients have a 
groundless fear of being persecuted, or the target of a conspiracy. Hallucinations, 
sensory perceptions that seem real to patients but cannot be perceived by others, are 
most commonly of an auditory nature (“hearing voices”)210, but other types of 
hallucinations, such as visual and olfactory ones, also occur209.
The domain of negative symptoms is characterised by social withdrawal, lack of 
pleasure, poverty of thought, avolition (i.e., the lack of initiative and perseverance)
209 212and blunted affected ’ . While the symptoms of psychosis often occur in episodes,
with significant inter-episode recovery, negative symptoms are more stable in nature 
and show greater persistence between psychotic episodes209. A subtype of 
schizophrenia, dominated by persistent negative symptoms and poor long-term 
outcome, has been suggested (the “deficit syndrome” of schizophrenia)213, and more 
recently, it has even been put forward that the deficit syndrome might represent a 
distinct disease entity214. As it occurs so often in psychiatric nosology, this putative 
disease entity has neither been disproved nor confirmed, and the true situation might 
yet again best be approximated by a disease spectrum concept.
The third symptom complex in schizophrenia, cognitive dysfunction, includes 
working memory defects, problems with verbal and visual learning, deficits in 
concentration, and the impairment of problem-solving capacities and abstract 
thinking209,212.
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Taken together, these three symptom complexes affect almost every aspect of 
psychosocial functioning. Although the severity and features of the course of illness, 
such as age of onset, inter-episode recovery, and prominence of symptoms, may vary 
between patients, schizophrenia is always a very debilitating condition, which in 
most cases leads to chronic disability and the need of life-long psychiatric care212.
Schizophrenia and BP are both characterised by the occurrence of psychosis, 
indicating that the two disorders might share part of their aetiology. This is further 
stressed by the fact that several genes have been found to be associated to both BP 
and schizophrenia16,146,193 (see chapter 1.4.3), as well as by the occurrence of both 
schizophreniform and affective symptoms in a disease phenotype called 
schizoaffective disorder (SAD). Although SAD is often classified as a schizophrenia 
spectrum disorder, it has been suggested that it should be regarded as an affective
9 1 Sdisorder with psychotic features , thereby bridging the gap between affective 
disorders and schizophrenia and lending support to the idea of a spectrum of 
psychiatric illness encompassing both mood disorders and schizophrenia.
1.5.2. Epidemiology
The lifetime prevalence of schizophrenia lies at around 0.45%216. There is an 
ongoing debate about whether the prevalence varies between populations216’217, and 
the figure cited above is the median of the prevalence estimates from nearly 200 
studies conducted in 46 populations from all continents216. There are some well- 
documented cases of populations with a particularly high (e.g., second-generation 
Afro-Caribbean immigrants in the UK) or low (e.g., the Hutterites in North Dakota,
911 9 1 7U.S.A.) prevalence ’ ; however, a lot of the inter-population variation is more
subtle and might, at least partly, be the result of methodological problems.
Schizophrenia is equally common in both sexes, but male sex is associated with 
lower levels of pre-morbid functioning, a younger average age at onset, and a more
9 0 0  9 1 7severe course of illness ’ . Typically, the onset of the disease occurs in late
adolescence or early adulthood, between 16 and 30 years of age, and onset after 40- 
45 years is rare209.
A number of environmental factors have been found to influence the risk of 
schizophrenia. A higher risk of developing the disease has been associated with
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winter/spring births218’219, urban upbringing218220, and complications during
'y-y i 'y y y
pregnancy and birth ’ , and an increased prevalence of schizophrenia is observed
'y/y'i 'yyA
in immigrants ’ . As for BP, however, there is strong evidence for the importance
of genetic factors in the development of schizophrenia.
1.5.3. Genetics of Schizophrenia
Family, twin and adoption studies have provided significant evidence for a genetic 
component to schizophrenia225, and as for BP, the heritability of the disorder is in the
00 f\order of 80-90% . Like BP, schizophrenia is a complex disease -  genetically as
well as clinically - ,  and a polygenic susceptibility model with many loci conferring
oonlow to medium risk has been suggested as early as the 1960s .
Despite the polygenic nature of the disease, several candidate regions and genes have 
now received substantial support through replication and/or meta-analyses. Most 
candidate loci for schizophrenia have emerged from positional cloning -  namely 
through the follow-up of linkage studies - ,  but association studies of functional 
candidates have also shown some success.
To date, there have been two meta-analyses of genome-wide linkage studies in 
schizophrenia. Badner and Gershon (2002)204 included 18 linkage scans from 
different populations and found significant support for loci on chromosomes 8p, 13q 
and 22q. The second published meta-analysis included 20 genome-wide scans, also 
from a range of different populations, and used a different methodology228. It found 
significant evidence for a susceptibility locus on chromosome 2q. A range of other 
regions were also strongly supported, although they did not reach genome-wide 
significance. These included a second locus on chromosome 2q and regions on 
chromosomes 1, 3p, 5q, 6p, 8p, 1 lq, 14, 20p, and 22. The great amount of candidate 
regions supported in the latter meta-analysis underlines the amount of heterogeneity 
in schizophrenia susceptibility, as does the lack of agreement between the two meta­
analyses.
A number of candidate genes in schizophrenia have been found through the follow- 
up o f linkage signals. The two loci for which an implication in schizophrenia is 
currently most strongly supported, the neuregulin gene (NRG1) and the dysbindin
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gene (DTNBP1), have been identified through such positional cloning approaches. 
NRG1 is localised on chromosome 8p22-pll, a locus that was identified through
171linkage analysis in a collection of Icelandic pedigrees . There is some evidence that 
NRG1 might be involved in glutamatergic neurotransmission; however, the locus 
encodes -15 different proteins with a variety of functions in the brain, so that it 
might influence the aetiology of schizophrenia through a different pathway229. The 
DTNBP1 locus on chromosome 6p22.3 has been identified by following up a signal 
from a genome-wide linkage study of Irish schizophrenia families ’ . As for
NRG1, its function remains unclear, but it has also been suggested to be involved in
7 7 0glutamatergic neurotransmission . Additional genes identified through positional 
cloning include the DAO A gene on chromosome 13q33-34 (also called G72) and the 
gene for the nitric oxide synthase 1 associated protein (NOS1AP or CAPON) on 
chromosome lq23.3. Interestingly, the proteins encoded by both these loci also play 
a role in glutamatergic neurotransmission, in agreement with several other lines of 
evidence pointing towards an implication of this pathway in schizophrenia232. An 
association analysis of the NOS1AP locus with schizophrenia in the paisa community 
has been carried out as part of this thesis; it is described in chapter 5, and the 
glutamatergic hypothesis of schizophrenia will be discussed in greater detail there. 
Finally, the regulator of G protein signalling 4 (RGS4) gene, located close to 
NOS1AP on chromosome lq23.3 and encoding a GTPase activator involved in G- 
protein mediated neuronal signal transduction, is another interesting candidate locus 
identified through positional cloning that has been found to be associated with
7^ 7schizophrenia .
Schizophrenia has been associated with a number of chromosomal abnormalities. 
Individuals with Velo-cardio-facial Syndrome (VCFS), caused by a microdeletion on 
chromosome 22ql 1, have an increased risk for schizophrenia, an observation that has 
prompted the search for susceptibility genes in that region. Several genes located in 
the region of the deletion have been implicated in the disorder, most prominently so 
the catechol-o-methyltransferase (COMT) gene. It encodes a dopamine metabolising 
protein, a functional variant of which has repeatedly been found to be associated with
7 'XAschizophrenia . Because of its location on chromosome 22ql 1 and its involvement 
in dopaminergic neurotransmission, another pathway implied in the aetiology of the 
schizophrenia, COMT is an excellent candidate gene, and the evidence for its
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importance in disease susceptibility has grown in recent years234. Further genes 
identified in the 22qll microdeletion region include the PRODH locus, which 
encodes a proline dehydrogenase that metabolises L-proline, and ZDHHC8, the gene 
product of which interacts with postsynaptic density protein 95 (PSD-95). Both gene 
products are involved in neurotransmission processes in the brain and therefore 
represent plausible candidate genes for schizophrenia .
Linkage analysis of a large Scottish pedigree found co-segregation between 
psychopathology including schizophrenia and a balanced translocation between 
chromosomes lq  and l lq  (lq42 .1; 1 lql4.3)235. Sequencing of the translocation 
breakpoint identified the DISCI locus (disrupted in schizophrenia 1) on chromosome 
lq42.1, a locus that has subsequently been found to be associated with schizophrenia. 
As for all of the loci mentioned here, there have also been negative association 
studies for D ISCI; the overall evidence suggests, however, that the locus is a good
O'!'I
candidate for causing susceptibility to schizophrenia . The function of the DISCI 
protein is not yet fully understood, but it is known that it is associated with a number 
of cytoskeletal proteins and might influence cell architecture233 and thereby possibly 
synaptic function236.
Most functional candidates have arisen from neuropharmacological studies225. 
Overall, they seem to have been less well replicated than positional candidates, but 
there are a few genes that have received support from meta-analyses. Among them 
are the serotonin receptor gene HTR2A on chromosome 13ql4-q21 and the dopamine 
receptor genes DRD2 and DRD3 on chromosomes 1 lq23 and 3ql3.3, respectively146.
As for BP, the list of candidate genes in this chapter is not exhaustive. Association 
with schizophrenia has been reported (but not necessarily replicated) for many 
different candidate genes and only the most convincing findings are discussed here. 
As for BP, a lot of work remains to be done before we can even begin to understand 
the complexity of the genetics of schizophrenia, but the progress that has been made 
over the past decades is very encouraging for future work on the genetics of 
schizophrenia.
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1.6. Psychiatric Genetics in Antioquia and the Central Valley of 
Costa Rica
Our group has been conducting psychiatric genetics studies in the population isolate 
of Antioquia for more than ten years. During this time, we have established an 
excellent collaboration with a team of clinicians at the Department of Psychiatry at 
Universidad de Antioquia (U de A) in Medellin, who in the course of, and inspired 
by, our joint work founded the Group of Psychiatric Investigation (GIPSI), with 
whom we continue to collaborate. Under the leadership of Drs Jorge Ospina, Jenny 
Garcia and Carlos Lopez, the clinical team has collected large case samples for 
different psychiatric disorders, including bipolar disorder, schizophrenia, alcoholism, 
and autism. All of these collections include several hundred cases and are constantly 
expanded. Both extended pedigrees and sporadic cases are available for most of the 
conditions studied by our groups, thereby enabling us to use both linkage and 
association approaches in our studies.
An integral part of the collaboration with Universidad de Antioquia is our special 
connection to the Molecular Genetics Laboratory (Genmol), which was established 
by Professor Ruiz-Linares whilst still in Medellin, and which continues to be under 
his leadership, in tight collaboration with Professor Gabriel Bedoya from U de A. 
The population genetics research conducted by our groups in London and Medellin 
has provided, and continues to provide, the basis for our research in psychiatric
1 8 0 -1 8 9  9 9 7  9 9 8genetics ’ ’ . Furthermore, as part of the studies of the population of
Antioquia, our colleagues at Genmol have collected large samples of healthy 
population controls, which are available for use in case control studies.
Our groups in London and Medellin also have a longstanding collaboration with 
Professor Nelson Freimer and his research group at UCLA, who have established a 
psychiatric genetics project in the Central Valley of Costa Rica, an isolated 
population that is genetically very similar to that of Antioquia173,180,239. The parallel 
study of two closely related population isolates holds the promise of maintaining the 
advantages of a genetically relatively homogeneous population while at the same 
time facilitating the access to a greater amount of samples for both family and 
population-based association studies. Laying the foundations for our joint research in 
psychiatric genetics, our groups have collaborated on a number of projects aimed at
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investigating the genetics of the populations of Costa Rica and Antioquia180, the 
patterns of linkage disequilibrium in population isolates161, and the genetics of 
admixture in Latino populations240.
An important condition for the genetic study of psychiatric disorders is the 
availability of a reliable diagnostic tool, such as the Diagnostic Interview for Genetic 
Studies (DIGS)241, a semi-structured interview for the use in research studies, which 
was originally developed in English. In order to be able to apply this valuable tool in 
the Spanish-speaking populations of Antioquia and the CVCR, our group has
9 4 9published a validated Spanish translation, which is now widely used .
For many years, the focus of our collaborations with U de A, UCLA and Costa Rica 
has been bipolar disorder. We have performed several association studies, linking a 
polymorphism in the promoter region of the 5-HTTL serotonin transporter, as well as 
the BDNF gene to the disorder208,243, and our most important project so far in the 
genetics of BP is a genome-wide linkage scan of six extended pedigrees from
1 84Antioquia segregating severe bipolar disorder . In this study, we have identified 
several candidate regions for BPI, including regions on chromosomes lp, 3q, 21q, 
and chromosome 5q. This last region was also implicated in the genetic susceptibility 
to the disorder in a large Costa Rican pedigree ascertained and studied by our 
collaborators178,244. Follow-up studies, conducted in pedigrees and trio samples from 
both Antioquia and the CVCR, continue to support the presence of a BPI 
susceptibility locus on chromosome 5q184,245, although it might be of greater 
importance in the CVCR than Antioquia. As part of this thesis, I have conducted a 
candidate gene study of the CLINT1 gene on 5q33 in Antioquia, the results of which 
are presented in chapter 3 .1 have also carried out a genome scan in an additional nine 
BPI families from Antioquia and conducted joint analysis of both our previous 
linkage scan and the one performed as part of this thesis. This work is presented in 
chapter 4.
In an attempt to direct our studies towards a more clearly defined phenotype and 
thereby further reduce trait heterogeneity, our groups have now embarked on an 
ambitious project aimed at the identification and study of BP endophenotypes, 
involving both study sites, Costa Rica and Antioquia. We are currently also 
collaborating on a whole-genome association analysis of TS as part of the Tourette 
Syndrome Association International Consortium for Genetics.
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The work conducted for this thesis therefore represents the continuation of a long and 
fruitful collaboration between researchers and clinicians from several continents and 
should be viewed in this context.
1.7. Thesis Overview and Aims
The central aim of this thesis is to make a contribution to the identification of genetic 
factors that confer susceptibility to two complex neuropsychiatric conditions, bipolar 
disorder and schizophrenia. The approach taken here is to perform gene mapping 
studies in a well-characterised population isolate, the paisa community of Antioquia, 
North West Colombia, thereby reducing the heterogeneity that complicates the 
genetic analysis of complex diseases.
Within this scope, the specific aims of this thesis are:
1. To follow up, by sequencing and association analysis, the most promising 
signal from a whole-genome linkage scan of six families segregating severe 
bipolar disorder (BPI) from Antioquia conducted in our group184. (Chapter 3)
2. To carry out a linkage scan of an additional nine BPI families from the paisa 
community, and to conduct joint analyses of the combined autosomal data 
sets of first and second linkage scans (i.e., the published scan184 and the one 
undertaken for this thesis). (Chapter 4)
3. To carry out an association analysis of the NOS1AP gene and schizophrenia 
in a trio sample from Antioquia, incorporating a categorical as well as a 
dimensional approach to the phenotype. (Chapter 5)
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C h a p t e r  T w o
S u b je c t s  A n d  M e t h o d s
2. Subjects and Methods
This chapter provides a general description of the subjects studied and the methods 
used in this thesis. Descriptions of specifically designed assays and specialised 
statistical methods that were of importance for specific projects can be found in the 
corresponding chapters, along with any reaction protocols deviating from the 
standard ones presented in this chapter.
2.1. Subjects
All patients studied for this thesis originate from the paisa community of North West
i so i soColombia ' (see chapter 1.2.4). The gene mapping project in bipolar disorder is 
based on both linkage and association approaches; therefore, a sample of extended 
pedigrees as well as a collection of nuclear families (mainly trios) for family-based 
association analysis were studied. The schizophrenia project is based on an 
association approach only; here too, a study design based on nuclear families, mainly 
trios, was used.
2.1.1. Patient Ascertainment and Diagnostic Procedure
Patients with clinical diagnoses of bipolar disorder or schizophrenia were recruited in 
the municipalities of Medellin and Envigado (Antioquia, Colombia) at Hospital 
Mental de Antioquia, Hospital San Vicente de Paul, Clinica Samein, Clinica Insam, 
and the Mental Health Centre of Envigado.
Both BP and schizophrenia are clinically heterogeneous disorders, and schizophrenia 
in particular can present with so many different symptom constellations that two 
patients may not share a single symptom246,247. Because phenotypic variation might 
reflect underlying genetic heterogeneity, which can mask linkage and association 
signals, it is crucial for the success of a gene mapping study to limit this variation as 
much as possible. One approach is to use a narrow and clear-cut definition of the 
phenotype. In the case of bipolar disorder, only individuals affected with bipolar 
disorder type I, the most clinically homogeneous type of the disorder, were therefore
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recruited as probands (however, relatives of BPI patients with different psychiatric 
diagnoses were studied in the context of the pedigree based linkage study, see 
below). In the case of schizophrenia, no other spectrum phenotypes were included.
To further ensure minimal diagnostic variation for both diseases, we aimed at 
assessing all patients following a standardised best estimate diagnostic procedure: As 
a first step, patients would be assessed by a psychiatrist using the Spanish version of 
the Diagnostic Interview for Genetic Studies (DIGS version 3) previously validated 
in Colombia241242. During the DIGS interview, it would also be established whether 
the patient had experienced psychotic episodes. The DIGS as well as all available 
clinical records would then be revised by two further, experienced psychiatrists (the 
best estimators) who were each required to reach an independent diagnosis based on 
DSM-IV-TR criteria11. A final diagnosis would then be obtained through consensus 
between the best estimators. In case no consensus diagnosis could be reached, a third 
psychiatrist would be consulted; failing this, the subject would be excluded from 
further study.
While most patients involved in this study were diagnosed based on the strict best 
estimate procedure described above (including all sporadic samples used for 
association analysis in BPI and schizophrenia), for some patients from the extended 
BPI pedigrees, the diagnostic procedure has not yet been completed and a definite 
best estimate diagnosis has not yet been established. However, all living, genotyped 
patients studied have been seen and interviewed by an experienced psychiatrist 
involved in this study. In all cases, the diagnoses for these patients are based on the 
DIGS interview and follow DSM-IV-TR criteria. See Figures 2.1 and 2.2 for details 
on which patients do not have a best estimate diagnosis.
Two affected individuals included in the study (both part of the BPI pedigree 
collection) were deceased at the time of the analyses; however, they were 
interviewed when still alive and were diagnosed according to the criteria outlined 
above.
To ensure the population homogeneity of the sample, an additional inclusion 
criterion required at least six out of the patients’ eight great-grandparents to be of 
Antioquian origin. For this reason, a genealogical interview was conducted with all 
patients. Furthermore, as part of the genealogical interview, the patients and/or their
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family members were asked for information about possible further cases of the 
disease under study, or any other psychiatric diseases occurring in the immediate or 
extended family. For the bipolar study, families with at least three cases were then 
chosen for pedigree extension using the Family Interview for Genetic Studies (FIGS) 
241, applied by an experienced social worker (a single family included in this study, 
ANT24, only has two BPI cases; it was included because it had an additional case of 
major depression and one case of schizophrenia). The other, sporadic BPI cases were 
included in the trio sample. For schizophrenia, only a trio sample was collected.
Following the FIGS, all potentially informative members of the extended pedigrees, 
possible cases as well as their relatives, were invited to participate in the study and, 
upon agreement to do so, assessed following the diagnostic procedure described 
above. Again, diagnoses were ideally based on a best estimate, but in some cases 
they were reached by a single experienced psychiatrist after revision of the DIGS and 
all available medical records (see Figures 2.1 and 2.2). All resulting psychiatric 
diagnoses were recorded, including bipolar disorder type I and II, major depression 
and any other mood disorders, schizophrenia and schizophrenia spectrum disorders, 
Gilles de la Tourette Syndrome, and substance abuse.
Any psychiatric diagnoses in patients with mental retardation and/or neurological 
lesions, as well as for cases of substance abuse, were disregarded, and such patients 
were excluded from the trio sample. For linkage analysis, even individuals with 
uncertain diagnostic status can be informative as they can provide haplotype phasing 
information and help infer missing parental genotypes. For this reason, patients with 
mental retardation and/or neurological lesions as well as cases of substance abuse 
could be included in the pedigree sample to help the reconstruction of missing data; 
however, their affection status was set to unknown. All schizophrenic patients were 
in remission during the entire assessment procedure.
A written informed consent was obtained from all subjects prior to enrolment in the 
study.
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2.1.2. Extended Bipolar Pedigrees
Extended pedigrees from the Antioquian population segregating BPI were identified 
through probands with a clinical diagnosis of bipolar disorder as described in chapter 
2.1.1. Altogether, patients from 15 families were studied for this thesis. While all 
probands were initially identified in the city of Medellin, 13 of these families 
originate in the Oriente region of Antioquia (family code beginning with ANT), and 
the two remaining families are from Aranzazu in the province of Caldas, Colombia 
(family code beginning with FAZU).
Of the 15 families studied in this thesis, six (all from the Antioquian Oriente region) 
had been genotyped and analysed as part of a previous genome-wide linkage scan for 
BPI184 (see Figure 2.1). The data resulting from that first linkage scan were re­
analysed together with the data for the nine remaining families (see Figure 2.2), 
which were obtained as part of this thesis (see chapter 4.1).
A total of 161 individuals were included in the pedigree sample. Although the 
families were ascertained through the recruitment of probands with a DSM-IV-TR 
diagnosis of BPI, there were a number of different psychiatric diagnoses amongst 
their relatives, most notably unipolar major depression (MD). The sample comprised 
90 cases of BPI (37.8% males, 62.2% females), 22 cases of MD (18.2% males, 
82.8% females), and one case each of BPII (one male) and schizophrenia (one 
female). Other diagnoses included alcohol and drug abuse and dysthymia; however, 
these phenotypes were not analysed in the linkage study and are therefore not 
discussed any further. Reliable information on age at onset was available for 62 out 
of the 90 BPI cases, and for 10 out of the 22 cases of MD. The average age at onset 
(± standard deviation) for BPI and MD were 22.2±7.6 years and 26.6±13.8 years, 
respectively. The age at onset for the schizophrenia patient was 27 years, and there 
was no reliable information about the age at onset for the BPII patient.
A summary of pedigree characteristics can be found in Table 2.1, and the pedigrees 
are shown in Figure 2.1 [pedigrees genotyped by Herzberg et al. (2006)184] and 
Figure 2.2 (pedigrees genotyped as part of this thesis).
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Table 2.1: Pedigree characteristics. For each pedigree, the number of individuals typed, and the 
number of patients with a specific diagnosis is shown. The number in brackets indicates how 
many of these cases have a best estimate diagnosis. MD, major depression; SCZ, schizophrenia. 
It is also indicated whether genome-wide genotype data were collected as part of this thesis.
P e d ig re e
n o .
#  in ­
d iv id u a ls  
ty p e d
BPI BPII MD SCZ P sychosis
G e n o ty p e  d a ta  
c o lle c te d  a s  p a r t  o f  
th is  th e s is ?
FAZU01 16 6(3) 0 2(1) 0 1 yes
FAZU28 12 7(3) 0 0 0 2 yes
ANT03 9 6(5) 0 3(3) 0 2 no
ANT04 15 8(8) 0 4(4) 0 3 no
ANT07 26 13(12) 1(1) 5(3) 0 8 no
ANT10 8 4(2) 0 3(3) 0 1 yes
ANT14 10 7(7) 0 KD 0 7 no
ANT15 5 3(3) 0 0 0 2 yes
ANT18 14 6(6) 0 0 0 3 no
ANT19 6 4(4) 0 KD 0 1 yes
ANT21 6 5(3) 0 0 0 3 yes
ANT23 8 6(5) 0 2(2) 0 3 yes
ANT24 5 2(1) 0 1(0) 1(1) 2 yes
ANT26 4 4(1) 0 0 0 0 yes
ANT27 17 9(9) 0 0 0 5 no
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Figure 2.1 (extends over the previous three pages): Set of six Antioquian pedigrees genotyped as 
part of the whole-genome linkage study performed by Herzberg et al. (2006) and re-analysed in 
the frame of this thesis. Individuals marked by a cross were available for genotyping. Filled 
symbols indicate BPI, symbols with a filled right half MD, symbols with a filled left half BPII. 
Individuals suffering from psychosis are labelled “Psy”. Individuals for whom no best estimate 
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Figure 2.2 (extends over the previous four pages): Set of nine paisa  pedigrees genotyped and 
analysed for this thesis. Individuals marked by a cross were available for genotyping. Filled 
symbols indicate BPI, symbols with a filled right half MD, filled symbols with the upper right 
quarter left blank indicate schizophrenia. Individuals suffering from psychosis are labelled 
“Psy”. Individuals for whom no best estimate diagnosis is available are indicated by a circle (see 
chapter 2.1.1 for an explanation).
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2.1.3. Bipolar Trio Sample
A sample of 176 unrelated BPI patients (64 males, 112 females; mean age 34.9 ± 9.8 
years; mean age of onset 24.1 ± 8.2 years; mean duration of illness 10.7 ± 8.5 years) 
was recruited in the city of Medellin as described in chapter 2.1.1.
The sample recollection aimed at obtaining a sample of affected offspring-parent 
trios to carry out transmission disequilibrium analysis and is therefore referred to as 
the BPI trio sample; however, not all sporadic BPI cases had both parents available. 
The inclusion of siblings paired with the use of special analysis programs facilitates 
the reconstruction of missing parental genotypes; wherever parents were not 
available, siblings were therefore collected.
The characteristics of the nuclear families included in the sample are summarised in 
Table 2.2.
Table 2 .2 : Characteristics of the sample for family-based association in B P I. nf, nuclear family.
n f s t ru c tu r e # a f fe c te d s # p a r e n t s
# u n a f f e c te d
sib lings
T o ta l #  
in d iv id u a ls  
in n f
#  n f  w ith  
sp ec ifie d  
s t ru c tu r e
Trio 1 2 0 3 81
Trio with sib 1 2 1 4 5
Duo 1 1 0 2 14
Duo with sib 1 1 1 3 68
Duo with 2 sibs 1 1 2 4 1
Three sibs 1 0 2 3 5
Two affecteds, one 
parent, one sib 2 1 1 4 2
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2.1.4. Schizophrenia Trio Sample
The sample for family-based association analysis in schizophrenia consisted of 102 
patients diagnosed as described in chapter 2.1.1 (79 males, 23 females; mean age 
34.3 ± 10.2 years; mean age of onset 21 ± 7.2 years; mean duration of illness 13.4 ± 
8.7 years), and their nuclear families.
As for the BPI trio sample, the schizophrenia sample was collected with the aim of 
performing transmission disequilibrium analysis. It was therefore attempted to 
collect parent-affected offspring trios, but again, not all patients had both parents 
available for study, and again, nuclear families of different structures were therefore 
collected, with an emphasis on collecting siblings where parents could not be 
obtained.
Table 2.3 shows an overview over the different types of nuclear families used in the 
schizophrenia association study.
Table 2.3: Characteristics of the sample for family-based association in BPI. nf, nuclear family.




# nf with 
specified 
structure
Trio 1 2 0 3 38
Duo 1 1 0 2 13
Duo with sib 1 1 1 3 45
Duo with two sibs 1 1 2 4 2
Three sibs 1 0 2 3 1
Two affecteds, one 
parent, one sib 2 1 1 4 1
Affected, sibling, 
aunt/uncle 1 0 1 3 2
2.1.5. Ethical Committee Approval
This study was approved by the Ethics Committees of all participating institutions.
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2.2. Laboratory Methods
2.2.1. Sample Collection and DNA Extraction
Blood samples were collected from patients and their relatives by our clinical 
collaborators at the Department of Psychiatry at Universidad de Antioquia, Medellin. 
In some cases where blood samples could not be obtained a saliva sample was taken 
instead. DNA was extracted at Laboratorio de Genetica Molecular (Genmol), 
Universidad de Antioquia, following a standard phenol-chloroform protocol. The 
DNA extraction was also done by our Colombian collaborators, and an aliquot of 
each DNA sample was then sent to our laboratory at UCL.
2.2.2. DNA Concentration Measurement and Adjustment
The DNA concentration of the samples was determined by photospectrometric 
measurement. Samples were diluted 1:100 with sterile de-ionized water (dH20) and 
their concentration was measured using a spectrophotometer (Biophotometer by 
Eppendorf), which records the absorption of the dilution at a wavelength (A,) of 
260nm, where an absorption of 1.0 corresponds to 50pg of double stranded DNA. 
Prior to every measurement, the spectrophotometer was calibrated by performing a 
blank measurement using dFUO only. After recording the concentration, samples 
were diluted to a working concentration of 20ng/pl. For some samples, the stock 
solution had a concentration of <20ng/pl; in these cases, the stock solutions were 
used for genotyping and sequencing.
2.2.3. The Polymerase Chain Reaction (PCR)
The polymerase chain reaction (PCR)248 is a standard and well-characterised tool in 
molecular genetics, which allows the in vitro replication (amplification) of specific 
DNA segments.
Both the genotyping assays and the sequencing performed for this thesis relied on 
performing a PCR as a first step. Primers were obtained from different sources: the 
whole-genome linkage scan was carried out using the ABI Linkage Mapping Set 
v2.5 (Applied Biosystems); this set contained all primers ready for use. All other
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PCRs for microsatellite markers were performed using primers published in the 
Genome Database (http://www.gdb.org). The remaining primers were designed using 
the Primer3 programme (available at http ://frodo.wi .mit.edu/). The following well- 
established criteria were taken into account for primer design:
1. Primers should be between 18 and 24 bp long: the length of a primer is key to
the specificity of the PCR; the shorter it is, the higher are the chances of
unspecific annealing at other sites than the target of the PCR. If, on the other
hand, the primer is too long, it might not properly anneal at all, and the
efficiency of the PCR might be compromised. Deviations from the optimal 
primer length were possible, but it was attempted to keep primer 
oligonucleotides in the size range specified above.
2. The GC content of a primer should be around 60%. Guanidin and Cytosin are 
paired via three hydrogen bonds, and therefore require a greater amount of 
energy to be separated from each other than Adenine and Thymine. If the GC 
content of a primer is too high, it might form more stable secondary 
structures (see 3.) than primers with a higher AT content and therefore be 
unavailable for the PCR reaction, thereby lowering its efficiency. If the GC 
content of a primer is too low, however, it might not anneal stably to the 
DNA template, thereby also decreasing PCR efficiency.
3. To avoid the formation of primer dimers, the sequences of a primer pair 
should not be complementary to each other. Primer dimers capture primer 
molecules and make them unavailable for PCR, again decreasing the 
efficiency of the reaction. A similar problem occurs if a primer shows self­
complementarity; it then forms a secondary structure, which keeps the primer 
from annealing at the target DNA.
4. The melting temperatures of the two primers constituting a pair should not lie 
too far apart as that might interfere with the annealing of at least one of the 
primers, thereby decreasing PCR efficiency. The annealing temperature of a 
PCR should be approximately 5°C below the primers’ average melting 
temperature.
PCR conditions varied according to the primers used. A standard reaction set-up that 
was used as the starting point for the optimisation of many PCR assays is presented
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in Table 2.4. Standard cycling conditions are presented in Table 2.5. For full 
information on PCR conditions for each assay refer to the corresponding chapters. 
All PCRs preceding genotyping were set up in 96-well plates, while PCRs preceding 
sequencing were set up in strips of 8 0.5pi tubes (both ABgene). PCR reactions were 
carried out in a 96-well plate DYAD™ DNA Engine Thermal Cycler or its disciple 
(MJ Research). Except for the primers that were part of the ABI linkage mapping set, 
all primers were purchased from Sigma Aldrich in lyophilised form. Primer stock 
solutions were prepared and kept at a concentration of lOOpM; working solutions 
were IOjuM. Each PCR included a negative and a positive control (dFhO and a 
CEPH sample, respectively).
Table 2.4: Set-up of a standard PCR reaction (per reaction).
PCR c o m p o n e n t v o lu m e  (pi)
fina l
c o n c e n tra tio n
fu n c t io n  in PCR
Buffer (Bioline) 2.5 lx Stabilisation of reaction environment
Co-factor for
MgCI2 (Bioline) 0.75 1.5 mM oligonucleotides, primers, 
and enzyme
dNTPs (Bioline) 0.625 25 pM Building blocks of nascent DNA
Taq polymerase (BIOTAQ™, 
Bioline) 0.1 0.5 U* Catalyses DNA replication
forward primer 1.5 0.4 pM The primers determine the 
fragment to be amplified and
reverse primer 1.5 0.4 pM serve as starting point for elongation.
DNA 2 1.6 ng/pl DNA template
dH20 16.025 - Concentration adjustment
total 25 - -
*As customary for enzymes, this figure does not denote a concentration but the total amount in 
the reaction.
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Table 2.5: Cycling conditions for a standard PCR.
PCR s te p te m p e r a tu r e tim e
1 -  Initiation 94°C 4 min
2 -  Denaturing 94°C 30 sec
3 -  Primer Annealing 55°C 30 sec
4 -  Elongation 72°C 45 sec
5 -  Repeat steps 2-4 29 x 
(for a total of 30 cycles) - -
6 -  Final Elongation 72°C 5 min
7 -  Cool-Down 4°C 15 min
2.2.4. Agarose Gel Electrophoresis
PCR amplification success was checked by means of agarose gel electrophoresis. In 
gel electrophoresis, DNA fragments are separated according to their size. This is 
achieved by applying an electric field to the gel. DNA molecules are negatively 
charged and will therefore migrate towards the plus pole of this field. Smaller 
molecules migrate faster through the gel matrix, while larger molecules are held back 
by the polymer structure of the gel. A base pair ladder, which consists of a mix of 
fragments of known sizes, is included in each run, allowing to determine the size of 
DNA fragments by comparison to the ladder. The resolution of an agarose gel 
depends on its concentration. PCR products in this thesis were between -100 and 
-500 bp long; an adequate agarose concentration to separate fragments in this size 
range is 2%.
DNA visualisation was achieved by staining agarose gels with ethidium bromide 
(EtBr), a reagent that intercalates between DNA base pairs. The region of inter­
calation shows intense fluorescence under a UV lamp, allowing the distinction of 
DNA bands.
Agarose gels were prepared as follows:
1. 2g of agarose were mixed with 100ml of lxTBE buffer (both Sigma).
2. The mix was heated in a microwave oven for approximately 2min at 800W, 
or until the agarose had completely dissolved and the solution appeared clear.
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3. 80pl EtBr (Gene Choice) were added to the gel solution to make for a final 
concentration of 0.5jag/ml.
4. The mix was gently stirred to avoid the formation of bubbles and carefully 
poured into a previously prepared gel chamber (Electro-fast® Stretch System 
by ABgene). The combs were added, and the gel was then left to polymerise 
for ~45min.
5. After polymerisation, lxTBE was poured into the chamber until the gel and 
the electrodes on both sides of the chamber were completely covered.
3 pi of each PCR product were then mixed with 2pi loading buffer and loaded onto 
the gel. 2pl of a lOObp size standard (500pg/ml, New England Biolabs) were loaded 
into a separate well, and the gel was run for 35min at 80V. Finally, the DNA was 
visualised with the help of a UV transilluminator (BioDoc-It™ System, UVP), and a 
picture was taken using the built-in digital camera. An example of an agarose gel 
picture is shown in Figure 2.3.
Figure 2.3: Agarose gel with PCR products.
BP pedigree samples
The gel picture shows the products of the amplification of STR marker D5S410 by PCR. A 
lOObp ladder is included. From comparison with this ladder, it can be seen that the PCR 
product is ~350bp long. A positive and negative control are also shown. Here, the positive 
control is the CEPH sample 1347-02.
2.2.5. Genotyping
Two basic methods of genotyping were used in this thesis: fragment length analysis 
for the genotyping of microsatellite markers, and restriction fragment length analysis 
for the genotyping of SNP markers.
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2.2.5.1. Microsatellite Markers
Microsatellite markers, also called short tandem repeats (STRs), are genomic DNA 
sequences consisting of a variable number of repeats of a short sequence motif249,250. 
The repeat motif is most commonly two to four bp long. The alleles of a 
microsatellite marker locus differ from each other in the number of repeat units (see 
Figure 2.4); amplification by PCR therefore results in differently-sized fragments, a 
property that can be used to separate the two fragments resulting from an individual’s 
alleles by electrophoresis and to determine the genotype according to the size of the 
amplified fragments (fragment length analysis, see chapter 2.2.5.2).
Figure 2.4: Schematic representation of a microsatellite locus.
Allele 1: 5 repeats 
GAGAGAGAGA 
GAGAGAGAGAGAGA 
Allele 2; 7 repeats
The microsatellite shown here has a dinucleotide repeat motif (GA)n. The two alleles differ from 
each other by the number of repeat units (five vs. seven). The sequences on both sides of the 
microsatellite locus (shown in grey) are the same for both alleles, and PCR primers would be 
designed to be complementary to a section of this surrounding sequence.
Microsatellite loci occur spread throughout the whole genome. Some are located 
within genes (such as the trinucleotide sequence in that, through expansion, causes 
Huntington’s Disease ), but most are located in non-coding regions and seem to 
evolve neutrally . Partly because of their mechanism of mutation, which involves a 
process called “slippage”, during which the DNA polymerase erroneously omits, or 
adds in, additional repeat units252, partly because of their neutrality in evolution, 
microsatellites mutate relatively fast and are therefore highly polymorphic. Because 
linkage analysis depends on the identification of recombinants, for which
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heterozygosity at both disease and marker loci is crucial, microsatellites are ideal 
markers for linkage analysis .
2.2.5.2. Fragment Length Analysis
Fragment length analysis consists in the electrophoretic separation of microsatellite 
alleles and the calling of the genotype based on the fragment lengths observed. 
Microsatellite alleles differ from each other by only a few base pairs, and the 
resolution of agarose gels is not high enough to separate them. For genotyping, 
microsatellite PCR products are therefore run through a high resolution 
electrophoresis that is able to detect size differences of less than a base pair. High 
resolution electrophoresis is either polyacrylamide gel- or capillary-based, but the 
principle of both methods is the same. Here, capillary electrophoresis was used. In 
both systems, DNA detection relies on a laser positioned near the plus pole, which 
records the signals emitted by a fluorescence labelled primer incorporated into the 
PCR product. Because the laser can detect a range of different fluorescence labels, an 
advantage of this system is the possibility of pooling several PCR products and 
running them in the same gel lane or capillary, thereby reducing genotyping costs.
The ABI linkage mapping set v2.5 is organised into 28 panels (i.e., groups of 
markers that can be run simultaneously owing to different combinations of size 
ranges and fluorescence labels). Panels comprised markers with three different 
fluorescence labels: FAM (blue), VIC (green), and NED (yellow). The ABI linkage 
mapping set (“ABI markers”) had originally been purchased for the previous linkage
1 84scan carried out in our lab , and the fluorescence of the primers had diminished 
somewhat over time. Therefore, the dilution of PCR products that is necessary prior 
to fragment length analysis could not always be done according to the 
manufacturer’s instructions. For example, ABI recommends diluting PCR products 
for FAM-labelled markers 1:20 before analysing it by polyacrylamide gel or 
capillary electrophoresis; however, to obtain a readable result, FAM-labelled markers 
with a weak PCR product had to be diluted 1:10. After PCR and agarose gel 
electrophoresis, each marker was therefore visually inspected to decide on a dilution. 
All dilutions were in the range of 1:20 -  3.5:20, and FAM- and VIC-labelled markers
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were generally diluted more than NED-labelled ones, because the yellow 
fluorescence of NED is naturally weaker than that of the other fluorophores.
PCR product dilution is achieved as the different PCR products are pooled together 
in a fresh 96-well plate; if markers cannot be diluted as intended by the 
manufacturer, the panel structure suggested by ABI will not hold anymore. For this 
reason, and because of the relatively weak fluorescence of NED, with which stronger 
fluorophores can interfere, FAM- and VIC-labelled markers were pooled together, 
while NED-labelled markers were pooled separately for each panel. Because panel 
28 contained X-chromosomal markers, which were not analysed in the BP linkage 
scan presented here, the ABI markers were run in 27x2 = 54 panels.
Non-ABI microsatellite markers were organised into panels by size ranges (as 
indicated on the Genome Database), and primers were ordered with different 5’ 
fluorescence labels so as to make the genotyping as efficient as possible. For green 
fluorescence, HEX was used instead of VIC. For blue and yellow fluorescence, FAM 
and NED were used, respectively. Non-ABI microsatellite markers were used to 
follow up the 5q region, a candidate region that had emerged from the linkage scan 
by Herzberg et al. (2006)184 (see chapter 3), and for some repeats in the BP linkage 
scan, where ABI primers had run out.
2.5pi of the pooling mix were transferred to a new 96-well plate, which was then 
handed over to the in-house genotyping service at the Centre of Comparative 
Genomics (CCG; http://www.ucl.ac.uk/biology/centre-for-comparative-genomics/). 
where both sequencing and genotyping are performed on a 96-capillary 373Ox/ DNA 
Analyzer (Applied Biosystems).
Raw genotyping data were returned by the CCG in ABI’s .fsa file format and 
subsequently analysed using the GeneMapper® software v 3.7 (Applied Biosystems). 
Fragment sizes were determined by calibration to the LIZ500 size standard (Applied 
Biosystems), and alleles were called using the standard microsatellite analysis 
procedure implemented in the GeneMapper® software. See Figure 2.5 for an example 
of the GeneMapper® output for one sample. After automatic calling, peaks were 
checked by eye and any mislabelled peaks were corrected. Genotypes were then 
exported into a table.
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This procedure, from importing the raw data into GeneMapper* to exporting the 
genotype data, was carried out by two independent researchers, including the author 
of this thesis, and the resulting genotypes were compared (“double scoring”). Any 
discrepancies between the results of the two double scorers were examined in detail 
by both researchers together. If the double scorers could not agree on a genotype, the 
allele calls were deleted and the sample repeated for the marker in question, until the 
maximum number of repeat rounds for a marker was reached (usually two, unless a 
new primer had been ordered or for any other reason it was sensible to perform more 
repeats).
Figure 2.5: Fragment length analysis with the GeneMapper software
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The figure shows an extract of an electropherogram for sample FAZU Ol-H-376. The different 
size ranges and fluorescent labels of different microsatellite marker systems allow them to be 
run together in one capillary. The top panel shows markers labelled with FAM (blue; from left 
to right: D2S286 and D2S165); the one below shows markers labelled with VIC (green; from left 
to right: D2S125 and D2S206). The second lowest panel shows markers labelled with NED 
(yellow fluorescence, however, on screen, it is represented in black; from left to right: D2S2333 
and D2S126). The LIZ500 size standard is shown in the bottom panel (orange peaks; the peaks 
shown in this extract correspond to the 100 bp, 139 bp, 150 bp and 160 bp peak). The analysed 
sample is homozygous for two systems and heterozygous for the remaining four.
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2.2.5.3. Single Nucleotide Polymorphisms
Single Nucleotide Polymorphisms, or SNPs, occur when two alleles at a locus differ 
by a single base pair. In order to be called a SNP, such a single base pair substitution 
must occur with a minor allele frequency (MAF) of at least 1% in the population254. 
SNPs mutate at a much slower rate than microsatellites and, by definition, cannot 
have more than four alleles. Most SNPs have two alleles, meaning that their 
maximum possible heterozygosity is 0.5 (if both alleles occur at equal frequencies). 
As mentioned in chapter 1.2.4.3, the current build of the NCBI’s dbSNP database 
(no. 128; http://www.ncbi.nlm.nih.gOv/SNP/i contains approximately 12 million 
SNPs, most of which are located in non-coding sequences. As opposed to 
microsatellites, however, there are a great number of SNPs occurring in coding 
regions, too255. This is an advantage for association analysis because it opens up the 
possibility that the causative SNP might be amongst the ones typed in an association 
study. There are a number of ways in which SNPs can be genotyped; in this thesis, 
restriction fragment length polymorphism (RFLP) analysis was used.
2.2.5.4. Restriction Fragment Length Polymorphism Analysis
RFLP analysis relies on the activity of restriction enzymes, or endonucleases. These 
enzymes recognise, and subsequently cut the DNA molecule at, specific short, often 
palyndromic sequences. A base pair change, such as it occurs in SNPs, can destroy 
such a recognition site, preventing the endonuclease from cutting at that position. 
Alternatively, a SNP can introduce a new restriction site. As a result, endonuclease 
assays can be used to distinguish two alleles of a SNP locus from each other. After 
amplifying the sequence surrounding a SNP by PCR, the PCR product is left to be 
cut (or digested) by an endonuclease. While one allele is cut during digestion with 
the enzyme, the other is not. This principle is illustrated in see Figure 2.6. An 
important limitation of this method is that the SNP has to be located at an 
endonuclease recognition site. If there is no endonuclease that cuts at the location of 
a SNP, another way of genotyping has to be found, e.g. single strand conformation 
polymorphism (SSCP) analysis.
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Figure 2.6: Principle of restriction fragment length polymorphism analysis.
From Syvanen (2001)255
The usual way of separating the different fragments resulting from an endonuclease 
digestion is by agarose gel electrophoresis. However, the assay used in this thesis 
(used to type a polymorphism in the CLINT 1 gene, see chapter 3) was designed in a 
slightly different way: because the DNA fragments resulting from the enzymatic 
digestion were too small to be distinguished by agarose electrophoresis, a 
fluorescently labelled primer was used, and the digestion product was run on a 
capillary sequencer instead. The design of the assay is explained in chapter 3.2. The 
reaction was set up in 96-well plates as shown in Table 2.6.
Table 2.6: Set-up of the Tsp509I digest (per reaction)
Reaction component volume (pi) finalconcentration
Buffer (New England Biolabs) 1.25 lx
Tsp509l Endonuclease (New 
England Biolabs)
0.4 4U*
PCR product 10 7
dH20 0.85 -
total 12.5 -
*As customary for enzymes, this figure does not denote a
concentration but the total amount in the reaction.
The reaction mix was incubated for 5h at 65°C in a DYAD™ DNA Engine Thermal 
Cycler or its disciple (MJ Research). Subsequently, 2jal of a 1:10 dilution of the 
digest were transferred into a new plate and sent to the CCG for electrophoresis in a
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capillary sequencer. After receiving the raw data back from the CCG, the results 
were analysed using the GeneMapper® software version 4.0, using the standard 
analysis procedure for microsatellites, which could also be applied for this RFLP 
assay.
2.2.6. Sequencing
Sanger-sequencing was performed as part of the effort to identify new variants 
potentially associated with psychosis in the CLINT 1 gene (chapter 3). The 
sequencing procedure consists of five steps: (1) amplification of the segment to be 
sequenced by PCR, (2) clean-up of the PCR product, (3) the sequencing reaction, (4) 
clean-up of the sequencing product, and (5) the sequencing run. Step (1), the PCR, 
was carried out as described in chapter 2.2.3, with some adjustments to the protocol 
(see chapter 3.2 for details).
After checking the amplification success on an agarose gel, the remaining 22pl of the 
PCR product were cleaned up (step 2) by adding a shrimp alkaline phosphatase 
(SAP), used to eliminate unincorporated dNTPs, and an exonuclease (Exo-I), used to 
digest left-over primer molecules, so that neither of these PCR reagents could 
interfere with the sequencing reaction. 2.5pl (2.5U) SAP and 0.1 pi (1U) Exo-I (both 
USB Corporation) were added to 22pl PCR product. The mix was then left to 
incubate for lh  at 37°C, followed by 15min at 72°C (enzyme deactivation step). This 
protocol was set up in strips of 8 0.5pi tubes.
l-1.5pl of the clean PCR product was then used in the sequencing reaction (step 3). 
Sequencing was carried out using the Big Dye Terminator v3.1 kit (Applied 
Biosystems). It was found that, instead of the 8pl/reaction of the Big Dye mix 
recommended by the manufacturer, 1 pl/reaction was enough to give good 
sequencing results, and the resulting reaction protocol is shown in Table 2.7. A 
positive sequencing control was included as provided in the Big Dye kit, and 
sequencing reaction was carried out following the manufacturer’s instructions.
100
Table 2.7: Sequencing reaction set-up (per reaction)
R e a c tio n  c o m p o n e n t v o lu m e  (pi)
fina l
c o n c e n tra tio n
Big Dye v3.1 1 ?
Buffer (from Big Dye kit) 1.5 lx
sequencing primer (5[iM) 0.64 0.32pM
PCR product 1-1.5 ?
dH20 5.81-5.86 -
total 10 -
The product of the sequencing reaction was subsequently cleaned up (step 4) by first 
adding 2.5pi of 125pM EDTA and 30pl of 100% ethanol to each sample and 
incubating the mix for lOmin at room temperature. The samples were subsequently 
centrifuged for lh  at high speed (3870 rpm) in order to precipitate the product of the 
sequencing reaction. The supernatant was subsequently removed by inverting the 
samples and centrifuging at low speed (1000 rpm) for lmin. As a second cleaning 
step, 30pl of 70% ethanol were then added to each sample, and the mix was again 
centrifuged at 3870 rpm, this time for lOmin. The samples were then again inverted 
and the supernatant removed by centrifuging at lOOOrpm for lmin. After this final 
centrifugation step, the samples were left to dry at room temperature and 
subsequently sent to the CCG for the sequencing run (step 5).
The raw data received from the CCG was analysed using the Sequencher software 
v4.7 (Demo version; Gene Codes Corporation) and the ChromasPro software 
(Technelysium). The freely available online version of the MAFFT v5.8 software 
(http ://ali gn. bmr .kvushu-u. ac. i p/mafft/online/server/) was used for sequence
alignments.
2.3. Data Analysis and Statistical Methods
A range of methods was used for the analysis of the genetic data collected for this 
thesis. The first method, presented in section 2.3.1, is not part of the actual data 
analysis but describes how the data, which was stored in the so-called “linkage
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format”, was recoded and converted into the different input file formats needed for 
the different analyses. In section 2.3.2, the SimWalk2 programme, a package for 
pedigree-based statistical genetics analysis, is introduced.
An important part of data analysis is concerned with the quality control of the 
genotyping data. Sections 2.3.3, 2.3.4 and 2.3.5, dealing with Hardy Weinberg 
equilibrium and the detection of genotyping errors, fall into this category. Section 
2.3.6 describes the estimation of population allele frequencies from pedigree data, an 
important step prior to linkage analysis.
Finally, the analysis methods that are at the core of this thesis, the tests for genetic 
linkage or association in the clean data, are presented in sections 2.3.7 to 2.3.12.
2.3.1. The Linkage Format, Recoding and File Conversion
All genotype data were stored in the “linkage format”, a straightforward computer 
readable format, which as well as assigning genotype data to each individual, 
describes the pedigree structure. In the linkage format, the data for each individual 
are displayed in one row: the first column contains the pedigree identifier, the second 
a unique personal identifier (PID), followed by the PID of the individual’s father and 
mother in the third and fourth columns, respectively. These columns take the value of 
0 for founder individuals. The fifth column contains the gender (1 = male, 2 = 
female) , the sixth the affection status (1 = unaffected, 2 = unaffected, 0 = unknown). 
The following columns contain the genotypes. For all microsatellite loci, genotypes 
were initially recorded in the form of either 2- or 3-digit alleles, according to the size 
of the corresponding DNA fragment. Because SimWalk2 does not handle 3-digit 
alleles, all microsatellite alleles were recoded to successive 2-digit alleles for all 
further analyses using the recoding facility of the programme Mega2, a file handling 
tool for linkage analysis
While many programmes for the analysis of gene mapping data use input files in the 
linkage format, some do not, including both the Mendel software v8.0.1 (used to 
estimate population allele frequencies from the pedigree data, see chapter 2.3.6) and 
the programme SimWalk2 v2.9.1 (used for a range of different analyses, see sections 
2.3.5 and 2.3.7 to 2.3.9). The linkage format input files were therefore converted into 
formats readable by these programmes using Mega2.
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2.3.2. The SimWalk2 Programme
")CH
SimWalk2 is a software package that performs a range of statistical genetics 
analyses on pedigree data. Available options include parametric and non-parametric 
linkage analysis, haplotype inference, mistyping analysis and the calculation of 
identity by descent probabilities. Several of the options available in SimWalk2 v2.9.1 
have been used to analyse the data from the whole-genome linkage scan for BP for 
this thesis (see sections 2.3.5 and 2.3.7 to 2.3.9). SimWalk2 operates in a maximum 
likelihood framework, where the likelihood of the observed pedigree data is 
represented as a function of a number of variables. These include allele frequencies, 
marker map and order, and a penetrance function linking genotypes and phenotypes. 
The different variables can then be varied until the point of maximum pedigree 
likelihood is reached.
The most distinct feature of the SimWalk2 programme, however, is that instead of 
performing an exact likelihood calculation, it relies on an approximation using a 
Markov Chain Monte Carlo (MCMC) algorithm. The MCMC method is a complex 
one; essentially, “Monte Carlo” refers to estimating an expectation by the sample 
mean of a set of simulated random variables. In the genetic analysis of pedigree data, 
the expectation represents the outcome of the pedigree likelihood function. A 
Markov Chain is a random walk procedure commencing at a (random) starting point 
and moving from one state to the next as determined by a matrix of transitional 
probabilities. Because of the inherent linearity of the process, the first steps will 
depend on the starting point, but as the Markov Chain continues, the state of the 
chain will become more and more independent of this starting position and will start 
to converge into a limiting probability distribution. The proportion of time the 
Markov chain spends in a certain state then tends towards the probability of that 
state. The first, starting position-dependent steps, referred to as “burn-in”, are 
discarded. The principle of the MCMC method in the context of pedigree analysis is 
that the pedigree likelihood will be estimated by a Monte Carlo process that relies on 
a Markov Chain to sample from a distribution of random variables (essentially, every 
pedigree/data conformation consistent with the given data).
Although exact methods should be preferred if possible, the MCMC approach is 
extremely useful when dealing with a sampling space that is too big for an exact 
likelihood calculation. In the context of pedigree analysis, this refers to pedigrees
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with a large amount of founder individuals, and to the simultaneous consideration of 
a large amount of marker loci. Other programmes available for linkage analysis are 
restricted either in the number of marker loci they can handle (programmes based on 
the Elston-Steward algorithm, e.g., Linkage258'260 and Vitesse261), or in the number of 
founding individuals in a pedigree (programmes based on the Lander-Green 
algorithm, e.g., GeneHunter116). Even newer programmes that have implemented 
improved versions of the original algorithms, such as Allegro262 and Merlin263, 
cannot handle extended pedigrees of a complexity similar to that of two of the 
pedigrees analysed as part of the genome-wide linkage study of BP, ANT07 and 
FAZU01 (see Figures 2.1 and 2.2). Therefore, to facilitate the joint analysis of all 
pedigrees, SimWalk2 was chosen for most pedigree-based analyses. Furthermore, 
although SimWalk2 does not provide exact results, its results have been found to 
show excellent agreement with those of software packages that are based on an exact 
algorithm264.
2.3.3. Hardy Weinberg Equilibrium
The Hardy Weinberg equilibrium (HWE) describes a situation, in which the 
genotype distribution at a genetic locus can be predicted for a population if the allele 
frequencies at that locus are known. For a biallelic locus with the alleles A and a and 
the allele frequencies f(A) = p and f(a) = q, the genotype distribution at HWE is:
f(AA) = p x p = p2 ; f(Aa) = p x q  + q x p  = 2pq ; f(aa) = q x q  = q2. (12)
Equivalently, the allele frequency distribution can be inferred from the genotype 
distribution.
A number of theoretical conditions have to be fulfilled for the HWE to hold: (1) the 
population has to be o f an infinite size, (2) there has to be random mating in the 
population, (3) there must not be any gene flow to and from the population, (4) no 
mutations must occur at the locus under consideration, and (5) there must be no 
selective pressure on that locus.
The Hardy Weinberg model is an idealised one, and no population can fulfil its 
theoretical conditions. In practice, the HWE is usually achieved in populations of 
moderate size, as well as for loci with a relatively high mutation rate, such as
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microsatellites. More significant deviations can be observed if any of the other 
conditions are violated. Especially the presence of population substructure (i.e. the 
absence of random mating) and the action of a selective force on the locus under 
consideration can result in significant deviations from the HWE265. However, the 
most common cause of deviations from the HWE in genotyping studies are 
systematic genotyping errors, such as the consistent mis-scoring of certain 
heterozygotes as homozygotes, or the failure to score a specific allele (e.g. because it 
presents as an unusually small peak in fragment length analysis and is therefore taken 
for an artefact and ignored). For this reason, an important part of the quality control 
procedure in genotyping projects consists in checking for HWE. Because selection 
might play a role in causing deviations from the HWE, only unaffected founder 
individuals were tested (i.e., the patients’ parents in the trio sample). Within an 
extended pedigree, genotypes are not independent of each other, and and the 
genotype distribution within a family is therefore likely to deviate from the HWE. 
One possible way to overcome this problem is to include only unrelated founders 
into the HWE test; however, there were too few of these available to obtain a 
meaningful result. Other means of genotyping quality control were therefore used in 
the families (see chapters 2.3.4 and 2.3.5).
The test for deviations from the HWE was carried out using the online version of the 
Genepop software v3.4 (http://genepop.curtin.edu.au/) . Genepop can test for either 
excess or deficiency of heterozygotes (one-tailed tests), as well as for a general 
deviation from HWE (two-tailed test). Since there was no a priori reason to assume a 
deviation in any one direction, the two-tailed test was performed.
The test for deviations from HWE implemented in Genepop is a Fisher’s Exact Test 
approximated using a Markov Chain Method, where the space of possible genotype 
tables given the allele frequencies is explored by a random walk procedure. The p- 
value for the test is obtained by comparing the observed genotype proportions with
267the distribution of possible genotype tables . The Genepop run parameters were set 
to 1000 dememorisations (equivalent to the burn-in period in MCMC), 100 batches 
and 1000 iterations per batch.
Some basic parameters for the data collected in the trio samples (allele and genotype 
frequencies, and expected and observed amount of heterozygotes and homozygotes) 
were also calculated using the Genepop software.
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2.3.4. Test for Mendelian Inheritance
When dealing with family data, an important part of the genotyping quality control 
procedure is to test for inconsistencies with Mendelian inheritance. Patterns of 
inconsistencies can help indicate whether there is a problem with the quality of the 
genotyping data, and of which kind the problem is. Sporadic inconsistencies indicate 
non-systematic genotyping errors; the occurrence of many inconsistencies for one 
marker might indicate systematic genotyping errors; and inconsistencies across 
markers between a child and one of its parents (or both) can uncover problems with 
the samples, such as false paternity and sample mix-ups.
Consistency with Mendelian inheritance was tested using the programme 
PedCheck . As a first and basic step, this program carries out a comparison of 
genotypes within a nuclear family, checking whether the children’s genotypes are 
consistent with their parents’, as well as their siblings’. In a second step of the 
analysis, genotypes are then compared and tested for consistency across the extended 
pedigree.
PedCheck was used to test both pedigree and trio data. Genotypes that were 
inconsistent with Mendelian inheritance were removed, and the sample was re-typed 
for the marker in question. If a marker showed a considerable amount of 
inconsistencies, it was checked for systematic genotyping errors and, if necessary, re­
typed for all samples using fresh and possibly newly designed primers. In cases of 
false paternity and sample mix-ups, the problematic samples were excluded from 
further analyses.
2.3.5. Test for Non-Mendelian Errors
Not all genotyping errors cause Mendelian inconsistencies. Simulation studies have 
shown that the percentage of genotyping errors consistent with Mendelian 
transmission can be up to -50%  for multiallelic markers, and as high as 87% for 
biallelic markers269, and a check for Mendelian inconsistencies only is unlikely to 
identify all problematic genotypes. However, genotyping errors can mask linkage 
signals and distort marker maps (this includes producing an inaccurate estimate of 
the trait location on the marker map)264, and it is crucial to obtain data as free of 
genotyping errors as possible before proceeding to linkage analysis. SimWalk2
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9 ^ 7v2.91 (see chapter 2.3.2) was therefore used to check for these “non-Mendelian 
errors”.
The mistyping analysis (option 5 of the SimWalk2 programme) detects genotypes 
that introduce recombination in a small region of the chromosome and are therefore 
unlikely to be correct, even though they are consistent with Mendelian transmission. 
While haplotype analysis, which can also be carried out using SimWalk2 (see section 
2.3.9) produces just one solution which might or might not contain double 
recombination around a problematic allele, there might be several equally likely 
solutions to the haplotype analysis, as well as solutions that are only slightly less 
likely. It is only by considering all solutions at the same time and weighting them 
according to their likelihood that it can be determined whether a genotype, or even a 
single allele, is likely to have been mistyped264.
After either rectifying or removing genotypes that were inconsistent with Mendelian 
inheritance as described in chapter 2.3.4, the pedigree data collected for the whole 
genome linkage scan (see chapter 4) was tested for “non-Mendelian errors” using 
option 5 of the SimWalk2 programme v2.9.1 (“mistyping analysis”). Genotypes with 
a mistyping probability > 0.5 were flagged by the programme and subsequently 
removed from the data set.
2.3.6. Estimation of Aliele Frequencies from Pedigree Data
Linkage analysis relies on the availability of allele frequencies in the population 
under study. Because the genotypes within a pedigree are not independent from each 
other, the allele frequencies obtained from it do not provide an accurate estimate of 
the population allele frequencies. One possible way to overcome this problem is to 
calculate the allele frequencies from unrelated founder individuals only. The other 
possibility consists in typing all markers to be analysed in a sample of unrelated 
individuals from the same population. However, both approaches are unsatisfactory: 
the former wastes a lot of the available information, the latter leads to a considerable 
increase in genotyping costs and ultimately also wastes the information contained in 
the pedigree data.
A third possibility is to estimate the population allele frequencies using the data from 
the complete pedigree data, thereby neither wasting available information not
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incurring additional genotyping costs. This can be achieved within a pedigree
770likelihood framework , where the likelihood of the observed data is maximised by 
varying the allele frequency estimates. An algorithm based on this approach is 
implemented in the programme Mendel271, and analysis option 6 (“Allele 
Frequencies”) of the Mendel software v8.0.1 was used in the genome-wide linkage 
study of BP to estimate allele frequencies from the pedigree data.
2.3.7. Parametric Linkage Analysis
Multipoint parametric linkage analysis (see chapter 1.2.3) was carried out using 
SimWalk2 v2.9.1 (see chapter 2.3.2). The whole-genome linkage scan data were 
analysed considering individuals diagnosed with BP1 as affected and all other family 
members as of an unknown phenotype. No family members were considered as 
unaffected. The following parameters were used:
• frequency of the mutant allele: 0.003
• penetrance of the homozygous mutant genotype: 0.9
• penetrance of the heterozygous genotype: 0.81
• phenocopy rate: 0.01
This genetic model has been established through segregation analysis of BPI in the 
population of the Central Valley of Costa Rica, which is genetically very similar to 
that of Antioquia and has been used previously for the analysis of BPI pedigree data 
from the paisa community173,184. Population allele frequencies were estimated from 
the pedigree data using Mendel v8.0.1 as described in chapter 2.3.6. A genetic 
marker map for each chromosome was obtained from the Marshfield Mammalian 
Genotyping Service (http://research.marshfieldclinic.org/genetics/home/ 
index.asp)272, and sex-specific recombination ratios were used. The output of the 
parametric linkage analysis using SimWalk2 are so-called location scores, which 
correspond to multipoint LOD scores, and multipoint HLOD scores.
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2.3.8. Non-Parametric Linkage Analysis
Multipoint non-parametric linkage analysis was also performed using SimWalk2 
v2.9.1 (see chapter 2.3.2; analysis option 3). Evidence for linkage was measured 
using the N P L pa ir s  statistic, which has previously been used to analyse pedigrees
• * 1 7 8  184 *from Antioquia and Costa Rica ’ . Allele frequencies and marker maps were used
as described in chapter 2.3.7. Only individuals with the phenotype under study were 
considered as affected (see chapter 4.1 for the phenotype models used in the analysis 
of the Antioquian pedigree data). All other individuals were considered as of an 
unknown phenotype; no family members were considered as unaffected.
2.3.9. Haplotype Analysis
Haplotype analysis is the reconstruction of haplotypes based on genotype data. It is a 
useful tool in linkage studies because it allows the comparison of potential risk 
haplotypes within and across families. Haplotype reconstruction in family data is 
relatively straightforward in theory; however, when analysing complex extended 
pedigrees, it becomes too complex to carry out by hand, and a computer programme 
is needed to complete the task. SimWalk2 was used for haplotype reconstruction. 
Haplotypes were then imported into the Haplopainter software v024 beta for easy 
visualisation.
2.3.10. Transmission Disequilibrium Analysis
The Transmission Disequilibrium Test (TDT)154 for single markers was carried out 
as implemented in the TRANSMIT program, version 2.5.4155’156. TRANSMIT carries 
out a generalised transmission/disequilibrium test that can be applied to situations of 
uncertain allele or haplotype transmission, allowing the analysis of data from patients 
with only one available parent, and to multilocus data even under uncertain phase, 
thereby permitting the use of all available genotypic data, including all nuclear 
family structures (data from unaffected siblings are used to infer parental genotypes). 
The statistic estimated by TRANSMIT follows a x distribution and is calculated as
(0-E )2= Var(0-E), (13)
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where O and E refer to the number of observed and expected transmissions of 
alleles/haplotypes. As an alternative method of determining the p-value, the program 
employs a bootstrap method which provides more accurate results than the x2 
approximation. The minimal haplotype frequency for all TRANSMIT analyses was 
set to 2%.
As part of the candidate gene study of the NOS1AP gene (see chapter 5), haplotype- 
based TDT analysis was carried out using the WHAP programme v.2.09274. WHAP 
has the advantage of offering a flexible, regression-based statistical framework, 
allowing the user to perform a variety of haplotype- and SNP-conditional tests, as 
well as a global test of haplotype association. As part of the NOS1AP study, two tests 
were performed: an omnibus haplotype test (testing the effects across all haplotypes) 
and a haplotype-specific test (testing the effect of each haplotype against all others). 
For these analyses, the prevalence of the disease in the population was set to
“) I f%0.55% , and the minimum frequency for a haplotype to be included in the analysis
was fixed at 1 %.
A further programme for single marker as well as haplotype-based TDT in unphased 
genotype data from nuclear families is TDTPHASE, which forms part of the 
UNPHASED suite o f genetic association programmes275. While in this thesis, TDT 
analysis was performed using TRANSMIT and WHAP, TDTPHASE offers the 
advantage of producing an estimate of the allele frequencies of transmitted and 
untransmitted alleles/haplotypes in a trio sample. TDTPHASE v.2.4 was therefore 
used to estimate allele frequencies of the untransmitted alleles in TDT analysis.
2.3.11. Linkage Disequilibrium Analysis
LD patterns across the NOS1AP locus (see chapter 5) were evaluated using the 
programme Haploview v3.2276. This programme calculates and visualises patterns of 
LD, as measured by either D’ or r2, as well as haplotype blocks, and may also be 
used to choose htSNPs, making it a very useful tool for LD analysis. To evaluate LD 
patterns in a population, an sample of unrelated individuals is needed; this analysis 
was therefore based on parental genotypes only.
Haploview offers the two general options of loading one’s own data set and of 
importing data from the HapMap project. This allows a quick and easy comparison
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of LD patterns in the study population (here the population of Antioquia) and the 
HapMap populations.
2.3.12. Quantitative TDT Analysis
The TDT analysis can be extended to quantitative traits (i.e., continuous traits, such 
as height or weight, as opposed to dichotomous traits such as whether or not a person 
suffers from a disease). Quantitative TDT (qTDT) is based on a regression approach, 
where it is assumed that the dose of a certain allele will increase or decrease the trait 
value. In this thesis, the programme QTDT v2.5.1277 was used to carry out a qTDT 
analysis of the NOS1AP gene with clinical dimensions in schizophrenia. The QTDT 
programme makes use of a variance components-framework, which distinguishes 
between-family and within-family association effects. In order to evaluate true 
genetic association effects without the confounder of population stratification, QTDT 
tests the within-family component.
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3. Analysis of the CLINT1 Gene as a Candidate Locus for
Psychosis
3.1. Background and Previous Work
We recently performed a genome-wide linkage scan of six extended pedigrees
1 Oyl
segregating severe bipolar disorder from Antioquia . One of the most promising 
regions identified in that linkage scan was on chromosome 5q31-34, with a 
maximum N P L PAirs score of 1.92 for marker D5S410. The same region had 
previously shown suggestive evidence for linkage in a large Costa Rican 
pedigree178,244, and fine mapping of chromosome 5q involving the original six 
pedigrees, eight additional pedigrees from Antioquia and three pedigrees from the 
Central Valley of Costa Rica, a population which is genetically very close to that of 
Antioquia (see chapter 1.3.2), resulted in a maximum N P L pairs  score of 4.40 (p < 
0.00004; see Figure 3.1). In a further follow-up study, two-point parametric linkage 
analysis was performed in the same collection of pedigrees for 1082 SNPs saturating 
the candidate region. The maximum LOD score obtained from these analyses was 
4.9245 (this study is included as a manuscript in appendix 8.3). The two follow-up 
studies of the original linkage scan therefore provide highly significant evidence for 
linkage of a locus predisposing to severe bipolar disorder on chromosome 5q31 -33.
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Figure 3.1: Results of the fine mapping of the candidate region on chromosome 5q31-34 in 17 
pedigrees from Antioquia and the Central Valley of Costa Rica.
A, individual and study-wide NPLpairs scores across the candidate region on chromosome 5q; B, 
location of some of the strongest candidate genes in this region. The black boxes represent 
genes; they are drawn approximately to scale with respect to gene size and position. From 
Herzberg et al. (2006)184.
Interestingly, whole-genome linkage scans in several populations have repeatedly 
implicated regions on chromosome 5q31 -35 in the genetic susceptibility to 
schizophrenia278,279, including two studies from the Central Valley of Costa 
Rica280,281. Under the current classification of psychiatric disease, BP and 
schizophrenia are categorised as distinct disease entities, a concept that goes back to 
the German psychiatrist Emil Kraepelin, who introduced the syndromes ‘dementia 
praecox’ (schizophrenia) and ‘manic-depressive illness’ (bipolar disorder) in the 
beginning of the 20th century. This ‘Kraepelinian dichotomy’, however, has been 
much criticised, and there is an emerging picture of a shared genetic susceptibility 
and hence, possibly -  at least partly -  shared aetiology between the two 
disorders15,16,193,282. The locus on chromosome 5q identified in our bipolar families 
might therefore predispose to psychosis, a symptom that is common in severe bipolar 
disorder and characteristic of schizophrenia, rather than bipolar disorder as such. In 
line with this interpretation, Kemer and colleagues recently reported evidence of 
linkage to psychosis for chromosome 5q33-34 in a collection of bipolar pedigrees
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from the NIMH Bipolar Genetics Initiative , and a Portuguese study including both 
schizophrenia and bipolar families and using psychosis as the phenotype also 
implicated the same region279. Furthermore, it is of interest that all of the 
schizophrenia linkage scans mentioned above used a phenotype definition including 
schizoaffective disorder, which is characterised by features of both schizophrenia and 
affective disorder.
Several possible candidate genes for psychiatric illness are located within the 
candidate region on chromosome 5q. The gene located directly under the linkage 
peak identified in the Antioquian study encodes the ENTH domain containing 
clathrin interactor protein 1, CLINT1 (see Figure 3.1; in the figure, the gene bears 
one of its alternative names, ENTH). Genetic variants in the CLINT1 gene region 
have recently been found to be associated with schizophrenia in a sample of 450
JO A
British and Irish cases and 450 matched controls , a finding that was replicated in a 
family-based sample from the Han Chinese population . Another, independent 
Chinese study failed to provide significant evidence for association after a promising
'yof.
signal did not survive the correction for multiple testing ; however, this might be 
due to low power of the study and does not exclude an effect of the CLINT 1 gene on 
genetic susceptibility to schizophrenia in that sample
CLINT 1, also known as EpsinR, Espin 4 and enthoprotin, is a member of a family of 
proteins containing an epsin NH2-terminal homology domain (ENTH) and has been
7 8 8  7Q0found to be enriched on clathrin coated pits and vesicles (CCPs and CCVs)
The ENTH functional domain is thought to be involved in the formation of 
membrane curvature, and the Epsin proteins, after which the domain is named, play
701 7Q7an essential part in the formation of CCVs and the endocytosis process ’ .
Likewise, CLINT 1 has been shown to participate in clathrin-mediated membrane 
budding and vesicular transport between intra-cellular compartments including the
7 8 8  7 8 0trans-Golgi network and the endosomes ’ .
In the brain, clathrin-mediated endocytosis plays an important role in the trafficking
7 0 7and recycling of neurotransmitter transporters at the presynaptic membrane , and of 
neurotransmitter receptors at the postsynaptic membrane294'296. The availability of 
neurotransmitter transporters and receptors at the synaptic membranes influences the 
concentration of neurotransmitters in the synaptic cleft on the one hand, and the 
efficiency of signal transmission on the other. Alterations in the endocytic pathway,
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potentially leading to a change in neurotransmitter transporter or receptor density, 
might therefore interfere with synaptic signal transmission, a process which is 
thought to be altered in psychiatric illness.
More recently, CLINT 1 has been shown to interact with the soluble N- 
ethylmaleimide-sensitive factor attachment protein receptor (SNARE) V tilb297. 
Through interaction with each other, SNARE proteins on vesicle and target 
membranes play a crucial role in the membrane recognition and fusion process of 
clathrin-mediated endocytosis, and different SNARE proteins therefore have to be 
sorted with great precision onto vesicle, cell organelle and plasma membranes, a
^QO ^QQ
process which is partly mediated by CLINT 1 ’ . Abnormalities in SNARE protein
interactions have been found in post-mortem brain studies of psychiatric patients, 
and it has been suggested that these abnormalities could contribute to the disturbed 
neural connectivity characteristic of schizophrenia and other major mental illness300.
Given the involvement of CLINT 1 in clathrin-mediated endocytosis, a process 
which, if disturbed, might contribute to altered neurotransmission and neural 
connectivity, as well as the recent association findings and the gene location at the 
height of the linkage peak identified in the Antioquian and Costa Rican families, 
CLINT 1 is a prime candidate gene for susceptibility to psychiatric disease. We 
therefore sequenced the CLINT 1 gene in those families that had contributed most to 
the linkage signal on chromosome 5q, and followed up a polymorphism identified in 
these families by transmission distortion analysis in a collection of 176 BP trios from 
Antioquia.
3.2. Materials and Methods
3.2.1. Sequencing of the CLINT1 gene in the Antioquian families
The ascertainment of the BPI families recruited for the linkage scan and followed up 
here, and all diagnostic procedures are described in chapter 2.1. Figure 2.1 shows the 
pedigrees of all six families. Follow-up by sequencing of the CLINT1 gene was 
conducted in those families with individual N P L pa ir s  scores > 1 in the 5q region. 
These families were ANT03 (maximum NPL = 1.20), ANT04 (maximum NPL = 
1.30), ANT07 (maximum NPL = 2.12) and ANT 15 (maximum NPL = 1.81). The
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choice of individuals for sequencing was based on haplotype analysis of the fine- 
mapped region on chromosome 5q. The haplotype analysis was carried out by Susan 
Service at UCLA using SimWalk2, based on the microsatellite fine mapping data 
which also formed the basis for Figure 3.1. For the results of this haplotype analysis, 
see Figure 3.2. For each family, an affected individual carrying the haplotype linked 
to disease was chosen for sequencing. This was judged by inspecting the haplotype 
between markers D5S487 and D5S1403, which frame the CLINT 1 gene on both sides 
and are highlighted by a black box in Figure 3.2. Where there were several potential 
disease-carrying haplotypes, several individuals were chosen from one pedigree so 
that each of these haplotypes would be represented in sequencing.
Altogether, six individuals from the Antioquian pedigrees were sequenced. In family 
ANT03, both the dark blue and the dark green haplotypes (see Figure 3.2) were 
present in all affected offspring; individual 03150 had most DNA available and was 
therefore chosen for sequencing. In family ANT04, the majority of affected 
individuals shared the light blue haplotype; one of these, individual 04149, was 
therefore chosen for sequencing. In pedigree ANT07, there were several potential 
disease-carrying haplotypes; three individuals were therefore sequenced from this 
family: 07T166 shares the green haplotype with several other affecteds, 07R259 
additionally carries part of a haplotype displayed in pink shared by his affected 
cousin (individual 21 in Figure 3.2), and 0711 shares the dark green haplotype with 
the majority of the remaining affecteds. From family 15, all affecteds again shared 
most of both haplotypes. Individual 15H135 had most DNA available and was 
therefore chosen for sequencing.
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Figure 3.2 (extends over the previous three pages): Results of the haplotype analysis of 
chromosome 5q in families ANT03, ANT04, ANT07 and AN TI5. The CLIJ\T1 gene lies between 
the highlighted markers D5S487 and D5S1403. Blackened symbols indicate BPI. The sequenced 
individuals are highlighted with a red rectangle. Figure produced together with Amy Roberts.
The CLINT 1 gene spans 73 kb on chromosome 5q33.3 (www.ensembl.org: last 
accessed 25/06/2008). It consists of 12 exons, most of which are under 300 bp long. 
The largest exon, exon 12, is 1704 bp long. In order to capture variation inside the 
exons as well as any changes in the gene sequence that might affect splicing, all 
exons and intron/exon boundaries were sequenced. Primers for 15 amplicons -  one 
covering each of exons 1-11 of the gene (amplicons 1 to 11), four covering the large 
exon twelve (amplicons 12.1 to 12.4) -  were provided by Hugh Gurling’s laboratory 
at the Department of Psychiatry, UCL.
All primers were initially provided with a universal 5’ tail consisting of a viral (M l3) 
sequence. The addition of a universal tail to the primers used in the PCR preceding 
sequencing enables the use of a single, universal sequencing primer matching this 
tail. PCRs for CLINT1 exons 1 and 9 could not be optimised with the original 
primers although the PCR conditions provided by Hugh Gurling’s lab were used. 
This might be due to differences between thermal cyclers and reactives used in both 
laboratories. New primers for exons 1 and 9 were therefore designed using the 
Primer3 software as described in chapter 2.2.3. These were ordered without an M13 
tail.
1 2 0
PCR of the CLINT 1 amplicons was carried out using a standard PCR cocktail set-up 
as shown in Table 3.1. A touch-down protocol with variable annealing temperatures, 
facilitating PCR specificity in early cycles and efficiency in later ones, was used for 
all amplicons (see Table 3.2). Primer sequences are shown in Table 3.3.
Table 3.1: Set-up of the PCRs for amplification of the CLINT1 gene.
PCR com ponent volume (pi) finalconcentration
Buffer (Bioline) 2.5 lx
MgCI2 (Bioline) 1.0 2 mM
dNTPs (Bioline) 0.625 25 pM
Taq polymerase (BIOTAQ™, Bioline) 0.5 2.5 U*
forward primer 1.0 0.26 pM
reverse primer 1.0 0.26 pM
DNA 2 1.6 ng/pl
dH20 16.375 -
total 25 -
Table 3.2: Touch-down PCR programme used for the CLINT1 amplicons.
PCR step tem perature time # cycles
Initiation 95°C 5 min
Denaturing 94°C 30 sec
Primer Annealing 63°C 30 sec 3 cycles
Elongation 72°C 30 sec
Denaturing 94°C 30 sec
Primer Annealing 60°C 30 sec 3 cycles
Elongation 72°C 30 sec
Denaturing 94°C 30 sec
Primer Annealing 57°C 30 sec 3 cycles
Elongation 72°C 30 sec
Denaturing 94°C 30 sec
Primer Annealing 54°C 30 sec 3 cycles
Elongation 72°C 30 sec
Denaturing 94°C 30 sec
Primer Annealing 51°C 30 sec 3 cycles
Elongation 72°C 30 sec
Denaturing 94°C 30 sec
Primer Annealing 48°C 30 sec 15 cycles
Elongation 72°C 30 sec
Final Elongation 72°C 10 min
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Table 3.3: Sequences of the primers used for the amplification of the CL1NT1 gene. All 
sequences are noted in 5’-3’ direction.
P rim e r  N a m e P rim e r  S e q u e n c e P ro d u c t  L eng th
Epsin4_ExonlF CGGCACTCAGGGAAAACTAC
380 bp
Epsin4_ExonlR CCAAG G CC AG CT CCTT CT
Epsin4_Exon2F ca cgacgttgta a a a cga c AGTGTCCTTGG GGTAG CTTG
464 bp
Epsin4_Exon2R ggataacaatttcacacaggGGAATGGATTGCATAAAA





Epsin4_Exon4R ca cgacgttgta a a a cga cG CCAGTCTTTTCTG CAAGTTC
Epsin4_Exon5F ca cga cgttgta a a a cga cTAG CACAACTTG CCCCTTTC
526 bp
Epsin4_Exon5R ggataacaatttcacacaggCTATTGCCGAACCCACAAGT





Epsin4_Exon7R cacga cgttgta a a a cga cGCCCAAG CCTACTAATGCAG
Epsin4_Exon8F ca cga cgttgta a a a cga cG CTTG CTG CCTCTCCATAAG
369 bp






Epsin4_ExonlOR ca cga cgttgtaa a a cga c AATG AAATGTG CAAATGCGTA





Epsin4_Exonl2.1R ca cga cgttgta a a a cga cG CA M il CCAT CCCAAC AT C






Epsin4_Exonl2.4F cacgacgttgtaaaacgacTGAAAATGI 111I G I 111ICTGC
469 bp
Epsin4_Exonl2.4R ggataacaatttcacacaggAAGAATGGAGCAGGTCAGGA
PCR product clean-up and sequencing were performed as described in chapter 2.2.6. 
Both forward and reverse sequencing were attempted for each exon, and for each of 
the samples. The CEPH sample 1344-03 was included as a positive control in both 
PCR and sequencing; in PCR only, dP^O was included as a negative control.
All sequences were visually checked for the presence of mutations or 
polymorphisms, initially using the Sequencher software v4.7 (Demo version). A
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license for the programme ChromasPro was purchased while this project was already 
underway, and analyses were continued using that software. The sequences obtained 
in this project were aligned with the human reference sequence using MAFFT v5.8 
to identify the reference allele for any polymorphism encountered. The CEPFI 
sample provided an additional healthy reference sample.
3.2.2. T ransm ission  D isto rtion  Analysis of a SNP in Exon 12 of the  CLINT1 
gene in a B ipolar Trio sam ple from  A ntioquia
Sequencing of CLINT1 in BP cases from the pedigrees, we identified a SNP in intron 
11 of the gene, close to the intron/exon boundary with exon 12 (see section 3.3). This 
SNP had been previously described as rsl 1955293 (NCBI dbSNP; 
http://www.ncbi.nlm.nih.gov/SNP/snp ref.cgi? rs=l 1955293). In order to investigate 
whether this SNP showed association with BP in the Antioquian population, we 
genotyped the SNP rsl 1955293 in a collection of 176 unrelated BP patients and their 
parents (or, if unavailable, their siblings) and performed a transmission distortion 
analysis in this sample. A detailed description of the sample can be found in chapter
2.1.3.
The SNP rsl 1955293 was genotyped using an RFLP-based assay. The T allele 
introduces a recognition site for the restriction enzyme Tsp509I at the SNP; this 
enzyme was therefore used in the RFLP assay. A difficulty lay in the fact that the 
recognition motif for Tsp509I, AATT, recurs several times in close proximity of 
rsl 1955293; the next one lies only 15 bp downstream of the SNP (see Figure 3.3).
Figure 3.3: Sequence of the amplicon designed for rsl 1955293 genotyping.
fW j-TG A G G T T C A C A G C T C C A A A A C T T T G A G T C A T C A C A T T C A T A G G C T G C T G C A T A T C T A C C A G A C G A
A A A C A G A C A G A A G A A C /T T T T A C C A C A A T A A A T T T T T A G G T T C A T A G A A C A G A G A A C T A A T A A C T T C T T
G A C C A T C T A T C T A T A C T T C T T T A G C C C C A A T A A A A T T C C T T T A C A G T G A T T T T A T T A G A A A T C A A T T A C
TCTGCACTGGTTCCTCTTGA
The two alleles of the SNP are represented in red. Tsp509I recognition sites are highlighted in 
yellow. PCR primers are shown in bold type. For detection of the digestion product on a 
capillary sequencer, the forward primer was labelled with FAM.
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Because a size difference of 15 bp cannot be reliably detected on an agarose gel, a 
suitable agarose electrophoresis-based assay could not be designed. Instead, the 
forward primer used to amplify the genomic DNA around the SNP was labelled with 
the fluorescent dye FAM, allowing the detection of the size-variable digestion 
product through electrophoresis on a capillary sequencer: while complete digestion 
of the 221 bp-amplicon shown in Figure 3.3 results in five short DNA fragments, 
only the fluorescently labelled fragments can be detected in capillary electrophoresis: 
a 78 bp long fragment for the T allele (cut at rsl 1955293), and a 93 bp long fragment 
for the C allele (uncut at rsl 1955293).
Figure 3.4: Electropherogram showing a heterozygous genotype for SNP rsl 1955293 (from the 
GeneMapper® software).
The fluorescent dye at the 5’ end of the forward primer allows the detection of the size-variable 
digestion product by capillary electrophoresis. The 15 bp-difference between both alleles is 
easily detectable using high-resolution electrophoresis.
As a first step, a 221 bp-fragment containing the SNP was amplified by PCR using a 
standard protocol as shown in Table 2.4. Modifications made to this protocol were:
• 1.5 pi MgCh were used per sample (final concentration 3.0 mM).
• 0.13 pi (0.65 U) Taq polymerase were used per sample.
• The volume of dh^O was adjusted accordingly to maintain a total volume of 
25 pi.
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PCR primers were designed using the Primer3 programme as described in section
2.2.3. Primer sequences were as follows:
forward primer: 5 ’ FAM-TGAGGTTCACAGCTCCAAAA-3 ’
reverse primer: 5’-TCAAGAGGAACCAGTGCAGA-3’
A touch-down cycling protocol was used, as shown in Table 3.4. A negative (dPhO) 
and a positive control (CEPH sample 1347-02) were included in each PCR.
Table 3.4: Touch-down PCR programme used for the amplification of the genomic sequence 
around rs!195S293.
PCR s te p t e m p e r a tu r e t im e #  cyc le s
Initiation 95°C 5 min
Denaturing 94°C 30 sec
Primer Annealing 63°C 30 sec 3 cycles
Elongation 72°C 30 sec
Denaturing 94°C 30 sec
Primer Annealing 60°C 30 sec 3 cycles
Elongation 72°C 30 sec
Denaturing 94°C 30 sec
Primer Annealing 57°C 30 sec 3 cycles
Elongation 72°C 30 sec
Denaturing 94°C 30 sec
Primer Annealing 54°C 30 sec 3 cycles
Elongation 72°C 30 sec
Denaturing 94° C 30 sec
Primer Annealing 51°C 30 sec 3 cycles
Elongation 72°C 30 sec
Denaturing 94°C 30 sec
Primer Annealing 48°C 30 sec 15 cycles
Elongation 72°C 30 sec
Final Elongation 72°C 10 min
After checking the amplification success by agarose gel electrophoresis (see chapter 
2.2.4), the PCR product was digested with Tsp509I following the standard protocol 
described in section 2.2.5.4. After the enzymatic digestion, the samples were sent to 
the Centre of Comparative Genomics, where they were run on an ABI 3730x1® 
genetic analyser (Applied Biosystems). The resulting raw data was sent back to our
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lab, and genotype analysis was performed with the GeneMapper® v3.7 software. All 
genotypes were visually checked by two independent researchers (“double scoring”). 
Upon disagreement between the two scorers, a single attempt was made to re­
genotype the sample in question. If re-genotyping was unsuccessful, the sample was 
excluded from the study.
The methods used for the statistical analysis of the trio data have are presented in 
detail in chapter 2.3. Briefly, the genotype data were checked for Mendelian 
inconsistencies using PedCheck . Hardy-Weinberg equilibrium was evaluated 
separately in founders and cases using the Genepop program . The Transmission 




3.3.1. Sequencing of the CLINT1 gene in the Antioquian families
Amplification success
Amplification by PCR was attempted for fifteen amplicons covering the twelve 
exons and the intron/exon boundaries of the CLINT1 gene. Amplicons 1-11 
correspond to exons 1-11; the large exon 12 was covered by amplicons 12.1-12.4.
Despite various attempts at optimisation of the PCR, including the design of a new 
primer pair, amplicon 1 could not successfully be amplified. This amplification 
failure might be due to the high GC content of this amplicon, which was 70%. 
Amplicon 9 could not be amplified using the original primers provided by Hugh 
Gurling’s lab; after re-designing the primers, however, amplification was successful. 
PCR for all other amplicons was successful in all six samples from the BP families, 
as well as in the CEPH sample 1344-03.
Sequencing success
Both forward and reverse sequencing were attempted for all successfully amplified 
amplicons in all samples, making for a total of 196 sequences (14 amplicons x 2 x 7 
samples). For most samples, at least one readable sequence, either forward or 
reverse, could be obtained for every amplicon (see Table 3.5 for details). For the 
following amplicons and samples, no readable sequence could be obtained: amplicon 
4 (sample 04149), amplicon 8 (07T166 and 15H135), and amplicon 12.4 (07R259).
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Table 3.5: Sequencing success for the C LIN T1  gene in Antioquian BP family samples.
S eq u en ce 03150 04149 0711 07T166 07R 259 15H 135 CEPH*
Amplicon 2-F sequenced X sequenced sequenced sequenced sequenced sequenced
Amplicon 2-R sequenced sequenced X sequenced sequenced sequenced sequenced
Amplicon 2 3'-gap 3'-gap 3'*gap 3'-gap 3'-gap 3'-gap 3'-gap
Amplicon 3-F sequenced sequenced sequenced sequenced sequenced sequenced sequenced
Amplicon 3-R sequenced sequenced sequenced sequenced sequenced X sequenced
Amplicon 3 complete complete 3'-gap complete complete complete complete
Amplicon 4-F sequenced X sequenced sequenced sequenced sequenced sequenced
Amplicon 4-R sequenced X X X X sequenced X
Amplicon 4 3'-gap X 3'-gap 3'-gap 3'-gap 3'-gap 3'-gap
Amplicon 5-F sequenced X sequenced sequenced sequenced sequenced sequenced
Amplicon 5-R sequenced sequenced sequenced sequenced sequenced sequenced sequenced
Amplicon 5 complete complete complete complete complete complete complete
Amplicon 6-F sequenced sequenced sequenced sequenced sequenced sequenced sequenced
Amplicon 6-R X X X X X X X
Amplicon 6 GBE GBE GBE GBE GBE GBE GBE
Amplicon 7-F sequenced sequenced sequenced sequenced sequenced sequenced sequenced
Amplicon 7-R sequenced sequenced sequenced sequenced sequenced sequenced sequenced
Amplicon 7 3'-gap 3'-gap 3'-gap 3'-gap 3'-gap 3'-gap GBE
Amplicon 8-F sequenced sequenced X X sequenced X sequenced
Amplicon 8-R sequenced X sequenced X X X sequenced
Amplicon 8 complete 5'-gap 3'-gap X 5'-gap X 3'-gap
Amplicon 9-F sequenced sequenced sequenced sequenced sequenced sequenced sequenced
Amplicon 9-R sequenced sequenced sequenced sequenced sequenced sequenced sequenced
Amplicon 9 5'-gap 5'-gap 3'-gap 5'-gap 5'-gap S'-gap complete
Amplicon 10-F sequenced sequenced sequenced sequenced sequenced sequenced sequenced
Amplicon 10-R sequenced sequenced sequenced sequenced sequenced sequenced sequenced
Amplicon 10 complete complete complete complete complete complete complete
Amplicon 11-F sequenced sequenced sequenced sequenced sequenced sequenced sequenced
Amplicon 11-R sequenced sequenced sequenced sequenced sequenced sequenced sequenced
Amplicon 11 complete complete 3'-gap complete complete complete complete
Amplicon 12.1-F sequenced sequenced sequenced sequenced sequenced sequenced X
Amplicon 12.1-R sequenced sequenced sequenced sequenced sequenced sequenced sequenced
Amplicon 12.1 complete complete 3'-gap complete complete complete complete
Amplicon 12.2-F sequenced sequenced sequenced sequenced sequenced sequenced sequenced
Amplicon 12.2-R sequenced sequenced sequenced sequenced sequenced sequenced X
Amplicon 12.2 GBE GBE GBE GBE GBE GBE GBE
Amplicon 12.3-F sequenced sequenced sequenced sequenced sequenced X X
Amplicon 12.3-R sequenced X sequenced sequenced sequenced sequenced sequenced
Amplicon 12.3 complete 3'-gap 3'-gap 5'-gap complete complete 3'-gap
Amplicon 12.4-F sequenced sequenced sequenced sequenced X sequenced sequenced
Amplicon 12.4-R sequenced sequenced sequenced X X sequenced sequenced
Amplicon 12.4 3'-gap 3'-gap 3'-gap 3'-gap 3'-gap 3'-gap 3'-gap
Sequencing of amplicon 1 was not attempted because of PCR failure. For each amplicon, success 
of forward and reverse sequencing is indicated separately; a third row then shows the overall 
success for the amplicon in each sample (i.e., whether the sequence is complete, or whether there 
is a gap at either of the two ends; 5’ and 3’ refer to the forward sequence), x, sequence could not 
be obtained/sequence not readable; GBE, gap at both ends. *CEPH 1344-03
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As shown in Table 3.5, many sequences have gaps at either or both ends, meaning 
that for none of the samples, the entire sequence was obtained. However, these gaps 
were typically only a few bp long. Because the PCR products were designed to 
include intron/exon boundaries, in most cases, the complete exon and the sequence 
immediately adjacent to it was therefore covered whenever sequencing in either 
direction was successful. The only exception was the large exon 12, which was 
amplified in several fragments, and where sequencing gaps therefore led to gaps in 
the assembly of exonic DNA.
Among all amplicons, the most sequences were missing for amplicon 8 and for 
reverse sequencing of amplicon 6. This might be explained by the fact that both 
amplicons contained long repeat stretches. In amplicon 6, a long mononucleotide T- 
repeat was located next to the reverse sequencing primer. Such long repeat stretches 
are extremely difficult to sequence because of polymerase slippage: during 
sequencing, template and product strands might denature and subsequently re- 
hybridise in the wrong position, forming a loop on either strand and thereby 
shortening or lengthening the repeat stretch. Because the repeat stretch was located 
next to the reverse primer in amplicon 6, forward sequencing worked without 
problems; reverse sequencing, however, was messed up from the beginning by the 
mononucleotide T-run. Several shorter repeat runs occur throughout the sequence of 
amplicon 8. The fact that the repeat runs were shorter than in amplicon 6 might 
explain why part of the sequences could be obtained.
In summary, exon 1 could not be sequenced in any sample. The remaining exons of 
the CLINT 1 gene were successfully sequenced in samples 03150, 0711, and in the 
CEPH sample 1344-03; although not for all amplicons, both forward and reverse 
sequences could be obtained. For the remaining samples, the majority of the 
amplicons were successfully sequenced, leaving only small segments of the coding 
region unsequenced.
Identification of sequence variants
We identified three sequence variants in the CLINT 1 gene region in the BP samples 
from Antioquia. In individual 0711, a T > C change was observed in the 3’ 
untranslated region of the gene, which forms part of exon 12 (amplicon 12.2). This
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SNP has been previously described as rs 12284 (NCBI dbSNP; 
http://www.ncbi.nlm.nih.gov/SNP/snp ref.cgi?rs= 12284, last accessed 27/06/2008). 
This change did not occur in any other individuals sequenced in this study, in line 
with the low frequency of the derived C allele in Europeans (~4-10%, dbSNP; the 
Antioquian population has highly predominant European ancestry, and allele
i
frequencies in Europeans are a proxy for those in Antioquia ).
The second sequence variation we identified was a C > T change, which occurred in 
intron 11 of the CLINT 1 gene, 27 bp away from the intron/exon boundary with exon 
12 (amplicon 12.1). This change was found in individuals 03150 and 15H135. It has 
been previously described as rsl 1955293, and the frequency of the rare T allele has 
been reported to be ~8% in Europeans (NCBI dbSNP).
Finally, a third change was found in the same two individuals who carried the rare 
allele for SNP rs 11955293, 03150 and 15H135. This SNP, which has equally been 
previously described and bears the number rs6682224, is a C > T change in intron 3, 
just four bp away from the intron/exon boundary with exon 4 (NCBI dbSNP, 
http://www.ncbi.nlm.nih.gov/SNP/snp ref.cgi?rs=6882224). As for rsl 1955293, the 
frequency of the rare T allele in Europeans is around 8%.
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3.3.2. TDT Analysis of a marker rsll955293
Test for Hardy-Weinberg equilibrium
The Hardy-Weinberg equilibrium at SNP locus rsl 1955293 was tested for parents 
and offspring separately. In none of the two groups, the genotype distribution 
showed a significant deviation from that expected under Hardy-Weinberg (parents: 
p-value = 0.16; affected offspring: p-value 1.0).
Transmission Distortion Analysis
The results of the TDT analysis of rsl 1955293 in a collection of 176 unrelated BPI 
patients and their parents/siblings are shown in Table 3.6. The observed allele 
transmissions correspond almost exactly to the expected transmission under 
Mendelian inheritance; thereby indicating that there is no transmission distortion at 
the SNP locus analysed here.
Table 3.6: Transmission distortion analysis of alleles at locus rsl 1955293.
A lle le 0 E V ar (O-E) X2 ( ld . f . ) p -v a lu e
b o o ts t r a p
p -v a lu e c
C 313 312.45 5.848 0.05 0.819 0.816
T 15 15.55 5.848 0.05 0.819 0.816
G lo b al 0 .0 5 0 .8 1 9 0 .8 1 6
O, observed allele transmission; E, expected allele transmission under Mendelian inheritance; 
Var(O-E), variance of O-E; d.f., degrees of freedom.
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3.4. Discussion
Sequencing of the CLINT 1 gene in six BPI patients from four extended pedigrees 
showing evidence of linkage for a region on chromosome 5q identified three 
sequence variants. These changes had been previously described as rs6682224, 
rsl 1955293 and rsl2284.
Rsl 2284 is located in the 3’ untranslated region of the CLINT I gene and is not 
predicted to have an effect on gene expression. Furthermore, this change was only 
seen in a single individual, 0711. Because the number of individuals sequenced for 
this study was very small, this fact alone does not exclude a potential role for SNP 
r s l2284 in bipolar disorder in the population of Antioquia; however, it was not a 
prime candidate for follow-up by association analysis.
The identification of the two SNPs rs6682224 and rsl 1955293 in two apparently 
unrelated individuals, 03150 and 15H135, seemed of greater interest. Both SNPs 
have a minor allele frequency of around 8% in Europeans (NCBI dbSNP, last 
accessed on 27/06/2008). The population of Antioquia is of predominantly European
I o?
ancestry ; allele frequencies in that population are therefore a good approximation 
of those in Antioquia. The shared occurrence of a rare allele in two out of four 
unrelated BPI families might indicate a possible role for this variant in the genetic 
susceptibility to bipolar disorder. Furthermore, individuals 03150 and 15H135 share a 
rare allele not just at one, but at both SNP loci, thereby opening up the distinct 
possibility of IBD sharing in families ANT03 and A N TI5. Inspection of the 
reconstructed haplotypes for the region on chromosome 5q (shown in Figure 3.2) 
additionally reveals that affected individuals from families ANT03 and ANT 15 also 
share alleles at the microsatellite markers on both sides of the CLINT 1 gene: allele 5 
at marker D5S487, and allele 4 at marker D5S1403. Although these alleles are not 
uncommon, with estimated frequencies of 14 and 23%, respectively, in the 
population of Antioquia (Susan Service, personal communication), this finding is in 
line with possible IBD haplotype sharing between the two families.
Both rs6682224 and rsl 1955293 are located in intronic sequence -  introns 3 and 11, 
respectively -  and are therefore not expected to influence the amino acid sequence of 
the CLINT 1 protein directly. However, because they are relatively close to the 
intron/exon boundary, they might affect the splicing of the CLINT 1 transcript. It was
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therefore of interest to investigate a possible association between these SNPs and 
BPI in the population of Antioquia. The TDT analysis of the SNP rsl 1955293 in the 
BPI trio sample, however, revealed no transmission distortion of alleles at that locus. 
Failure to detect association at a single SNP locus does not exclude the possibility of 
finding association for other markers in the same gene because there may be several 
LD blocks within a gene. However, HapMap data show that LD across the entire 
CLINT 1 gene is extremely high, with a single haplotype block covering the whole 
gene region in all HapMap populations (Figure 3.5 shows the data for Europeans 
only; patterns in the Asian and Yoruba populations are the same).
Figure 3.5: LD structure across the CLINT1 gene region the European HapMap population.
11 III 111 I I I ! 111111 III II! 11111 III 1111! 1111 III 11II III 111 III 1111 III I ! 11111
Shown are pairwise D’ values for position 157145 -  157218 kb on chromosome 5q, covering the 
CLINT1 gene region. The vast majority of D’ values between marker pairs are 1.0; for D’ values 
< 1.0, values in the boxes refer to % D’ Red boxes indicate a LOD score of > 2.0 (D’ significant); 
blue and boxes indicate a LOD score of < 2.0 (D’ not significant).
Our analyses provided no evidence for an implication of the CLINT1 gene in genetic 
susceptibility to bipolar disorder. The haplotype sharing between affected individuals 
from families ANT03 and ANT 15, which prompted the association study in the trios, 
might be a chance event. Alternatively, and independently from the question whether 
CLINT 1 is a predisposing locus for bipolar disorder or psychosis, it might indicate 
that these families are distantly related. Given that both families stem from the
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Antioquian sub-isolate of Oriente, this is a distinct possibility. Such a connection 
between the two pedigrees might prove useful for future gene mapping studies 
because it increases the probability that individuals from these families will share 
predisposing variants, which might be localised through the identification of shared 
haplotypes in candidate regions.
The lack of even a trend towards association in our BPI trio sample seems surprising, 
given the fact that CLINT 1 is located at the height of the highly significant linkage 
peak detected in the Antioquian families. There are several possible interpretations 
for our findings. The simplest of these is that our study did not have sufficient power 
to detect an existing weak association. Given the modest size of the trio sample 
examined here, this possibility cannot be disregarded. However, as noted above, we 
did not even observe a trend towards overtransmission of one allele in our data, so 
that, if there is indeed an association between rsl 1955293 and BPI, the effect size for 
this variant is likely to be small and might not be able to explain the highly 
significant linkage peak obtained in the families. Further explanations for the 
discrepancy between the results in families and trios should therefore be explored.
A fundamental question emerging in this context is that of the adequacy of following 
up linkage signals from extended pedigrees by means of association studies, which 
are typically conducted in sporadic cases. This approach can only be successful if the 
same predisposing factors are acting in familial and sporadic cases. However, this is 
not necessarily true. Alzheimer’s disease and breast cancer are only two examples of 
complex diseases where different genes are involved in sporadic and familial cases. 
These examples are different from familial psychiatric disease in that the familial 
forms are truly Mendelian, and the distinction between susceptibility to familial and 
sporadic forms of psychiatric illness might not be as clear-cut as that seen in 
Alzheimer’s and breast cancer. However, these examples do show that different loci 
might be involved in familial and sporadic disease, and this might at least partly 
explain why the follow-up of the linkage peak in a collection of unrelated sporadic 
samples was unsuccessful.
CLINT 1 was chosen for candidate gene analysis because of functional evidence 
linking it to psychiatric disease, because of evidence for association to schizophrenia, 
and because of its location directly beneath the linkage peak on chromosome 5q in 
the BPI families. However, several other interesting candidate genes for major
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psychiatric illness are located within this linkage peak (see Figure 3.1). Amongst 
them are a cluster of gamma-aminobutyric acid receptor subunit genes (GABRA1, 
GABRA6, GABRB2, GABRG2), the gene encoding the glutamate receptor 1 subunit 
of the ionotropic AMPA receptor (GRIA1), and the serotonin receptor gene HTR4X84. 
GRIA1 has been linked to both schizophrenia and affective disorder by mRNA
™ i
expression analysis in the cells of the dorsolateral prefrontal cortex , and a fine 
mapping study in pedigrees from the NIMH Genetics Initiative which had produced 
evidence for linkage of psychosis to chromosome 5q33-34 , found association of
that phenotype to polymorphisms in the GRIA1 gene . Findings of association of 
the major psychoses to the HTR4 gene, and to the cluster of GAB A receptor subunit 
genes found on chromosome 5q have also been reported ' . Therefore, it seems
possible that one of these genes, rather than CLINT7, could be at the root of the 
linkage signal obtained in our genome scan for chromosome 5q, and it would be of 
great interest to further explore a possible role of these genes in predisposition to 
bipolar in our Antioquian sample.
It is noteworthy that a whole-genome linkage scan of bipolar disorder performed as 
part of this thesis and incorporating a further nine Antioquian families in addition to 
those included in our original study, did not provide evidence for linkage on 
chromosome 5q. The results of this linkage scan are presented in chapter 4 of this 
thesis. As noted in the discussion of that chapter, the lack of a signal for chromosome 
5q in the new study does not invalidate our original report of linkage, but it might 
nevertheless indicate that the locus on chromosome 5q is of greater importance in the 
Costa Rican families than in those from Antioquia. This is in line with the fact that 
our collaborators had previously reported linkage for that region in a very large Costa 
Rican pedigree, which was also included in the finemapping efforts preceding the 
present study of the CLINT1 gene178 244. One final interpretation of our failure to find 
association between BPI and CLINT 1 is therefore that the 5q-locus might not be as 
important in the Antioquian population as appears from the results of our first 
linkage scan184, and that the exploration of other candidate regions might be of 
greater interest.
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3.5. Conclusion and Future Work
In this study, we have followed up the results of a previous linkage scan by 
sequencing and association analysis of the CLINT1 gene on chromosome 5q33 as a 
possible candidate gene for psychosis. We have found no evidence for a contribution 
of this gene to disease susceptibility in the population of Antioquia.
In our effort to sequence the CLINT1, some portions of the genomic sequence, 
including the entire exon 1 and small segments of exon 12, could not be covered. It 
might be o f interest to obtain the missing parts of the CLINT1 sequence in our 
samples in order to ensure that no sequence variants that might be of importance in 
the families have been missed. Sequencing of the promoter region, which plays an 
important part in the regulation of gene expression, is already underway. However, in 
the light o f the results presented here, it might be of greater interest to focus on 
follow-up studies o f other genes in the 5q region, including GRIA1, HTR4, and the 
GABA receptor subunit genes. In an approach equivalent to that taken in the CLINT1 
study, these genes could be sequenced in the Antioquian families first. Interesting 
variants could then be further investigated in the BPI trio sample. It would also be 
interesting to conduct follow-up studies in the Costa Rican pedigrees, which might 
have been the main contributors to the 5q linkage signal.
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C h a p t e r  F o u r
G e n o m e -W id e  L in k a g e  S c a n  In  15 
E x t e n d e d  B ip o l a r  P e d ig r e e s  F r o m  T h e
P a is a  C o m m u n it y
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4. Genome-Wide Linkage Study in 15 Extended Bipolar 
Pedigrees from the Paisa Community
4.1. Background and Previous Work
As discussed in previous chapters of this thesis (see chapters 1.6 and 3), we have 
recently conducted a whole-genome linkage scan of six extended pedigrees 
segregating severe bipolar disorder from the paisa community184. In that study, we 
conducted both two-point parametric and multipoint non-parametric linkage analysis 
using bipolar disorder type I as the phenotype definition.
Our analyses identified several candidate regions for BPI, which are presented in 
Tables 4.1 (two-point parametric analysis) and 4.2 (multipoint non-parametric 
analysis). The most important of these regions are located on chromosomes 6q22, 
15q26, and 21q21 in parametric analysis, and on chromosomes 3q28, 5q33 and 
21q21, and lp22 in non-parametric analysis.
Table 4.1: Markers with heterogeneity LOD scores > 1.3 in two-point parametric linkage 
analysis of genome scan data from six Antioquian BPI pedigrees.
From Herzberg et al. (2006)184. Families C 03 to C027 correspond to the families named ANT03 
to ANT27 in this thesis. See Figure 2.1 for the pedigrees.
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Table 4.2: Markers with the highest combined NPL scores (p < 0.05) in the genome scan of six 
Antioquian pedigrees.
From Herzberg et al. (2006)184. Families C03 to C027 correspond to the families named ANT03 
to ANT27 in this thesis. See Figure 2.1 for the pedigrees.
We initially chose to follow up the signal on chromosome 5q33-34, because our 
collaborators had found the same region to be implicated in susceptibility to BPI in a 
very large pedigree from the genetically closely related population of the Central 
Valley o f Costa Rica178,244. While follow-up studies in pedigree and trio samples 
from Antioquia and Costa Rica continue to support the existence of a susceptibility 
locus for severe bipolar disorder on chromosome 5q in both populations184 245, the 
most important contribution to the linkage signal is made by the Costa Rican 
pedigrees, indicating that that there might be other predisposing loci of greater 
relevance in the Antioquian population (see also the discussion of the previous 
chapter, section 3.4).
We wanted to explore this possibility further by performing a linkage scan in an 
additional nine BPI families from the paisa  community that had become available for 
study. O f these, seven families stem from the Oriente region in Antioquia, while two 
families originate in the village o f Aranzazu in the Colombian province of Caldas. 
As described in chapter 1.3.2, the population of Caldas forms part o f the paisa 
community through historical connections. Furthermore, a genealogical study of the 
families from Aranzazu conducted by our collaborators in Medellin has shown that 
the founder o f these families immigrated from the village of Marinilla in the Oriente 
region of Antioquia. This places all fifteen paisa pedigrees (six families from the 
original linkage scan and nine newly ascertained families) in the same circumscribed 
and genetically homogeneous sub-isolate of Oriente, making them an ideal pedigree 
collection for the study of a complex disease such as BP. We therefore decided to 
genotype the same set o f microsatellite markers used for the original scan in the nine
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new families and carry out a joint analysis of the two data sets with the aim of 
identifying chromosomal regions harbouring potential susceptibility variants for 
bipolar disorder in the population of Antioquia.
4.2. Study Design
Ascertainment and diagnostic procedures for all fifteen pedigrees are described in 
detail in chapter 2.1. Genotype data were obtained for 382 evenly spaced autosomal 
microsatellite markers from the ABI Linkage Mapping Set v2.5 (average distance 
~10cM) were analysed. Data for nine extended pedigrees (Figure 2.2) were obtained 
for this thesis and combined with data from the earlier genome-wide linkage scan of 
six BPI families (Figure 2.1). All analyses were carried out on the combined data set. 
Because the patterns o f disease transmission did not support an X-chromosomal 
mode of inheritance in the Antioquian pedigrees, the X-chromosome was not 
analysed. The present study therefore represents an autosome-wide linkage scan.
The original design o f this study was focused on the phenotype of bipolar disorder 
type I, and before embarking on the data collection, a simulation analysis based on 
this phenotype was carried out to assess the power of the pedigrees for linkage 
analysis (see section 4.3). However, because of the uncertainties attached to the 
nosological classification o f mood disorders, including bipolar disorder, and the 
difficulties in choosing an adequate definition of the phenotype to study, it was 
decided to analyse the data under three different models as follows:
1. “Narrow model” : As discussed previously, BP is a complex disorder, whose 
considerable genetic heterogeneity is reflected in a broad range of clinical 
phenotypes. One strategy to reduce the genetic heterogeneity within a linkage 
study lies in focussing on a particular, well-defined subtype of the disorder. 
Furthermore, severe forms of the disorder might have a greater genetic 
component than milder phenotypes. In this model, only patients diagnosed 
with BPI are considered as affected. All other family members were 
considered of unknown phenotype.
2. “Broad model”: All pedigrees were ascertained through probands with a 
diagnosis of BPI as described in chapter 2.1; however, several other
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psychiatric diagnoses occurred in the relatives of the BPI probands, most 
notably major unipolar depression (see Table 2.1). This is consistent with 
epidemiological findings of an increased rate of unipolar depression in the 
first-degree relatives of patients with BP307 and lends support to the notion of 
a genetic relatedness between bipolar and unipolar affective disorders. To 
explore the possibility of a shared genetic susceptibility between the major 
mood disorders in the pedigrees from Antioquia, all family members 
diagnosed with BPI, BPII and unipolar depression were considered as 
affected under this broad model; the phenotype of all other family members 
was considered unknown.
3. “Psychosis model” : This last model is concerned with the phenotype of 
psychosis, the experience of perceptions that are not grounded in reality. 
Psychosis does not occur in all BP patients and might therefore characterise a 
distinct subtype o f the disorder. Selecting patients for psychosis might further 
reduce the genetic heterogeneity within the sample. On the other hand, as 
discussed in chapter 3, there is a growing amount of evidence for an at least 
partially shared aetiology between BP and schizophrenia, and there might be 
genetic variants predisposing to psychosis rather than to the phenotypes of 
schizophrenia or BP as such. The “psychosis model” therefore considers 
those pedigree members as affected that have experienced psychosis at some 
point o f their illness. This includes many of the BPI patients, but also one 
schizophrenic and two individuals with a psychotic mood disorder that did 
not meet the full criteria for BP (these individuals are from family ANT24 
and families ANT14 and ANTI 5, respectively; see Figures 2.1 and 2.2). A 
similar approach has been taken by Kemer and colleagues in analysing a 
collection o f BP pedigrees from the U.S. National Institute o f Mental 
Health283. As for the other two models, all other family members were 
considered as o f an unknown phenotype. Importantly, not all families 
included two or more members affected by psychosis, so that the analysed 
data set for this model comprised only eleven extended pedigrees (see Figures 
2.1 and 2.2).
The pedigree data from Antioquia were analysed using both parametric and non-
parametric linkage approaches. Because a genetic model based on epidemiological
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data was only available for the narrow model of disease classification (see chapter 
2.3.7), parametric linkage analysis was only performed for this model. Non-
parametric linkage analysis was carried out for all three phenotype models.
The exploration o f three different models of disease classification introduces a 
problem of multiple testing into the analyses carried out on the Antioquian pedigree 
data (further to the one caused by the analysis of a large amount o f markers, which is 
inherently corrected for by the use of the recommended significance thresholds as 
discussed in chapter 1.2.3). Formally, this might be corrected for by applying a 
simple Bonferroni correction, taking the form of
a ’ = a/t, (14)
where a  is the nominal level of significance, a ’ is the corrected level of significance, 
and t is the number o f models tested308. Likewise, the use of both parametric and 
non-parametric linkage approaches in the analysis under the narrow model must 
formally be seen as multiple testing and should be corrected for in order to control 
the false positive rate. LOD scores should be adjusted using the following equation:
z ’ = z + logio(t), (15)
where z is the LOD score threshold for genome wide significance (i.e., 3), and z’ is 
the LOD score to be achieved for significance after correction for multiple testing; t 
is the number o f models tested308. Here, t = 4; the formal significance levels for this 
study are therefore LOD > 3.60 and N P L p a ir s  > 4.49.
However, this study is a hypothesis-generating one and, considering the genetic 
heterogeneity o f the disorder under study, even linkage peaks that do not fulfil the 
formal criteria for genome-wide linkage might contain susceptibility variants. In the 
interpretation of results, failure to achieve a formally significant LOD score or NPL 
statistic should therefore not lead to completely disregarding a chromosomal region 
as potentially harbouring a predisposing variant. While any follow-up studies of the 
present linkage scan should naturally be informed by the LOD score or NPL statistic 
of a potential candidate region, other important factors also need to be considered. 
These include consistencies between the analyses performed within this study and 




The power of a study is defined as the probability of rejecting a false null hypothesis 
(Ho) based on the data collected. In linkage analysis, the Ho corresponds to the 
absence of linkage. A straightforward way to assess whether the available pedigrees 
will have sufficient power to reject this Ho, and thus provide evidence for genetic 
linkage, is by using a simulation-based approach. In such power simulation, 
genotype data are generated for pedigrees of a given structure, corresponding to the 
real pedigrees available for study. Simulations are carried out under the assumption 
of linkage and, for parametric analysis, based on a specific genetic model, which is 
thought to best describe the inheritance of the disease and which will also be used in 
the subsequent linkage analysis. The process of generating genotypes for the 
complete set of pedigrees available for study is repeated many times, until a large 
number of simulated data sets are available, each of them representing a study 
equivalent to the one to be carried out. Linkage analysis is then performed on each of 
these replicates, resulting in a set of pedigree and study-wide linkage statistics for 
each replicate (i.e., LOD scores for parametric analysis, NPL scores for non- 
parametric analysis). Because all marker data are simulated assuming linkage, if a 
sufficient number o f replicates is generated, the distribution of the resulting statistics 
indicates whether the pedigrees are powerful enough to allow a rejection of the null 
hypothesis o f no linkage.
This approach was first implemented for parametric linkage analysis in the 
programme SLINK309,310. In this study, for the majority of analyses, its faster (but 
otherwise unchanged) successor FastSLINK v2.51 was employed (distributed by Dr 
Daniel Weeks from the University of Pittsburgh; http://watson.hgen.pitt.edu/ 
register/soft doc.html). One exception, where the SLINK programme v2.60 was 
used, is discussed below. The FastSLINK analysis was performed within the frame 
of the easyLINKAGE Plus package v5.05, a tool for the easy execution of a variety 
o f linkage programmes, which was chosen because of its comprehensive visual 
output311,312.
SLINK and FastSLINK perform simulations of parametric linkage (LOD score) 
analysis only. As discussed in the previous section, a genetic model of inheritance 
based on epidemiological data was only available for the narrow model where BPI
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was considered as the phenotype. Parametric linkage analysis, and hence simulation- 
based power analysis for parametric linkage analysis, were therefore only carried out 
for the narrow model. It would have been of interest to assess the power of the 
Antioquian pedigree collection for non-parametric linkage analysis. However, the 
only programme that implements this type of analysis, Allegro262, cannot handle 
pedigrees as complex as the ones used in this study. The power for non-parametric 
linkage analysis could therefore not be assessed.
For the power analysis under the narrow model, pedigree data were simulated using 
the parameters specified in chapter 2.3.7: frequency of the mutant allele = 0.003; 
penetrance o f the homozygous mutant genotype = 0.9; penetrance of the 
heterozygous genotype = 0.81; and phenocopy rate = 0.01. It was furthermore 
assumed that the disease locus was 5 cM away from the nearest marker locus. Given 
the average marker distance o f -10  cM, this is a reasonable assumption: the maximal 
possible distance between a marker and the disease locus, reached if the disease 
locus lies right in the middle between two markers, is ~5 cM. Genotype data was 
generated for a marker with four equifrequent alleles, resulting in an average marker 
heterozygosity o f 0.75, a typical value for microsatellites. The analysis was based on 
1000 replicates.
Both SLINK and FastSLINK cannot handle inbreeding loops such as they occur in 
family FAZU01 (see Figure 2.2), and a cut-down version of this pedigree, in which 
all loops have been eliminated, had to be used for the simulation study (see Figure 
4.1).
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Figure 4.1: Cut-down version of pedigree FAZU01 used for the power simulations.
34 12 It
Inbreeding loops have been eliminated from the pedigree for power analysis. Double mating 
lines from the original pedigree have been preserved in this figure so as to indicate where the 
inbreeding loops are located. Filled symbols indicate a diagnosis of BPI; only those individuals 
were considered as affected in the power analysis. Symbols with a filled right half indicate a 
diagnosis of major unipolar depression; these patients were considered as of an unknown 
phenotype for the analyses. A cross next to a symbol indicates the availability of a DNA sample.
The results o f the simulation-based power analysis are presented in Figure 4.2 and 
Tables 4.3 and 4.4. Average, minimum and maximum expected LOD scores 
(ELODS) were obtained for the complete study, as well as for individual pedigrees.
145
Tabic 4.3: Study-wide results o f the power simulation for parametric linkage analysis under the
narrow model.




0.05 5.12 1.99 -1.66 11.06
0.10 4.82 1.56 -0.38 9.67
0.15 4.21 1.24 0.20 8.19
0.20 3.48 0.93 0.24 6.67
0.25 2.70 0.74 0.19 5.16
ELOD, expected LOD score.
Figure 4.2: Results of the power simulation for parametric linkage analysis under the narrow 
model.
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Average study-wide expected parametric LOD (ELOD) scores are shown for 0 between 0.05 and 
0.5 (filled grey bars). Maximum LOD scores are indicated by the black lines. The exact values 
are presented in Table 4.3. The box on the right side of the graph shows the first lines of the 
pedigree input file used in the simulation.
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Table 4.4: Pedigree-wise results of the power simulation for parametric linkage analysis under the narrow model.
T h e ta FAZU01 FAZU28 ANT03 ANT04 ANT07 ANT10 ANT14 ANT15 ANT18 ANT19 ANT21 ANT23 ANT24 ANT26 ANT27
Av ELOD 0.08 0.20 0.03 0.15 0.25 0.70 0.63 0.46 0.59 0.76 0.49 0.14 0.13 0.19 0.31
St Dev 0.26 0.39 0.16 0.32 0.53 0.71 0.71 0.58 0.68 0.79 0.63 0.32 0.29 0.32 0.50
0 .0 5 Min
ELOD -0.68 -0.77 -0.56 -1.03 -0.97 -1.80 -1.52 -1.44 -1.74 -1.44 -1.42 -1.19 -0.61 -1.20 -1.08
M ax
ELOD
0 .5 9 0 .7 8 0 .2 4 0 .5 4 1 .61 2 .07 2 .3 1 1 .29 2 .0 1 2 .6 4 1 .8 2 0 .6 7 0 .5 1 0 .4 2 0 .7 8
Av ELOD 0.08 0.19 0.03 0.14 0.24 0.66 0.59 0.44 0.55 0.71 0.46 0.13 0.12 0.19 0.30
0 .1 0
St Dev 0.21 0.30 0.12 0.24 0.44 0.55 0.54 0.47 0.54 0.64 0.49 0.24 0.22 0.22 0.40
Min
ELOD -0.44 -0.53 -0.37 -0.68 -0.76 -1.22 -1.01 -1.08 -1.27 -1.02 -1.00
-0.77 -0.40 -0.76 -0.73
M ax
ELOD
0 .5 0 0 .6 7 0 .1 9 0 .4 4 1 .42 1 .81 1 .9 6 1 .14 1 .79 2 .3 4 1 .5 8 0 .5 7 0 .4 5 0 .3 4 0 .6 8
Av, average; Min, minimum; Max, maximum; ELOD, expected LOD score; St Dev, standard deviation.
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Although none of the pedigrees on its own reaches the significance thresholds in any 
instance (see Table 4.4), Table 4.3 shows that for a 0 up to 0.15, the average study- 
wide expected LOD score is well above the widely accepted genome-wide LOD 
score threshold of 3.00, and even above the LOD score threshold for significance 
after correction for multiple models (LOD = 3.60, as discussed in chapter 4.1). 
However, the standard deviation for the average expected LOD scores are relatively 
large, and it is difficult to make inferences about the power of the Antioquian 
pedigrees to detect linkage from these figures alone. A direct power estimate is 
therefore given in the FastSLINK output by listing the percentage of simulated 
studies that achieved a study-wide LOD score above a certain threshold for any 0. 
When running FastSLINK within the easyLINKAGE package, these thresholds are 
fixed at LOD = 1.0, LOD = 2.0 and LOD = 3.0. In the present power simulation, 
99.6% of all simulated studies achieved a LOD score > 1.0; 96.7% resulted in a LOD 
score > 2.0; and 87.6% gave a LOD score > 3.0. The power of the present study to 
detect linkage at a genome-wide significance level of LOD = 3.0 using a parametric 
approach under the narrow model as defined in chapter 4.1 is therefore estimated to 
be 87.6%. Because the design o f the study entailed the analysis of multiple disease 
models, increasing the formal threshold for significance of linkage to 3.60, it was of 
interest to gauge the power o f the study to reach this level of significance. Changing 
the thresholds for significance was not possible within the easyLINKAGE package; 
this last analysis was therefore performed using SLINK v2.60. The same parameters 
were used as for the FastSLINK analysis performed with the easyLINKAGE 
package. 79.0% of the studies reached a LOD score > 3.60, translating into an 
estimated study-wide power o f 79% to detect linkage even in the context of testing 
multiple models.
It is widely accepted that the power o f a study to reject the Ho should be at least 80%. 
The power of the present study to result in a LOD score > 3.0, and thus to detect 
genome-wide linkage, lies above this threshold. Even in the context of testing 
multiple phenotype models, the power of the Antioquian pedigree collection to reach 
significance is very close to 80%. Under the given models (i.e., both the genetic and 
disease classification models), the present study has therefore a high chance in 
succeeding to reject the null hypothesis of no linkage.
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The main limitation of the simulation-based power analysis presented here lies in its 
being restricted to parametric analysis. On the one hand, this allowed only the 
assessment of power for the narrow model of phenotype classification, because a 
genetic model was not available for broad and psychosis models. On the other hand, 
although based on epidemiological data, it is not certain whether the assumed model 
is correct. Indeed, in view o f the fact that the model specifies a near-dominant pattern 
o f inheritance, for which a gene should be straightforward to localise, yet no single 
major locus has been identified for bipolar disorder, there is the distinct possibility of 
it not being correct. It would therefore have been of great interest to perform a power 
analysis for non-parametric linkage, which, due to computational restrictions of the 
Allegro programme, could not be accomplished. However, this is part of the 
difficulties inherent to the analysis of complex disorders and should not deter us from 
the study of a collection of pedigrees comprising as many heavily BP-loaded 
pedigrees as that from Antioquia.
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4.4. Data Collection
This section deals with the process of obtaining the joint data set for linkage analysis 
of the 15 extended BP families available. First, a description of the data collection 
for the nine extended pedigrees genotyped as part of this thesis is given in section
4.4.1. Section 4.4.2 then explains how the final data set for analysis was constructed 
by adding the genotype data that had previously been obtained by Herzberg and 
colleagues184 to those obtained here.
4.4.1. Genotype Collection for Nine Extended Bipolar Pedigrees from the 
P aisa  Community
PCRs for all 382 autosomal microsatellite markers from the ABI Linkage Mapping 
Set v2.5 were performed for all samples from the nine Antioquian BPI families 
shown in Figure 2.2. Every run included a negative and a positive control (dFLO and 
the CEPH sample 1347-02, respectively). The CEPH sample 1347-02, for which ABI 
provides genotype information for each of the markers that are part of the Linkage 
Mapping Set, was used for genotype calibration within and between runs.
The aim was to collect at least 90% of the data for each marker, and 95% of the data 
for each chromosome. A maximum of three repeat rounds were performed for 
markers with a data completeness under 90%, unless it seemed sensible to perform 
more, e.g. because a new pair o f primers had been ordered that was expected to yield 
better results.
PCRs for all markers were initially carried out using the primers provided in the ABI 
Linkage Mapping Set. However, whenever it was necessary to re-order primers for a 
marker, primer sequences were obtained from the Genome Database 
(http://www.gdb.org). and primers ordered from Sigma Aldrich. To reduce 
genotyping costs, marker-specific primers were not fluorescently labelled; instead, 
each forward primer was designed to contain a universal 5 ’ tail, whose sequence 
stemmed from the M l3 virus, so as not to interfere with PCR in humans. This tail 
matched a third, fluorescently labelled, primer (see also chapter 3.2). The universal 
primer was available with different fluorescent labels, enabling a flexible approach to
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setting up panels for fragment length analysis313. Markers for which repeats were 
performed using the M 13 system are listed in Table 4.5.
Table 4.5: Microsatellite markers for which repeats were performed using M13-tailed primers.








All PCRs using ABI primers were set up according to the manufacturer’s 
instructions. PCRs using M l 3-tailed primers were set up according to the protocol 
shown in Table 4.6, and cycling conditions for the M13-PCRs are listed in Table 4.7. 
Amplification using the M l 3-tailed primers resulted in fragment sizes that were 
different from the ones obtained using the original ABI primers, and consistency 
between runs was achieved by calibration to the CEPH sample 1347-02.
Table 4.6: Set-up for PCRs using the M13-tailed primers (per reaction).
PCR c o m p o n e n t V o lu m e  (pi) Final
c o n c e n tra t io n
HotStar Mastermix (Qiagen) 5 ?
M13-tailed forward primer 0.25 0.25 pM
reverse primer 1 1.0 pM
M13 primer 1 1.0 pM




Table 4.7: Cycling conditions for the PCRs with M 13-tailed primers.
PCR s t e p T e m p e r a tu r e T im e C ycles
Initiation 94°C 15 min
Denaturing 94°C 30 sec
Primer Annealing 56°C 45 sec 30
Elongation 72°C 45 sec
Denaturing 94°C 30 sec
Primer Annealing 53°C 45 sec 8
Elongation 72°C 45 sec
Final Elongation 72°C 5 min
Cool-Down 4°C 15 min
In five cases, M13-based repeats had to be performed for the entire set of samples. 
PCR products for four o f these markers were pooled together in a panel prior to 
fragment length analysis as shown in Table 4.8. The fifth marker, D7S2465, was not 
included in this panel because the repeats were performed at a later time than those 
for the other markers. PCRs for the remaining M l 3-markers (D14S68 and D20S889) 
were only used to perform repeats of few samples at a time. For these markers, the 
data obtained from the M13-PCR repeats were integrated with the data obtained 
using the ABI-primers. In these cases, genotype calibration based on the CEPH 
sample was o f particular importance.
Table 4.8: Pooling panel comprising four of the M13-PCR products.
M a rk e r  n a m e F ra g m e n t le n g th  ra n g e  (b p ) F lu o re s c e n t lab e l
D20S117 170-196 FAM (blue)
D15S994 209-233 FAM (blue)
D21S263 190-220 HEX (green)
D20S195 262-280 HEX (green)
152
Fragment length analysis, genotyping and double scoring were done as described in 
chapter 2.2.5.2. When data completeness for a chromosome had reached 95%, and at 
least 90% of the data for each marker on that chromosome were available, the 
PedCheck programme was used to test the genotype data for consistency with 
Mendelian transmission as described in chapter 2.3.4. The data were also checked for 
non-Mendelian errors using SimWalk2 (see chapter 2.3.5). Any inconsistent 
genotypes were removed and, if as a consequence the genotyping completeness for a 
marker or the whole chromosome dropped under 90% or 95%, respectively, the 
samples in question were repeated. As mentioned above, however, generally no more 
than three repeat rounds were performed for any one marker. The data set resulting 
from this procedure was then merged with the data collected in the earlier BPI 
linkage scan performed in Antioquia184 as described in section 4.4.2.
A schematic overview of the data collection procedure is shown in Figure 4.3.












primer left for 
repeats?
M endelian/non-M endelian 
genotyping errors?
Amplification of 382 autosomal 
microsatellites with ABI primers
Check data completeness:
At least 90% for each marker?
At least 95% for each chromosome?
1
FINAL DATA
See text for details.
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4.4.2. Building the Joint Data Set
The genotype data that formed the basis of the linkage study carried out by Herzberg 
and colleagues184 were available as final clean data. The original samples, as well as 
most of the raw data, were also available. The data from Herzberg and colleagues 
will from now on be referred to as data set 1, while the data obtained as part of this 
thesis will be called data set 2.
To enable a straightforward joint analysis o f both data sets, all genotypes have been 
obtained using the ABI Linkage Mapping Set v2.5. In theory, because all genotypes 
in a run are calibrated to the same CEPH sample -  1347-02 - ,  it should have been 
possible to simply join both data sets, which had separately undergone strict 
genotyping quality controls including double scoring and checks for genotyping 
errors. However, when attempting to join the two data sets, it became evident that 
although the genotypes in data set 1 had been calibrated to the CEPH sample 1347- 
02, this sample had not been assigned its genotype as provided by ABI in the 
analysis of data set 1. Instead, the alleles were named after the size of the PCR 
product as it resulted from fragment length analysis. An example shall be given to 
clarify this problem: for marker D5S410, ABI provides the genotype 331/341 for 
sample 1347-02. In the analysis of data set 2, this genotype was assigned to the 
CEPH sample, and all other genotypes were calibrated to this sample. The genotype 
for the CEPH sample 1347-02 in data set 1, however, read 333/343, indicating that 
instead of applying the nomenclature provided by ABI, the alleles were called after 
the fragment length. Because ABI’s nomenclature is also based on fragment sizes, 
the two calls are very close; however, the same PCR product may appear to be of a 
slightly different length when run on different DNA sequencers, so that a consistent 
nomenclature is difficult to achieve if allele calls are based on the apparent fragment 
length in a genotyping run. It would therefore have been desirable to follow ABI’s 
nomenclature, allowing an easier comparison of the obtained data with future data 
sets. Note that this discrepancy in allele callings is a problem for linkage analysis 
because allele frequencies are an important input parameter for both parametric and 
non-parametric analyses. If  the alleles are not called in a consistent manner, the allele 
frequencies will be skewed, and any results obtained from joint analyses are likely to 
be inaccurate, or even wrong. In haplotype analysis, a consistent nomenclature is
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essential in order to be able to detect similarities in potential disease-carrying 
haplotypes between families.
Before being able to carry out any analysis on the joint data, the genotypes from both 
data sets therefore had to be adjusted to each other. In order to achieve this, the 
difference between the CEPH genotype calls in both data sets was noted, and all 
genotypes from data set 1 were corrected by this difference, thereby resulting in an 
adjusted data set which was compatible with the genotypes provided by ABI for 
sample 1347-02, and therefore with the genotypes in data set 2. In some instances, 
calibration was not possible based on the original data because the CEPH genotype 
had not successfully been obtained in one of the data sets. In these cases, a PCR 
involving two samples from each data set and the CEPH sample 1347-02 was carried 
out for calibration purposes. After this additional experiment, the great majority of 
marker genotypes were successfully calibrated. There were only four markers for 
which the calibration process was unsuccessful because the genotypes of the samples 
from data set 1 obtained in the calibration experiment differed from the genotypes 
that were originally included in data set 1. Since it was impossible to decide which 
genotypes were wrong, the genotypes from data set 1 for these makers were excluded 
from the joint analysis. These markers were D13S159, D17S798, D19S221, and 
D21S263.
A further problem was the presence of “intermediate” alleles in the data. In contrast 
to the usual microsatellite variation, where alleles differ from each other by complete 
repeat motifs, “intermediate” or “odd-sized” alleles fall outside the normal allele 
ladder, i.e., in between regular alleles. This phenomenon seems to be particularly 
common in compound microsatellites of the form (CA)m(CG)n, possibly because of 
the tendency of CG-rich repeats to form secondary hair-pin structures that might alter 
the motility of the PCR product during gel electrophoresis314. Some of the markers 
for which intermediate alleles were observed in this study are of this structure (e.g. 
D6S434); other markers have a different complex repeat structure, such as 
(TA)m(CA)n (e.g., D7S486). Alternative sources of intermediate alleles can lie in 
deletions/insertions interrupting the homogeneous repeat stretch315, or variation in 
the flanking non-repeat sequence .
While genotyping the ABI microsatellite markers for data set 2, intermediate alleles 
were identified at 21 markers. After cross-checking with data set 1, it was found that
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the occurrence of intermediate alleles had not been taken into account for ten of these 
markers in that data set. It was therefore attempted to re-analyse available raw data 
for data set 1 at these markers. These raw data were in the format of GeneMapper’s 
precursor programme, the Genotyper® software v3.6 (Applied Biosystems); this 
programme was therefore used for their re-analysis.
Genotypes could successfully be obtained for five markers (D6S434, D7S486, 
D11S925, D15S127, and D18S70). Re-analysis of markers D1S498, D1S2836, 
D6S262, and D15S994 was not possible because the correspondent raw data were 
not available. For these markers, genotypes from data set 1 were therefore excluded 
from the joint analyses.
Additional problems were encountered with the following markers:
P5S2115
In data set 1, the genotypes labelled as D5S2115 really belonged to marker D6S462. 
This was discovered because the genotype patterns seemed exactly the same for both 
markers; i.e., all heterozygotes for one marker were also heterozygous for the other, 
and the distances in bp between the two alleles were always the same. In the same 
manner, all homozygotes for one marker were homozygous for the other, and allele 
differences between two individuals were the same for both markers. Since it is 
highly improbable for such a situation to occur naturally, the raw data for both 
markers were checked. It was discovered that the marker D6S462, which belongs to 
the same genotyping panel as D5S2115 and occupies an adjacent size range in the 
same colour lane (green), produced a “mirror image”, where there are two PCR 
products for each allele, which differ by a constant number of bp (see Figure 4.4).
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Figure 4.4: “Mirror image” for marker D6S462.













Electropherograms for three samples (from GeneMapper®). What initially looks like the 
product of two different markers could be identified as a “mirror image” phenomenon. The 
group of peaks at the left lie within the predicted size range for marker D6S462 (103-120 bp). 
The peaks at the right lie close to, or even within, the predicted size range for marker D5S2115 
(142-170 bp). In data set 1, they were therefore mislabelled as marker D5S2115. In reality, this 
is a mirror image o f marker D6S462, as can be seen from the equal patterns of the peaks in both 
groups. Although this pattern is only shown for three samples here, it could be observed 
throughout all samples.
The biological explanation for this phenomenon might be that the binding site for 
one of the primers lies in a duplicated segment. Alternatively, this pattern might be 
due to primer degeneration. Degeneration might reduce primer specificity, thereby 
allowing it to anneal at a close-by site which might be similar, but not identical, to 
the targeted primer binding site. Upon discovering this issue, it was also found out 
that the genotypes that really belonged to marker D5S2115 were labelled as D5S418, 
another marker from panel 10 (see below). These genotype data were correctly re­
labelled as D5S2115 and could subsequently be analysed as part of the joint data set.
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D5S418
As explained above, the genotypes included in data set 1 for marker D5S418 really 
belonged to marker D5S2115. This is likely to be a consequence of the mix-up 
between markers D6S462 and D5S2115 as described above. Because the peaks that 
were interpreted as D5S2115 really belonged to marker D6S462, the peaks that really 
belonged to D5S2115 were taken for marker D5S418, although they did not lie 
within the size range for the latter marker (207-227 bp; see Figure 4.5 for 
clarification). This suspicion was confirmed by the genotype for the CEPH sample, 
which corresponded to that for marker D5S2115 (168/168) and not to that for marker 
D5S418 (209/211). As already mentioned above, the data was relabelled as 
D5S2115. Although some peaks could be distinguished within the expected size 
range for marker D5S418, they were extremely low (see Figure 4.5). This might 
indicate that the PCR for this marker had not worked very well, or there had been a 
problem during marker pooling. At the time, this might not have been noticed 
because o f the appearance o f the “additional marker” (the mirror image o f D6S462). 
It is, however, surprising that the inconsistencies with the size ranges provided by 
ABI were not taken notice of.
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Electropherogrammes showing the green lane of panel 10 from the ABI Linkage Mapping Set 
for samples from data set 1 (from Genotyper® v3.6). To clarify the mix-up in genotype calling, 
the labels at the bottom of the figure describe which marker truly lies within each marked size 
range, and for which marker the genotypes might have been mistaken. The presence of very low 
PCR products within the size range of marker D5S418 indicates that the PCR for this marker 








This marker contained intermediate alleles but was very difficult to retype for data 
set 1 based on the available raw data. Because a new primer had to be ordered to 
carry out repeats in data set 2, this marker was retyped for all samples from families 
o f data set 1. Samples were typed and genotypes analysed as described for data set 2, 
and the resulting genotypes were included in the joint data analysis.
D11S905
There were no genotype data for this marker in data set 1. Since no raw data were 
available for this marker, the joint analysis did not include any genotypes from data 
set 1 for this marker.
In conclusion, there were ten markers for which there were no genotypes from data 
set 1 to be included in the joint analysis (D1S498, D1S2836, D5S418, D6S262, 
D11S905, D13S159, D15S994, D17S798, D19S221, and D21S263). For these 
markers, only the data obtained as part of this thesis (data set 2) were analysed. For 
the remaining 372 markers, a joint data set was obtained for linkage analysis.
4.5. Data Analysis
The aim of this section is to provide an outline of the analysis procedure. For details 
o f the methods employed, please refer to chapter 2.3.
As a first step, the programme Mega2 was used to recode allele labels from the 2- or 
3-digit fragment size-based nomenclature used in data collection, to a consecutive 
numeric nomenclature running from 1 to n, where n is the number of alleles observed 
at each locus. After allele recoding, Mega2 was used to convert the linkage format 
files, in which the genotype data were stored, to the input format for Mendel v8.0.1. 
Mendel was then used to estimate population allele frequencies from the pedigree 
data as described in chapter 2.3.6. After completing these preparatory analyses, 
Mega2 was used to create the input files for the SimWalk2 programme based on the 
recoded genotypes and incorporating the population allele frequency estimates 
obtained from the Mendel programme. Finally, SimWalk2 was used to carry out the 
analyses that are at the core of this chapter: parametric and non-parametric linkage 
analyses, as well as haplotype analysis.
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A flow chart summing up the analysis procedure is presented in Figure 4.6.



















In this section, I present a description of the results obtained in the genome-wide 
scan of 15 extended pedigrees from the paisa community segregating severe bipolar 
disorder. First, an overview on data completeness shall be given. Subsequently, the 
results of the linkage scan for each phenotype model will be summarised. Haplotype 
analyses have been conducted to facilitate the identification of potential common 
disease-carrying haplotypes in regions selected for a high LOD or NPL score; 
therefore, results from haplotype analyses will be presented together with the results 
o f the linkage analyses.
4.6.1. Data Completeness
Genotyping o f 382 autosomal microsatellite markers was attempted in 75 samples 
from nine pedigrees (data set 2). Genotype data for a further 91 samples from six 
pedigrees that had been subject of a previous linkage study were available for the 
same set of markers (data set 1).
In collecting the genotypes for data set 2, it was aimed at obtaining at least 90% of 
the genotypes for any one marker, and at least 95% of all genotypes for each 
chromosome. It was generally not attempted to obtain missing genotypes from data 
set 1; changes that were made to data set 1 in order to prepare a merged data set for 
joint analysis were described in chapter 4.4.2. The most important reasons for 
excluding genotypes from data set 1 from the joint analyses were the presence of 
intermediate alleles in the data which had not been accounted for in the genotype 
scoring of data set 1, and problems in calibrating genotype data from both data sets 
to the CEPH genotypes. Genotypes from data set 1 had to be excluded for ten 
markers (D1S498, D1S2836, D5S418, D6S262, D11S905, D13S159, D15S994, 
D17S798, D19S221, and D21S263).
Overall and chromosome-wise data completeness
The overall completeness of the data collected here (data set 2) was 97%, with 
chromosome averages ranging from 94% (for chromosome 16) to 98% (for 
chromosomes 5, 6, 9, and 11; see Table 4.9 on page 164). The overall completeness 
o f data set 1 was 93%. Chromosome averages for data set 1 ranged from 72%
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(chromosome 21) to 97% (chromosome 10; see Table 4.9). The low value for 
chromosome 21 results from there only being five markers on that chromosome, of 
which one (D21S263) had to be excluded because the genotypes of both data sets 
could not be calibrated to each other.
Data completeness bv marker
For data set 2, data completeness for single markers ranged from 83% for marker 
D6S516, to 100% for 72 out of 382 markers (average 97 ± 3%). Overall, there were 
15 markers for which less than the targeted 90% of genotypes could be collected in 
data set 2. In all cases, the maximum number of repeat rounds had already been 
completed, and in all but one case (marker D16S516 on chromosome 16), 
chromosome averages of at least 95% were achieved nonetheless. For data set 1, the 
lowest percentage o f completeness of all markers for which genotypes were available 
(i.e., disregarding the 10 markers for which genotypes from data set 1 could not be 
used for joint analysis) was 77% (D8S1784). For 51 of the 382 markers, 100% of 
genotypes were available. The average single marker data completeness for data set 1 
was 93 ± 16%. This high variability is due to the markers for which genotypes could 
not be used in the joint analyses; without these markers, the average data 
completeness for single markers was 95 ± 4%.
For details o f marker data completeness by chromosome, see Tables 8.1 to 8.22 in 
the Appendix.
Data completeness bv sample
Data completeness for individual samples lied between 57% and 97% for data set 1 
(average 93 ± 6%), and between 74% and 100% for data set 2 (average 97 ± 4%) 
(data not shown).
In conclusion, the genotyping success for both data sets was very high (93% and 
97% for data sets 1 and 2, respectively), and variation in genotyping success was 
small for both markers and samples. Also, the standard deviations of the averages of 
data completeness for markers and samples are very similar, both within and between 
data sets (when excluding the markers for which data set 1 genotypes were not used 
in the joint analyses); thereby indicating that neither DNA quality nor PCR 
efficiency represented a major source of variation in genotyping success. High 
genotyping success was o f particular importance for the families from data set 2, for
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which linkage analysis was performed here for the first time. With an overall data 
completeness of 97%, it can be said that this has been achieved. Furthermore, the 
genotypes included in the final data set were subject to strict quality checks, and the 
resulting data therefore represent a solid basis for all analyses to be performed in the 
frame of this thesis.
Table 4.9: Completeness of the data obtained for the genome-wide linkage scan in fifteen 
extended pedigrees from Antioquia (by chromosome).
C h ro m o s o m e
D a ta  C o m p le te n e s s  (%)
D a ta  S e t 1 D a ta  S e t 2 W e ig h te d  A v e ra g e 1
1 0 .8 7 0 .9 7 0 .9 2
2 0 .9 7 0 .9 7 0 .9 7
3 0 .9 4 0 .9 6 0 .9 5
4 0 .9 3 0 .9 7 0 .9 5
5 0 .9 3 0 .9 8 0 .9 5
6 0 .9 0 0 .9 8 0 .9 3
7 0 .9 6 0 .9 7 0 .9 6
8 0 .9 6 0 .9 7 0 .9 6
9 0 .9 6 0 .9 8 0 .9 7
10 0 .9 7 0 .9 7 0 .9 7
11 0 .8 9 0 .9 8 0 .9 3
12 0 .9 4 0 .9 5 0 .9 5
13 0 .8 8 0 .9 6 0 .9 2
14 0 .9 5 0 .9 6 0 .9 5
15 0 .9 0 0 .9 7 0 .9 3
16 0 .9 4 0 .9 4 0 .9 4
17 0 .8 9 0 .9 6 0 .9 2
18 0 .9 5 0 .9 6 0 .9 5
19 0 .8 7 0 .9 6 0 .9 1
2 0 0 .9 5 0 .9 6 0 .9 5
21 0 .7 2 0 .9 5 0 .8 2
2 2 0 .9 4 0 .9 7 0 .9 5
W e ig h te d
A v e ra g e 2
0 .9 3 0 .9 7
-  .  ■ 2 n r  • t-x j
0 .9 4
Weighted by the number of individuals in each sample. 2Weighted by the number of markers
per chromosome.
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4.6.2. Linkage Analysis: Narrow Model
4.6.2.I. Parametric Analysis
Parametric linkage analysis of the fifteen extended Paisa pedigrees under the narrow 
model identified three genomic regions with study-wide multipoint heterogeneity 
LOD scores > 1.3 (see Table 4.10). The threshold of 1.3 is arbitrary; however, the 
same cut-off has been chosen by Herzberg and colleagues to indicate the most 
important results of their genome scan for bipolar disorder184. The highest HLOD 
score (2.14) was obtained for chromosome 21q21.1-q22.13 at marker D21S1914. 
The proportion o f families linked to this locus (a) was 0.15. The two other regions 
identified are located on chromosomes 13q33 and lp22-31. No LOD scores above 
the previously defined thresholds for genome-wide significance were obtained (LOD 
= 3.0, or LOD = 3.6 after correction for multiple models; see chapter 4.1); and for a 
= 1.0, i.e., under the assumption of locus homogeneity, no LOD scores > 1 . 3  
occurred anywhere in the genome (data not shown).
Plots showing multipoint HLOD scores and a-values along each of the chromosomes 
for which HLOD scores > 1.3 were found, are displayed in Figures 4.7 to 4.9.
Table 4.10: Regions with study-wide HLOD scores > 1.3.
C h ro m o s o m e
re g io n
C e n tro m e r ic
m a r k e r
T e lo m e ric
m a rk e r
h ig h e s t
HLOD
c lo s e s t
m a rk e r1 a
21q21.1-q22.13 D21S1256 D21S1252 2.14 D21S1914 0.15
13q33.1-q33.3 D13S158 D13S173 1.46 D13S158 0.3
Ip22.1-p31.1 D1S2868 D1S2841 1.32 D1S207 0.35
b a rk er  at the shortest genetic distance from the position at which the highest HLOD score has 
been obtained.
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Multipoint study-wide HLOD scores for chromosome 21 are plotted against the genetic distance 
on the chromosome in cM (blue line). Also shown are the estimates of the proportion of families 
showing linkage to each point along the map (a; red line).
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Multipoint study-wide HLOD scores for chromosome 13 are plotted against the genetic distance 
on the chromosome in cM (blue line). Also shown are the estimates of the proportion of families 
showing linkage to each point along the map (a; red line).
166
























-H LO D   a lp h a
Multipoint study-wide HLOD scores for chromosome 1 are plotted against the genetic distance 
on the chromosome in cM (blue line). Also shown are the estimates of the proportion of families 
showing linkage to each point along the map (a; red line).
In order to determine which were the pedigrees that most contributed to the linkage 
signals, particularly in view of the generally small a-values, maximum multipoint 
LOD scores for each individual family in all three candidate regions were examined 
(Table 4.11). The highest LOD score (3.21) occurred in family ANT07 at marker 
D21S1914 on chromosome 21, at the location of the maximum overall HLOD score. 
Additional individual multipoint LOD scores > 1 . 3  were found for the candidate 
region on chromosome 13q in families FAZU01 and ANT07, and for the candidate 
region on chromosome lp  in family ANT27.
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Table 4.11: Maximum multipoint LOD scores for each of the 15 extended pedigrees in the three 
chromosomal regions with a study-wide HLOD score > 1.3.
2 1 q 2 1 .1 -q 2 2 .1 3 1 3 q 3 3 .1 -q 3 3 .3 Ip 3 1 .1 -p 2 2 .1
Fam ily
M ax  LOD
c lo s e s t
m a r k e r1
M ax  LOD
c lo s e s t
m a rk e r1
M ax  LOD
c lo s e s t
m a rk e r1
FAZU01 -1.15 D21S263 1.38 D13S158 -0.89
D1S207/
D1S2868
FAZU28 -0.39 D21S1256 -0.54 D13S158 -0.18 D1S2841
ANT03 -0.11 D21S1914 0.27 D13S173 0.55 D1S2868
ANT04 -3.08 D21S263 1.11 D13S173 -1.47 D1S207
ANT07 3 .2 1 D21S1914 1.47 D13S158 0.19 D1S2841/D1S207
ANT10 -0.19 D21S1256/D21S1914 -0.45 D13S173 0.85 D1S2868
ANT14 0.80 D21S1914 -1.16 D13S173 -0.53 D1S207
ANT15 0.38 D21S263 0.30 D13S158 0.29 D1S2841/D1S207
ANT18 0.13 D21S1914 -1.29 D13S173 -1.35 D1S2868
ANT19 -0.01 D21S263 -0.97 D13S173 0.82 D1S207
ANT21 -0.95 D21S1252 -0.82 D13S173/D13S158 -0.04 D1S2868
ANT23 -0.59 D21S1256 0.37 D13S158 0.37 D1S207
ANT24 0.28 D21S1256 0.00 wholeinterval 0.28 D1S207
ANT26 -1.26 D21S1252 -0.61 D13S158 0.86 D1S207
ANT27 -0.81 D21S263 -2.29 D13S158 1.52 D1S207
All 2 .1 4 D 21S 1914 1 .4 6 D 13S158 1 .32 D 1S207
1 Marker at the shortest genetic distance from the position at which the highest LOD score 
(HLOD score for “All families”) has been obtained. If the highest LOD score occurred right in 
between two markers, both have been named. Instances where the LOD score was constant for 
the whole interval have been indicated. Individual multipoint LOD scores >1.3 are underlined; 
LOD scores > 2.0 are printed in bold.
In addition to considering regions identified based on study-wide heterogeneity LOD 
scores > 1.3, single-family results were scanned for the occurrence of individual 
LOD scores > 2.0 anywhere along the genome (Table 4.12). O f the five 
chromosomal regions for which individual LOD scores > 2 . 0  were obtained, one 
showed a study-wide HLOD score suggestive of linkage (chromosome 21q). In 
addition, a LOD score of 2.06 in family ANT27 occurs close to the candidate region
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on chromosome lp. For the other three regions on chromosomes 3q, 15q and 1 lq, no 
study-wide signal was picked up.
Table 4.12: Chromosome regions with single-family LOD scores > 2.0.
Fam ily
C h ro m o s o m e
re g io n
M ax  LOD1 c lo s e s t m a rk e r2
ANT07 21q21.2 3.21 D21S1914
ANT07 3q27.3 2.57 D3S1262
ANT18 15q26.3 2.46 D15S120
FAZU01 llq l2 .2 2.19 D11S4191
ANT27 lp31.3 2.06 D1S230
fFor each region with LOD scores > 2.0, the highest LOD score is given. 
2Marker at the shortest genetic distance from the position at which the 
highest LOD score occurred.
Haplotype analysis
In determining regions of potential interest in individual families, the threshold of 
LOD = 2.0 was chosen because it is commonly considered to indicate suggestive 
evidence for linkage (see chapter 1.2.3). To explore the basis for the linkage signals 
detected, haplotypes at each of the regions with LOD scores > 2 . 0  were visually 
inspected in each family. These haplotypes are shown below (Figures 4.10 -  4.14). 
Haplotypes are displayed for the candidate regions listed in Table 4.12. For 
chromosome 21, on which only five markers have been typed, the whole 
chromosome is shown. For all other chromosomes, haplotypes are limited by 
markers with LOD scores < -2.0 (i.e. where there is significant evidence for 
exclusion of linkage).
Despite the high LOD score for family ANT07 on chromosome 21q, there is no co­
segregation of one haplotype with the disease phenotype. There is, however, co­
segregation of a haplotype in the leftmost branch of the pedigree with BPI (light blue 
haplotype; see Figure 4.10), and partial co-segregation of another haplotype in the 
other branches of the pedigree: the majority of all individuals that do not share the 
light blue haplotype, do share a haplotype comprising alleles at markers D21S1814 
to D21S266 (dark blue haplotype in Figure 4.10; the allele at marker D21S1914 is
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represented in red in some individuals, indicating that it is assumed to be part of a 
different haplotype; however, it cannot be distinguished with certainty where the 
crossovers in individuals 8 and 13 have happened, and there is a possibility of 
identity by descent for all three markers).
On chromosome 3q -  again for family ANT07 - ,  there is co-segregation of a 
haplotype ranging from marker D3S1614 to marker D3S1580 (inclusive) with BPI 
within the left branch of the pedigree (dark red haplotype; see Figure 4.11). As is the 
case for chromosome 21, there seems to be no co-segregation within the right branch 
of the pedigree.
For family AN TI8, no co-segregation of a chromosome 15q haplotype and the 
disease phenotype could be identified (see Figure 4.12): although some alleles are 
identical by state in affecteds, they do not seem to be identical by descent.
In family FAZU01, for the candidate region on chromosome l lq,  there is a 
haplotype showing near perfect co-segregation with BPI (because BP is a complex 
disease, in this context, “near perfect co-segregation” only refers to affecteds sharing 
a haplotype, while it is not taken into account whether family members of an 
unknown phenotype status share this haplotype or not). In Figure 4.13, a haplotype 
comprising markers D11S904 to D11S4191 occurs in all but one (individual 55) of 
the affecteds. In most individuals, this haplotype is represented in light red; however, 
in individuals 40 and 376, parts of the haplotype are shown in blue; this is probably 
due to the fact that the family is inbred, which might cause the SimWalk2 
programme difficulties in assigning the most probable haplotypes. However, 
inspection of the alleles shows that there is co-segregation between disease and 
haplotype. Similarly, for individual 34, part of the haplotype is shown in green. This 
means that SimWalk2 inferred the occurrence of a crossover between markers 
D11S905 and D11S935 (e.g. because it is likely that at least one crossover occurs on 
this chromosome), but this inference, although based on a maximum likelihood 
approach, might be wrong, and the haplotype shown in green in individual 34 might 
indeed be identical by descent to the light red and the blue haplotypes in the 
remaining affecteds.
Inspection of the haplotypes on chromosome lp  in family ANT27 shows co­
segregation o f a putative disease-causing haplotype comprising markers D1S207 and
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D1S2868 with the phenotype (see Figure 4.14). This haplotype is represented in blue 
for some individuals, and in pale green for others because the maximum likelihood 
approach employed by SimWalk2 did not result in an IBD-inference for these 
haplotypes. It has to be stressed that this is a statistical inference, which does not 
preclude that in reality, these haplotypes might be identical by descent.
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Blackened symbols represent individuals diagnosed with BPI; all other individuals were considered as of an unknown phenotype for linkage analysis and are 
therefore labelled with a question mark. See Figure 2.1 for full affection status information of these individuals; refer to the text for further explanations.
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Figure 4.12: Haplotype reconstruction for a candidate region on chromosome 15 in family ANT18.
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Blackened symbols represent individuals diagnosed with BPI; all other individuals were considered as of an unknown phenotype for linkage analysis and are 
therefore labelled with a question mark. See Figure 2.1 for full affection status information of these individuals and refer to the text for further explanations.
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Blackened symbols represent individuals diagnosed with BP1; all other individuals were considered as of an unknown phenotype for linkage analysis and are 
therefore labelled with a question mark. See Figure 2.2 for full affection status information of these individuals and refer to the text for further explanations.
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Blackened symbols represent individuals diagnosed with BPI; all other individuals were 
considered as of an unknown phenotype for linkage analysis and are therefore labelled with a 
question mark. See Figure 2.1 for full affection status information of these individuals and refer 
to the text for further explanations.
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4.6.2.2. Non-Parametric Analysis
Non-parametric linkage analysis of  the fifteen bipolar pedigrees from Antioquia 
under the narrow model identified no region showing genome-wide evidence for 
linkage (i.e., regions with an N P L pairs score > 3.88, or N P L PAirs > 4.49 accounting 
for the testing of  multiple models; see chapters 1.2.3 and 4.1). Figures 4.15 to 4.17 
(pages 179-181) show plots of  the combined N P L pairs scores along the entire 
genome (note that the level of  significance was measured with the N P L pairs statistic 
for all non-parametric analyses; in the text, it shall therefore simply be referred to as 
NPL score).
Nine markers provided nominally significant evidence for linkage, with combined 
NPL scores > 1.3, corresponding to a p-value of  < 0.05. They are listed in Table 
4.13, together with the NPL scores obtained for individual families at the same 
markers. These nine markers define six separate candidate regions:
1. Chromosome 1 p 13-31 (limited by markers D1S230 and D1S2726). 
While the NPL score for marker D1S2841 is only 1.26, it is 
immediately adjacent to markers D1S207-D1S206, for which NPL 
scores are > 1.3, with a maximum of 2.13 at D1S2868; it is therefore 
considered to be part of  the candidate region.
2. Chromosome 1 q25-31 (limited by markers D 1S218 and D 1S413);
3. Chromosome 5ql 1-12 (limited by markers D5S407 and D5S424);
4. Chromosome 9p 13-21 (limited by markers D9S171 and D9S1817);
5. Chromosome 12p 12-12ct (telomeric limit: marker D 12S1617);
6. Chromosome 12ct-12ql4 (telomeric limit: marker D12S83).
The highest combined NPL scores were observed on chromosomes 12q and lp (2.55 
and 2.13, respectively). Several of  the pedigrees show individual NPL scores >1.3 
within these candidate regions (see Table 4.13). The highest individual statistic in 
any of these candidate regions was obtained for family ANT27 on chromosome 
lp31.1 (marker D1S207; NPL = 2.0).
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Table 4.13: Markers with combined NPLpairs scores > 1.3 (equivalent to p < 0.05) in the genome scan of fifteen BP1 pedigrees (narrow model).
Chromosome Position on NPLpairs
region chromosome all FAZU01 FAZU28 ANT03 ANT04 ANT07 ANT10 ANT14 ANT15 ANT18 ANT19 ANT21 ANT23 ANT24 ANT26 ANT27
D12S85 12ql3.11 68.90 2.55 0.54 0.84 0.47 1.57 0.17 0.23 0.17 0.36 0.90 0.62 0.76 0.23 0.12 1.37 0.51
DIS2868 lp22.1 136.57 2.13 0.11 0.28 1.10 0.26 0.84 0.75 0.47 0.08 0.65 1.21 0.24 0.03 0.13 0.38 1.58
D12S368 12ql3.3 74.12 1.93 0.56 0.84 0.41 1.69 0.01 0.21 0.15 0.30 0.86 0.59 0.86 0.25 0.10 1.23 0.24
D1S207 lp31.1 122.43 1.90 0.14 0.02 0.07 0.31 1.01 0.26 0.57 0.35 0.08 1.33 0.32 0.24 0.52 0.73 2.00
D5S647 5ql2.3 81.62 1.85 0.26 0.85 0.24 1.35 0.32 0.59 0.16 0.15 0.60 0.14 0.00 1.14 0.08 0.06 1.77
D12S345 12pll.21 56.90 1.77 0.60 0.71 0.62 0.18 0.44 0.22 0.12 0.51 0.87 0.52 0.76 0.24 0.12 1.42 0.35
D1S238 lq31.1 221.17 1.71 0.49 1.48 0.33 0.48 0.59 0.23 0.24 0.35 0.09 0.28 0.07 1.26 0.00 0.44 1.10
D9S161 9p21.2 46.90 1.61 0.53 0.82 0.31 0.74 0.38 0.24 0.13 0.35 1.20 0.15 0.13 0.21 0.60 0.27 1.64
D1S206 lp21.2 145.27 1.37 0.13 0.44 1.05 0.33 0.68 0.65 0.10 0.08 0.42 1.15 0.25 0.07 0.13 0.23 1.06







Figure 4.15: Combined N P L pairs scores for chromosomes 1-5 (narrow model).
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Figure 4.16: Combined NPLpairs scores for chromosomes 6-12 (narrow model).
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Dotted lines separate individual chromosomes. The X-axis represents the cumulative genetic distance from chromosome lpter.
Figure 4.17: Combined NPLPAirs scores for chromosomes 13-22 (narrow model).
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Dotted lines separate individual chromosomes. The X-axis represents the cumulative genetic distance from chromosome lpter.
♦
















*  ♦ ♦ ♦
♦ ♦
► ♦ ♦ ♦
♦  ♦ 1
♦ ♦♦
* ♦  V / ♦ ♦♦ ♦
*  ♦ ♦  






Markers, for which single-family NPL scores > 2.0 were obtained under the narrow 
model, are listed in Table 4.14. Haplotype reconstructions for these regions are 
shown in Figure 4.18 (chromosome 16, family ANT07) and Figure 4.19 
(chromosome 21, family ANT27). Haplotypes for chromosome 3q in family ANT07 
have already been examined in the previous section, in the frame of the results from 
the parametric linkage analysis (see also Figure 4.11). Haplotypes for chromosome 
21 are again shown for the entire chromosome, whereas haplotypes for chromosome 
16 in family ANT07 are displayed for all markers with NPL > 1.3, as well as for the 
adjacent markers on both sides.
Table 4.14: Markers with single-family NPLpairs scores > 2.0 (narrow model).
Fam ily
C h ro m o s o m e
reg io n NPLpairs M a rk e r
ANT07 16pl2.2 2.49 D16S3046
ANT07 3q26 2.32 D3S1580
ANT14 21q21.2 2.32 D21S1914
ANT07 16pl2.1 2.07 D16S3068
ANT27 lp31.1 2.00 D1S207
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Haplotype analysis
The haplotype reconstruction for chromosome 16p in family ANT07 shows the 
occurrence of a particular haplotype (shown in light brown in Figure 4.18) in the 
majority of the affecteds. Haplotype patterns in the remaining affecteds, however, 
provide a less clear picture.
On chromosome 21, haplotype reconstruction for pedigree ANT 14 shows near­
perfect co-segregation of a haplotype comprising markers D21S1256 and D21S1914 
with BPI (the blue haplotype in Figure 4.19). Individual 172, the only one not to 
display the “blue” haplotype, nonetheless shares the same alleles at the markers in 
question. Since the mother of individual 172, individual 188, is homozygous for both 
markers, the haplotype for individual 172 cannot be confidently reconstructed, and it 
is indeed possible that all affecteds share a haplotype that is identical by descent.
The reconstruction o f haplotypes on chromosome lp  in family ANT27 has already 
been discussed in the context of parametric linkage analysis in the previous section 
(chapter 4.6.2.1; see also Figure 4.14).
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Blackened symbols represent individuals diagnosed with BPI; individuals 57, 100, 89, 275 and 281 are diagnosed with MD, and individual 102 has a diagnosis of 
BPII. Individuals suffering from psychosis are labelled “Psy”. Diagnoses differing from BPI are indicated in this pedigree because the region on chromosome 16p 
was picked up under all three analysis models for family ANT07. All other pedigree members are of an unknown phenotype status. See text for further 
explanations.
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Figure 4.19: Haplotype reconstruction for chromosome 21 in family ANT14. Marker D21S263,
for which no genotype data were available in data set 1, is not shown.
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Blackened symbols represent individuals diagnosed with BPI; individuals suffering from 
psychosis are labelled “Psy”. They are indicated because chromosome 21 was also picked up as 
a region of interest under the psychosis model. All other individuals were considered as of an 
unknown phenotype. See Figure 2.1 for full affection status information of these individuals, 
and refer to the text for further explanations.
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4.6.3. Linkage Analysis: Broad Model
Under the broad model, where all family members diagnosed with BPI, BPII or 
major depression were considered affected, only non-parametric analysis was 
performed. The results of this analysis are summarised in Figures 4.20 to 4.22. No 
marker showed genome-wide significance for linkage. Twelve markers had 
combined NPL scores >1.3;  these markers are listed in Table 4.15. Individual NPL 
scores for all fifteen pedigrees at these markers are also shown. The twelve 
nominally significant markers define seven candidate regions:
1. Chromosome lp l3-31 (limited by markers D1S230 to D1S2726). 
Like for the non-parametric analysis under the narrow model, the NPL 
score for marker D1S2841 did not quite reach 1.3; however, it is close 
to this cut-off (1.28), and the marker is therefore considered to be part 
o f the candidate region.
2. Chromosome 1 q25-31 (limited by markers D 1S218 and D 1S413);
3. Chromosome 6pl2-22 (limited by markers D6S422 and D6S257);
4. Chromosome 7pl 5-21 (limited by markers D7S513 and D7S493);
5. Chromosome 9 p l3-21 (limited by D9S171 and D9S1817);
6. Chromosome 12p 12-12ct (telomeric limit: marker D12S1617);
7. Chromosome 12ct-12q21 (telomeric limit: D12S351; marker 
D12S326, which is directly adjacent to the markers with NPL > 1.3, 
has an NPL score of 1.24 and might therefore still considered to be 
part of the candidate region).
The candidate regions with the highest combined NPL scores (> 2.0) were 
chromosome 12p and q, and lp  and q (NPL scores between 2.07 and 2.35).
Several of the families show individual NPL scores > 1 .3  within these candidate 
regions (see Table 4.15). Again, the highest individual statistic in any of these 
candidate regions was obtained for family ANT27 on chromosome lp 3 1.1 (marker 
D1S207; NPL = 2.0). This NPL score is the same as for the analysis under the 
narrow model because all affected pedigree members in family ANT27 are 
diagnosed with BPI, rendering the analyses under the two different models identical 
(see Figure 2.1).
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O f the seven candidate regions identified in non-parametric analysis under the broad 
model, five overlap partly or completely with the ones identified in non-parametric 
analysis under the narrow model; these are the regions on chromosome lp, lq, 9p, 
12p, and 12q. The candidate region on chromosome lp  was also identified in 
parametric linkage analysis.
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Table 4.15: Markers with combined NPLpairs scores > 1.3 (equivalent to p < 0.05) in the genome scan of fifteen extended paisa  pedigrees (broad model).
Chromosome Position on NPL,Mrs
region chromosome all FAZU01 FAZU28 ANT03 ANT04 ANT07 ANT10 ANT14 ANT15 ANT18 ANT19 ANT21 ANT23 ANT24 ANT26 ANT27
D12S85 12ql3.11 68.90 2.35 0.38 0.84 0.36 0.73 0.51 0.71 0.31 0.36 0.90 0.62 0.76 0.28 0.35 1.37 0.51
D1S2868 lp22.1 136.57 2.22 0.19 0.28 1.06 0.10 1.39 0.57 0.77 0.08 0.65 1.21 0.24 0.09 0.00 0.38 1.57
D12S345 12pll.21 56.90 2.10 0.58 0.71 0.43 0.26 0.91 0.65 0.12 0.51 0.87 0.52 0.76 0.29 0.35 1.42 0.35
D12S368 12ql3.3 74.12 2.07 0.31 0.84 0.34 1.19 0.33 0.64 0.29 0.30 0.86 0.59 0.86 0.32 0.28 1.23 0.25
D1S207 lp31.1 122.43 1.68 0.10 0.02 0.16 0.23 0.80 0.66 0.70 0.35 0.08 1.33 0.32 0.23 0.31 0.73 2.00
D1S238 lq31.1 221.17 1.68 0.50 1.47 0.18 0.49 0.36 0.33 0.23 0.35 0.09 0.28 0.07 1.87 0.00 0.44 1.10
D7S507 7p21.1 26.00 1.67 0.40 0.01 0.94 0.15 1.13 0.62 0.54 0.35 0.01 0.59 0.07 0.78 0.78 0.87 0.68
D6S1610 6p21.2 48.86 1.54 0.21 0.04 0.13 0.49 0.19 1.29 1.73 0.00 0.47 0.78 0.84 0.27 1.21 0.22 0.54
D9S161 9p21.2 46.90 1.50 0.75 0.82 0.62 0.61 0.47 0.36 0.10 0.35 1.20 0.15 0.13 0.25 0.00 0.27 1.64
D1S206 lp21.2 145.27 1.46 0.25 0.44 1.05 0.17 1.24 0.65 0.16 0.08 0.42 1.15 0.24 0.05 0.00 0.23 1.06
D6S276 6p22.2 38.44 1.37 0.19 0.20 0.15 0.53 0.11 1.33 1.57 0.00 0.37 0.71 0.72 0.30 1.23 0.17 0.57
D12S83 12ql4.1 84.54 1.32 0.25 0.54 0.23 0.52 0.92 0.28 0.35 0.18 0.47 0.52 0.84 0.32 0.22 1.09 0.12
Individual NPL scores > 1.3 are underlined; N P L PAir s  scores > 2.0 are additionally printed in bold.
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Figure 4.20: Combined N P L PAirs scores for chromosomes 1-5 (broad model).
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Figure 4.21: Combined N P L PAirs scores for chromosomes 6-12 (broad model).
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Figure 4.22: Combined NPLPA|r$ scores for chromosomes 13-22 (broad model).
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Single-family NPL scores > 2.0 were found in three pedigrees (see Table 4.16). 
Haplotype reconstructions for these families are discussed below; as in section
4.6.2.2, haplotypes are displayed for all markers with NPL > 1.3, as well as for the 
adjacent markers on both sides.
Table 4.16: Markers with single-family N P L PAir s  scores > 2.0 (broad) model).
Family Chromosomeregion NPLpairs Marker
ANT23 2q33.3 2.23 D2S325
ANT23 2q32.3 2.19 D2S117
ANT07 16pl2.1 2.12 D16S3068
ANT27 lp31.1 2.00 D1S207
Visual inspection of the results o f the haplotype analysis suggests that in family 
ANT23, a 3-marker haplotype comprising markers D2S117 to D2S2382 on 
chromosome 2 is co-segregating with the broadly defined phenotype (see Figure
4.23). Although according to the reconstruction by SimWalk2, the haplotypes do not 
seem to be identical by descent in all affecteds, it has to be remembered that 
SimWalk2 uses a maximum likelihood approach, and it is possible that there is 
another, equally likely haplotype configuration (or even several), which allows for 
the two haplotypes that are identical by state (dark green and light blue in Figure
4.23) to be also identical by descent. Note that at first sight, the haplotype 
reconstruction as shown in Figure 4.23 seems less likely than an alternative where 
the potential disease-carrying haplotype is identical by descent in all affecteds; 
however, this has to do with the fact that only a limited region on chromosome 2 is 
shown in the figure, whereas the haplotypes were reconstructed based on information 
for the whole chromosome.
The haplotypes on chromosome 16p in pedigree ANT07 have been previously 
discussed in section 4.6.2.2 (see Figure 4.18); however, in the present analyses, 
individuals diagnosed with BPII and MD were also considered affected. This makes
192
the co-segregation patterns between haplotypes and phenotypes less clear; however, 
the light brown haplotype (as shown in Figure 4.18) still shows co-segregation with 
the phenotype in part of the pedigree.
Co-segregation patterns between haplotypes in a candidate region on chromosome lp 
and the phenotype in family ANT27 have equally been previously discussed (see 
section 4.6.2.1 and Figure 4.14). Because there are no individuals affected with either 
BPII or MD in this family, the conclusions remain the same: there is co-segregation 
of a putative disease-carrying haplotype comprising markers D1S207 and D1S2868 
with BPI, the only affecteds without the haplotype under consideration being 
individuals 284 and 291.
193
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Blackened symbols represent individuals considered affected in linkage analysis; all other 
individuals were considered as o f an unknown phenotype and are therefore labelled with a 
question mark. See Figure 2.2 for full affection status information of these individuals. See text 
for further explanations.
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4.6.4. Linkage Analysis: Psychosis Model
Non-parametric linkage analysis of the fifteen bipolar pedigrees from Antioquia 
under the psychosis model provided no genome-wide evidence for linkage. Plots of 
the combined NPL scores along the genome are shown below (Figures 4.24 to 4.26). 
For five markers in five different chromosomal regions, combined NPL scores > 1.3 
were obtained, indicating nominally significant evidence for linkage; they are listed 
in Table 4.17, along with single-family NPL scores for these markers. The candidate 
regions identified through the analysis under the psychosis model are:
1. Chromosome 2q24-31 (limited by markers D2S142 and D2S335);
2. Chromosome 6q24-25 (limited by markers D6S308 and D6S1581);
3. Chromosome lOql 1-22 (limited by markers D10S196 and D10S537);
4. Chromosome 12q21 -23 (limited by markers D 12S326 and D 12S346);
5. Chromosome 16pl2-ql2 (limited by markers D16S3046 and 
D16S3136).
The highest combined NPL scores were achieved for chromosomes 2q (2.09) and 
16p (2.05). Within these candidate regions, several of the pedigrees show individual 
NPL scores >1.3.  The highest individual statistic was obtained for family ANT07 for 
the candidate regions on chromosome 16p and 6q (NPL scores for both marker 
D16S3068 and marker D6S441 were 1.90).
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Table 4.17: Markers with combined NPLPAirs scores > 1.3 (equivalent to p < 0.05) in the genome scan of fifteen extended paisa  pedigrees (psychosis model).
Chromoso Position on NPLpairs
MaiKci me region chromosome all FAZU28 ANT03 ANT04 ANT07 ANT14 ANT15 ANT18 ANT21 ANT23 ANT24 ANT27
D2S2330 2q24.3 178.85 2.09 0.60 0.37 0.02 0.98 0.80 0.60 0.29 0.36 0.60 0.13 0.26
D16S3068 16pl2.1 41.82 2.05 0.60 0.00 0.00 1.90 0.53 0.62 0.26 1.09 0.12 0.61 0.09
D6S441 6q25.2 166.61 1.44 0.13 1.20 0.06 1.90 0.05 0.58 0.11 0.00 0.60 0.05 0.33
D12S351 12q21.33 106.94 1.39 0.12 0.01 0.62 0.13 1.44 0.13 0.17 0.33 0.61 0.41 0.33
D10S1652 10q21.2 87.87 1.36 0.23 0.00 0.00 1.68 0.42 0.37 0.17 0.36 0.13 0.13 0.57






Figure 4.24: Combined N P L PAirs scores for chromosomes 1-5 (psychosis model).
chr1 chr2 chr3 chr4 chr5
♦
♦♦ ♦ # ♦«• . 
♦ #
♦ ♦♦ ♦
% x* ♦ * * *♦ ♦«
♦
♦ ♦ ♦ ♦♦♦ ♦ ♦ < 
v  **'v ♦*** *
♦♦♦♦*♦ ♦%♦ ♦ ♦ ♦♦♦
♦ A ♦ ♦V ♦♦♦ ♦
♦ V %♦ ♦ ♦ ♦ v
♦* ♦ ♦ 
..... ♦
0 200 400 600 800 1000 1200
cM






Figure 4.25: Combined NPLPAirs scores for chromosomes 6-12 (psychosis model).
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Figure 4.26: Combined NPLPAirs scores for chromosomes 13-22 (psychosis model).
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Individual NPL scores >2 .0  were found in two families for three markers, as shown 
in Table 4.18.
Table 4.18: Markers with single-family N P L PAir s  scores > 2.0 (psychosis model).
Family Chromosomeregion NPLpAIRS Marker
ANT07 16pl2.2 2.40 D16S3046
ANT14 21q21.2 2.33 D21S1914
ANT14 4q31.21 2.30 D4S424
Haplotvne analysis
In family ANT07, chromosome 16p was picked up as a region of interest in non- 
parametric analysis under all three models (see sections 4.6.2.2 and 4.6.3). The 
haplotype reconstruction is shown in Figure 4.18; visual inspection of the haplotypes 
suggests co-segregation of the light brown haplotype with psychosis in the left 
branch of the pedigree.
Haplotype reconstructions of chromosome 21 in pedigree ANT 14 are shown in 
Figure 4.19 and have been previously discussed in section 4.6.2.2. The only 
individual that was not considered affected in the analysis under the narrow model, 
individual 185, a woman with an affective disorder that did not meet the criteria for 
BP but who is affected by psychosis, displays the same haplotype comprising 
markers D2IS 1256 and D21S1914 as the other affecteds in that family, making 
chromosome 21 an interesting candidate region in that family.
A haplotype reconstruction for chromosome 4q in family ANT 14 is shown in Figure 
4.27. Shown are all markers with NPL scores > 1.0, as well as one adjacent marker 
on each side. Co-segregation of a haplotype comprising the three bottom markers 
with psychosis is nearly perfect; individual 172 alone does not share this haplotype 
with the remaining affecteds.
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Blackened symbols represent individuals with psychosis; all other individuals were considered 
as of an unknown phenotype in linkage analysis and are therefore labelled with a question 
mark. See Figure 2.2 for full affection status information of these individuals, and refer to the 
text for further explanations.
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4.6.5. Summary of the Linkage Results
Linkage analysis o f fifteen extended pedigrees segregating severe bipolar disorder 
from the paisa  community in Colombia was performed under three different 
phenotype models -  narrow, broad and psychosis models (see chapter 4.1) -  and 
using both parametric and non-parametric approaches. The use o f these different 
approximations has yielded a wealth of results (presented in the previous sections, 
4.6.2 - 4.6.4), and this subchapter shall provide a summary of these results.
None of the analyses performed resulted in significant evidence for linkage on a 
genome-wide level, neither with nor without accounting for the testing o f multiple 
models (thresholds: LOD > 3.60 / NPL > 4.49 and LOD > 3.00 / NPL > 3.88, 
respectively). However, several regions showed study-wide suggestive evidence for 
linkage, and a number o f regions of interest were identified in different pedigrees. 
Tables 4.19 and 4.20 provide a synopsis of the results for the whole set of pedigrees 
and single families, respectively.
Several regions were picked up in more than one analysis. The candidate region on 
chromosome lp  was identified through both parametric and non-parametric analyses 
under the narrow model, as well as under the broad model, and candidate regions on 
chromosome lq, chromosome 12p and q and chromosome 9p showed nominal 
significance in non-parametric analysis under both narrow and broad models. The 
region on chromosome lp  produced consistently high LOD/NPL scores under 
narrow and broad models in family ANT27. On chromosome 21q, parametric linkage 
analysis produced high LOD scores both study-wide and for family ANT07, and 
non-parametric analyses under both narrow and psychosis models resulted in NPL 
scores > 2.0 for family ANT 14 in the same chromosomal region. Finally, for family 
ANT07, the candidate region on chromosome 16p was identified through non- 
parametric analysis under all three models.
2 0 2
Table 4.19: Synopsis of the chromosomal regions for which a HLOD score (in parametric 
analysis) or a combined NPLPAirs score (in non-parametric analysis) >1.3 were obtained (across 
all diagnostic models).
Narrow Model Broad Model Psychosis Model
Parametric LA Non-param etric LA (Non-parametric LA) (Non-parametric LA)
chr lp22-31 (1.32) chr lp l3 -3 1  (2.13) chr lp l3-31  (2.22) chr 2q24-31 (2.09)
chr 21q21-22 (2.14) chr lq25-31 (1.71) chr lq25-31 (1.68) chr 16pl2-q l2  (2.05)
chr 13q33 (1.46) chr 12pl2-ct (1.77) chr 12pl2-ct (2.10) chr 6q24-25 (1.44)
chr 12ct-12ql4 (2.55) chr 12ct-12q21 (2.35) chr 12q21-23 (1.39)
chr 9pl3-21 (1.37) chr 9pl3-21 (1.50) chr 10q ll-22  (1.36)
chr 5 q ll-1 2  (1.85) chr 7pl5-21 (1.67)
chr 6pl2-22 (1.54)
LA, Linkage analysis. Maximum HLOD (for parametric analysis) or combined N P L PAirs (for 
non-parametric analyses) scores for each region are shown in brackets.
Table 4.20: Synopsis of the chromosomal regions for which a LOD score (in parametric 
analysis) or an individual NPLPAirs score (in non-parametric analysis) > 2.0 were obtained for in 
a single pedigree (all diagnostic models).
Narrow Model Broad Model Psychosis Model






























chr lp31  (2.06)
LA, Linkage analysis. Maximum LOD (for parametric analysis) or NPLPA|rs (for non-
parametric analyses) scores for each region are shown in brackets.
Haplotype analyses showed co-segregation of specific haplotypes with the disease 
phenotype in several cases. The most consistent pattern of co-segregation was seen 
between BPI and a haplotype comprising markers D2IS 1252 and D21S1914 on 
chromosome 21 in family ANT14 (Figure 4.19). This co-segregation is also seen 
when psychosis is considered as the phenotype. A comparison between chromosome 
21 haplotypes in families ANT 14 and ANT07 shows that the former pedigree and the
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left branch of the latter share an allele at marker D21 SI 914 (allele 3, see Figure 4.10 
for haplotypes in family ANT07). Whether it is identical by state or identical by 
descent, however, cannot be decided based on the available information. Inspection 
of haplotypes for chromosome 21 in the remaining pedigrees showed that the same 
allele was present in a haplotype co-segregating with BPI and psychosis in family 
ANTI5 (see Figure 4.28). The potential susceptibility haplotype additionally shows 
the same allele at marker D2IS 1256 in family ANT 15 and the left branch of family 
ANT07 (allele 1).
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Blackened symbols represent individuals diagnosed with BPI; individuals suffering from  
psychosis are labelled “Psy”. Individual 143 was considered as of an unknown phenotype in 
linkage analysis. See text for further explanations.
Haplotype comparison between pedigrees ANT07 and ANT 15 furthermore reveals 
the occurrence of a shared haplotype comprising markers D21S1525 and D21S266 
(different from the potential susceptibility haplotype discussed so far), possibly 
indicating that members of these two pedigrees are related.
A haplotype comprising markers D1S207 to D1S206 co-segregates with the 
phenotype of BPI in family ANT27 (see Figure 4.14). For two other families, 
individual NPL scores > 1.0 were obtained for the same region under both narrow 
and broad models: ANT03 and ANT 19 (see Table 4.14 and Table 4.16 for narrow 
and broad models, respectively). Haplotype analysis of these two families showed 
that, although they do not share any alleles with family ANT27, they do share a
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common haplotype between them, which comprises markers D1S206 to D1S252 (see 
Figure 4.29 on page 206). Visual inspection of the haplotypes for this region in the 
remaining pedigrees revealed that BPI affecteds in one nuclear family (forming part 
o f pedigree FAZU01) also shared the same haplotype (see Figure 4.30 on page 207).
The common region o f co-segregation with BPI (but not o f haplotype sharing 
between families) in all three families is around marker D1S206 on chromosome 
lp21.2. Co-segregation between chromosome lp and the broadly defined phenotype 
is far less consistent, with two individuals diagnosed with unipolar depression in 
families ANT03 and FAZU01 not sharing the haplotype.
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Figure 4.29: Haplotype reconstruction for a candidate region on chromosome lp  in pedigrees
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Blackened symbols represent individuals diagnosed with BPI. Individuals 238, 38 and 39 in 
family ANT03 (top), and individual 197 in family ANT19 (bottom) have a diagnosis o f major 
unipolar depression. See text for further explanations.
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Figure 4.30: Haplotype reconstruction for a candidate region on chromosome lp  in a nuclear
family forming part of pedigree FAZU01.
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The nuclear family shown here is the leftmost from pedigree FAZU01 as shown in Figure 2.2; 
blackened symbols indicate individuals with a diagnosis of BPI. Individual 36 has a diagnosis of 
major unipolar depression. See text for further explanations.
In family FAZU01, a haplotype comprising alleles at markers D11S904 to 
D ll S4191 is shared between all but one affecteds, making this an interesting region 
in this family (see Figure 4.13). This is all the more interesting because the affecteds 
in this family are quite distantly related and a haplotype shared between all affecteds 
should be a rare event in the absence of linkage.
Also of interest are the co-segregation of a haplotype on chromosome 3q with BPI in 
family ANT07 (see Figure 4.11) and that of a haplotype on chromosome 2q with the 
broadly defined phenotype in family ANT23 (see Figure 4.23). Finally, a haplotype 
on chromosome 4q shows near-perfect co-segregation with psychosis in family 
ANT14 (Figure 4.27), and a haplotype on chromosome 16p occurs in most affecteds 
under any phenotype definition in family ANT07 (Figure 4.18).
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4.7. D iscussion
I performed linkage analysis in a collection o f fifteen extended pedigrees segregating 
severe bipolar disorder from the paisa community in Colombia. In view of the 
uncertainties attached to the nosological classification of mood disorders in general, 
and BP in particular, I explored different diagnostic models for linkage analysis: a 
narrow model considering only BPI as affected, a broad model considering BPI, BPII 
and major depression as affected, and a model under which only individuals affected 
by psychosis were considered affected. As a first step, I shall therefore discuss how 
the results obtained from the different analyses compare to each other, before putting 
the findings from the present study into the context of previous reports in the 
literature.
Under the narrow model, parametric and non-parametric linkage analyses have 
yielded somewhat differing results. Regions on chromosome 21q and chromosome 
13q have been highlighted by parametric linkage analysis only, while regions on 
chromosomes 12p and q, lq , 5q and 9p have provided suggestive evidence for 
linkage in non-parametric, but not in parametric analysis. The only region supported 
by both analyses is that on chromosome lp. These discrepancies are most likely due 
to the different characteristics o f parametric and non-parametric analyses: while 
LOD score analysis is more powerful upon specification o f an (at least 
approximately) correct genetic model112, non-parametric analysis is more suitable to 
detecting signals when the mode o f inheritance is unknown115. In the context o f the 
present study, a possible interpretation is that co-segregation of loci on chromosomes 
21q and 13q with the disease phenotype, BPI, in the Antioquian families is 
compatible with the specified, near-dominant genetic model, while segregation 
patterns o f the loci identified in non-parametric analysis were more complex. On the 
other hand, the regions on chromosome 2 1  q and 13q might not have been picked up 
by the non-parametric analysis because o f lack of power.
When comparing the non-parametric analyses under the three different models, it can 
be seen that the analyses under the narrow and the broad models yielded similar 
results, i.e., several chromosomal regions were highlighted by both analyses, while 
none o f the regions identified in the study-wide analysis under the psychosis model 
overlapped with any o f the regions o f highest significance under narrow and broad
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models. This might be due to real differences between susceptibility factors 
implicated in psychosis on the one hand, and affective disorder as such on the other. 
Alternatively, the differences between findings might reflect differences between the 
samples on which the analyses are based: only eleven out of the fifteen families 
available for analysis under the narrow and broad models could be analysed under 
the psychosis model. Families FAZU01, ANT10, ANT19 and ANT26 comprised less 
than two cases o f psychosis and were therefore not included in the analysis under the 
psychosis model. Furthermore, most other families had less affecteds under the 
psychosis model than under the other two models, most notably families FAZU28, 
ANT03, ANT04 and ANT23. However, these two explanations (based on real 
aetiological differences and power issues, respectively) are not mutually exclusive. 
Some o f the regions highlighted under narrow and broad models could also be 
implicated in the aetiology o f psychosis, but might have a weak effect on 
susceptibility, thereby being more difficult to detect with a smaller sample. On the 
other hand, the fact that some regions, such as those on chromosomes 2 q and 16p, 
reach suggestive linkage only in the analysis under the psychosis model, might imply 
that there are indeed real differences in predisposition to psychosis and to mood 
disorders as such. There are very few examples in the literature of the analysis of 
psychosis as a phenotype in extended bipolar pedigrees; however, the available 
results are consistent with findings from the present study in that they implicate a 
number o f regions in the predisposition to psychosis, which have not been found to 
be linked to the phenotype o f bipolar disorder317,318, thereby strengthening the 
hypothesis that there are genetic loci conferring susceptibility to psychosis rather 
than affective disorders per se. This is also in line with the growing body of evidence 
supporting shared genetic susceptibility between bipolar disorder and 
schizophrenia16,193 (see also chapter 3).
As mentioned above, the results obtained in the analyses under narrow and broad 
models show many overlaps. Most notably, both analyses provide study-wide 
suggestive evidence for the involvement o f chromosomal regions l p l3-31, lq25-31, 
12ct-12ql4 and 12pl2-12ct in disease susceptibility. A possible explanation is that 
some o f the factors causing susceptibility to narrowly defined bipolar disorder type I, 
might also predispose to affective disorders in general, including major unipolar 
depression. This is consistent with reports that unipolar depression occurs more often
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in the first-degree relatives o f BP patients than in the general population307. There 
are, however, some regions that are only supported by one of the two analyses, such 
as chromosome 5ql 1-12, which has only been detected under the narrow model, and 
chromosomes 6 p 12-22 and 7p 15-21, for which suggestive evidence for linkage was 
provided under the broad, but not under the narrow model. This might again either be 
due to changes in sample composition (although the same families were analysed, the 
analysis under the broad model included more affecteds and should therefore have 
had more power to detect susceptibility regions), or it might reflect real differences 
in genetic predisposition to the two phenotypes. Analysis of the same linkage data 
under both narrow and broad models is common in the BP gene mapping literature; 
the most distinctive difference between the two models is usually the addition of 
recurrent unipolar depression as a phenotype under the broad model, while the 
narrow phenotype definition mostly considers only BPI, or BPI and II as affected. 
The results o f these studies are consistent with findings from this thesis in that they 
show important overlaps between the analyses under the different models, while at
1 f t  ^  A  A
the same time, some regions are only highlighted under one of the models ' . It
seems therefore likely that there are loci which confer susceptibility to developing a 
mood disorder in general, while others predispose specifically to bipolar disorder. 
This might help explain why, although unipolar depression is more common in the 
relatives o f bipolar probands, the opposite is not true307: families segregating bipolar 
disorder might carry susceptibility loci for both mood disorders in general and 
bipolar disorder in particular, while the risk o f carrying a predisposing variant for 
bipolar disorder is not elevated in relatives o f unipolar patients, in whom “only” 
genetic variants predisposing to mood disorders in general are enriched.
The most important findings o f the present study will now be discussed individually. 
Chromosome lp
Non-parametric analysis under both narrow and broad models provided suggestive 
study-wide evidence for linkage to a region on chromosome 1 p i 3.3-31.1, a region 
that was also found to be o f interest in our previous linkage scan, where markers 
D1S2868 and D1S207 produced NPL scores of 1.53 and 1.33, respectively. The 
evidence o f linkage has increased in the present genome scan, where we obtained a
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maximum NPL score of 2.13 for marker D1S2868 under the narrow model. For the 
broad model, the NPL score for this marker is even higher (2.22). The addition of a 
further nine families has therefore strengthened the evidence for the presence of a 
susceptibility locus for severe mood disorder on chromosome 1 q in Antioquia.
Chromosome lp22-31 is also the only region picked up by both parametric and non- 
parametric analyses under the narrow model. One interpretation of this consistency 
between parametric and non-parametric analyses might lie in the possibility that 
inheritance patterns in the region are consistent with the mode of inheritance 
specified for the parametric analysis, while at the same time, the signal is strong 
enough across families to be detected in the non-parametric analysis o f lesser power.
This region is also supported by previously published findings. Ewald and colleagues 
obtained a two-point LOD score o f 2.75 for marker D1S216 on chromosome lp31.1 
in a sample o f Danish BP pedigrees, using a broad affection model similar to the one 
used here . The NIMH Genetics Initiative also found significant evidence for 
linkage to chromosome 1 p 3 1.1 using affection models very similar to the ones used 
in the present study including BPI, BPII and unipolar depression (broad model), or 
only BPI/II (narrow model)326. Interestingly, the bipolar genome scan meta-analysis 
for linkage by Segurado and colleagues ranked a 30 cM-bin on chromosome lp, 
delimitated by markers D1S2742 and D1S226, third (out of 120 bins covering the 
entire genome) for significance under a narrow model, where only BPI and 
schizoaffective disorder are considered as affected205. Under a model that 
additionally included BPII, the same bin was still ranked 10th. The most significant 
marker identified here, D1S2868, lies outside this bin; however, there is an important 
overlap between the region identified in the meta-analysis and the candidate region 
found here. The fact that the region on chromosome lp31.1 has been implicated in 
bipolar disorder in a number o f other studies, as well as in a comprehensive genome 
scan meta-analysis, adds to the interest o f this finding.
Haplotype analyses o f the three families that contribute most to the linkage signal in 
this region -  families ANT03, A N TI9 and ANT27 -  revealed co-segregation of 
marker D1S206 with BPI in all three pedigrees. At the same time, families ANT03 
and ANT 19 share a haplotype comprising marker D1S206 and two additional makers 
centromeric o f the latter. The same haplotype is additionally shared by the affecteds 
o f a nuclear family belonging to pedigree FAZU01. Although the alleles forming this
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haplotype are common, with frequency estimates between 1 1 .6 % for allele 1 1  at 
marker D1S252 and 41.4% for allele 4 at marker D1S2726, the fact that these 
families stem from the same population isolate allows for the possibility o f identity 
by descent-sharing o f this haplotype. Co-segregation of a possible IBD-haplotype 
with the disease phenotype means that the shared haplotype might carry a founder 
mutation conferring susceptibility to BPI in these three pedigrees.
In conclusion, parametric and non-parametric analyses under different models, as 
well as haplotype analyses, suggest the presence of a susceptibility locus for bipolar 
disorder on chromosome lp 2 1-31 in the sample from Antioquia. The region 
identified in this study overlaps with previously reported candidate regions, although 
there is some evidence from both linkage and haplotype analyses pointing towards a 
slightly more centromeric location o f the locus identified here. In any case, there is 
accumulating evidence for an important susceptibility locus for BPI on chromosome 
lp, which has consistently been replicated in a number of different populations.
Chromosome lq
Non-parametric analysis under both narrow and broad models has yielded suggestive 
evidence of linkage to a region on chromosome lq25-31. This initially suggests a 
possible involvement o f a locus in this region in genetic susceptibility to mood 
disorders, rather than bipolar disorder as such. However, in the two families that 
contributed the highest individual NPL scores to the combined score, ANT27 and 
FAZU28, all affecteds have a diagnosis o f BPI, and it remains therefore possible that 
the locus on lq  is involved in susceptibility to BPI, and not so much to mood 
disorders in general.
A number of studies have reported linkage o f BP to loci on chromosome lq 319’327'330, 
and this region has also repeatedly been implicated in genetic susceptibility to 
schizophrenia228,331'333. Most notably, the genes encoding the regulator of G 
signalling protein, RGS4, and the nitric oxide synthase 1 (neuronal) adaptor protein, 
NOS1AP, which have both been found to be associated to schizophrenia146,229,334,335 
(see also chapter 5), are located on the long arm of chromosome 1 (lq23.3). In view 
of the possible shared genetic susceptibility to schizophrenia and bipolar disorder, 
there have been attempts to replicate the association results obtained for
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schizophrenia in bipolar disorder, and a study carried out in a Brazilian population 
has indeed found RGS4 to be associated to BP336. Later studies in Scottish and 
Ashkenazi Jewish samples, however, failed to replicate this result337,338. There are no 
published genetic association studies between NOS1AP and BP, but Xu and 
colleagues reported increased expression of the NOS1AP protein in the prefrontal 
cortex of bipolar subjects339.
Together, these results indicate that there might be at least one locus predisposing to 
both schizophrenia and BP on the long arm of chromosome 1; however, the exact 
location of that locus, and whether it is indeed the same locus that confers 
susceptibility to both disorders, is not clear. Results from this thesis place the 
candidate region for BPI on chromosome lq25-31, while previously published 
results point at slightly different locations including chromosome lq23 and lq32. 
More work remains to be done in order to establish how many susceptibility loci for 
BP there are on the long arm o f chromosome 1, and what their role might be in 
predisposition to affective disorders in general, to BP in particular, and to 
schizophrenia.
Chromosome 2q
A candidate region on chromosome 2q24-31 provided suggestive evidence for 
linkage to psychosis in the pedigree sample from Antioquia. The same region 
showed suggestive linkage to bipolar disorder in a study including families of 
German, Israeli and Italian origin; however, that study used a broad phenotype 
definition, which included BPI and II, schizoaffective disorder and recurrent unipolar 
depression340. A recent linkage study by Zandi and colleagues, found -  again 
suggestive -  evidence for linkage to chromosome 2q24 in a collection of North 
American BP pedigrees using both narrow (including BP and schizoaffective 
disorder, manic type) and broad (additionally including major depression) phenotype 
definitions341. There seem to be no published studies reporting linkage to 
chromosome 2q24-31 using psychosis as a phenotype, making this the first study to 
implicate that region in genetic susceptibility to psychosis rather than mood disorders 
in general, or bipolar disorder in particular. It is, however, of interest that a meta­
analysis of linkage studies in schizophrenia ranked a 30cM-bin adjacent to the locus
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reported here 5th for significance (out of 120 bins covering the whole genome), 
thereby corroborating the hypothesis that there might be a locus predisposing to 
psychosis on chromosome 2q228. Further work needs to be carried out in order to 
evaluate the possible role of the region identified here in BP and psychosis.
Chromosome 12q
In the present study, the most significant evidence for linkage to BP was found for a 
region on chromosome 1 2 q, stretching from the centromere to 12ql4/12q21 (for 
narrow/broad models, respectively). While a locus on chromosome 12q23-24 has 
consistently been implicated in susceptibility to bipolar disorder in a number of
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studies ’ ’ ’ , so far, there has only been one report of linkage for a locus
centromeric of that region: a French Canadian study reported suggestive LOD scores 
for chromosome 12ql3.12-ql4.1, under a recessive model of inheritance, and using a 
broad affection model including BPI, BPII, schizoaffective disorder and recurrent 
unipolar depression as affected343. However, the authors of that study conclude that 
the main susceptibility locus in their sample coincides with the previously reported 
locus on chromosome 12q23-24, where they identified two shared, possibly disease- 
carrying haplotypes in two branches o f the largest pedigree analysed in their study; 
thereby making this the first study to identify the region on chromosome 12ct-12ql4 
as the most significant finding in a genome-wide linkage scan. Also, to the best of 
my knowledge, there are no reports on candidate gene association studies for the 
region reported here. It is therefore possible that we have identified a novel locus, 
possibly one that might be o f major importance for BP susceptibility in the 
population o f Antioquia. Because this locus was supported by both narrow and broad 
analyses, it might represent a predisposing locus for mood disorders including both 
BP and major unipolar depression.
Chromosome 12p
Like the candidate region on the long arm o f chromosome 12, the candidate region 
on chromosome 1 2 p was supported by suggestive evidence for linkage in non- 
parametric analysis under both narrow and broad models. There are no previous 
reports in the literature explicitly implicating this region in the genetic susceptibility
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to bipolar disorder, neither from linkage nor from association studies, although the 
Canadian linkage study that also found linkage on chromosome 12q, reported a near- 
suggestive LOD score of 1.61 for marker D12S87 on chromosome 12pl 1.22, under a 
recessive model343. However, the authors of that study have not discussed their 
finding any further, and it is not clear what importance they attribute to it.
Like the region on chromosome 12q, the candidate region on the short arm of 
chromosome 1 2  is a novel finding, and because o f it being identified under both 
narrow and broad models, it might contain a susceptibility locus for mood disorders 
in general. On the other hand, however, it is noteworthy that the region on 
chromosome 12p is supported by linkage o f a single marker, D12S345, to the disease 
phenotype. This marker is immediately adjacent to the first marker analysed on the 
long arm o f chromosome 12, D12S85, which is part o f the candidate region on 
chromosome 12q. Recombination maps o f single chromosomes344, as well as of the 
entire human genome345,346, show a suppression o f recombination events in 
centromeres, with cross-overs concentrated towards the telomeres in males. While in 
females, recombination events near the centromeres seem to be more common344,345, 
it is nevertheless possible that a reduced recombination rate around the centromere 
leads to the chromosome 1 2 q signal stretching into the short arm of the chromosome. 
One possible interpretation of our findings is therefore that the region on 
chromosome 1 2 p does not represent an independent candidate region; instead, the 
“real” candidate region might be that on chromosome 12q. It remains, of course, 
possible that there is an additional susceptibility locus for mood disorders on 
chromosome 1 2 p l 2 -ct, and further work is needed to establish the role of 
chromosome 12p in BP.
Chromosome 13q
Parametric linkage analysis under the narrow model yielded some evidence for 
linkage o f chromosome 13q33 to severe BP. This region was not identified in the 
non-parametric analysis, possibly because o f the reduced power of that approach. 
Chromosome 13q33 has been implicated in BP through linkage analysis of a series of 
North American pedigrees347, and this finding was later confirmed in an expanded 
sample from the same North American population; although the linkage peak in that
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second study occurred on chromosome 13q32.3 rather than 13q33, it is still located 
very close to the region identified here348. Chromosome 13q is also the region that 
obtained strongest support in a meta-analysis of BP linkage scans performed by 
Badner and Gershon (2002)204. It is of interest that the DAO A gene, which encodes 
the D-Amino Acid Oxydase Activator, a protein involved in glutamatergic 
neurotransmission and which has been found to be associated with both BP and 
schizophrenia, is located in the same region172,349'352. In fact, this gene is only one of 
nine in the candidate region identified here. It would be extremely interesting to 
investigate whether association to the DAOA locus can be detected in a sample of 
unrelated bipolar patients from Antioquia.
Chromosome 16p
Marker D16S3068 on chromosome 16 p l2.1 provided suggestive study-wide 
evidence for linkage to psychosis, and family ANT07 yielded high individual NPL 
scores for markers in that region (including D16S3068) under all three phenotypic 
models (see Table 4.20). When comparing the individual NPL scores for pedigree 
ANT07 under the three models, an interesting observation is that, in spite o f the 
lower power o f analyses under narrow and psychosis models compared to that under 
the broad model (due to the reduced number of affecteds), it was under these more 
stringently defined phenotypic models that higher NPL scores for chromosome 16p 
in family ANT07 were reached. Together with the study-wide evidence for linkage in 
the psychosis analysis, this might indicate that chromosome 16p carries a 
predisposing locus for severe BPI with occurrence of psychosis.
There are numerous reports o f linkage and association of bipolar disorder to 
chromosome 16pl2-13 in the literature. While some studies have identified a locus
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telomeric o f the region found to be linked to the disease here ’ ’ ’ , there have
also been reports o f linkage to chromosome 16pl2, the same region that was 
highlighted by analyses in the present study. A sample of BP pedigrees from an 
isolated Finnish population showed linkage to that region under a broad phenotype 
definition including bipolar spectrum disorders and major unipolar depression320, and 
pedigrees from the NIMH Genetics Initiative were found to be linked to 16pl2 using 
a range o f diagnostic models including one that considered only cases o f BPI that
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had also experienced psychosis as affected318. Interestingly, chromosome 16pl2 also 
contains the SNP that shows the most significant association to BP in a whole- 
genome association scan carried out as part of the Wellcome Trust Case Control 
Consortium initiative, rs420259, located in the gene encoding the partner and 
localiscr o f BRCA2, PALB249. Taken together, there is accumulating evidence for an 
involvement of a candidate region on chromosome 16pl2 in susceptibility to BP, to 
which the findings from the present study add.
Chromosome 21q
Parametric linkage analysis under the narrow model produced suggestive evidence 
for linkage o f BPI to a candidate locus on chromosome 21q21-22. Non-parametric 
analyses failed to provide study-wide evidence for this locus; as discussed above, this 
might reflect the greater power to detect linkage using a parametric approach when 
an approximately correct model o f genetic inheritance is specified. The genetic 
model used in the parametric analysis specifies a near-dominant mode o f inheritance 
(see chapter 2.3.7), and, as discussed in section 4.3, it is far from certain, even 
unlikely, that this model holds for the inheritance of bipolar disorder per se. 
However, it has been shown that the crucial condition for parametric linkage analysis 
consists in that the specified mode of inheritance should hold at the locus under 
consideration, even though it might not be true for the disease as such121. It seems 
therefore possible that a locus on chromosome 2 1 q2 1 - 2 2  acts as a major 
susceptibility locus in the present sample, most notably so in pedigree ANT07, for 
which the LOD score at this locus was 3.21. On inspecting the reconstructed 
haplotypes for this family, however, it becomes evident that there are at least two 
haplotypes co-segregating with the phenotype; one in the left branch of the pedigree 
(shown in light blue in Figure 4.10 on page 172), and a different one in the remaining 
branches o f the pedigree (shown in dark blue/red; see also section 4.6.2.1). In view 
of the complex mode o f inheritance o f bipolar disorder, it would seem likely that, if 
there were one locus of major impact on the genetic susceptibility to the disease, it 
should be a rare event, accounting only for a minute fraction o f affecteds, and all 
affecteds in a family with a high LOD score should share one haplotype. In other 
words, in the -  perhaps unlikely, but possible -  event of there being one major locus 
responsible for the susceptibility to disease in one family, it would seem unlikely for
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the different branches o f this family to show allelic heterogeneity. This, however, is 
the case in family ANT07, thereby somewhat weakening the evidence for linkage in 
that pedigree.
On the other hand, family ANT 14 produced NPL scores suggestive of linkage under 
both narrow and psychosis models for marker D21S1914, thereby implicating the 
same locus on chromosome 21 q in disease susceptibility in that family. Additionally, 
haplotype analysis o f families ANT 14 and ANT 15 revealed that these two families 
share an allele at locus D21S1914 with the left branch o f family ANT07 (allele 3). 
Family ANT 14 and the left branch o f family ANT07 furthermore share an allele at 
the telomeric neighbouring marker D2IS 1252 (allele 8 ), while the latter and ANT 15 
share an additional allele at the centromeric adjacent marker D21S1256 (allele 1). 
Although all o f these alleles are relatively common, with population allele frequency 
estimates ranging from 10.3% for allele 8  at locus D21S1252 and 11.5% for allele 3 
at marker D2IS 1914, to 36.5% for allele 1 at marker D21S1256, the sharing o f a 
haplotype that is identical by state and that additionally co-segregates with the 
disease in three different pedigrees might indicate the presence o f a common disease- 
predisposing founder mutation at a locus on chromosome 2 1 q in these three families. 
None o f the other families have produced evidence for linkage at markers on 
chromosome 21q, and the a-value o f 0.15 corresponding to the study-wide HLOD 
score o f 2.14 at this locus further corroborates the notion that the linkage signal is 
mainly driven by the three families discussed here: ANT07, ANT14 and ANTI5. 
This heterogeneity between pedigrees, however, is to be expected in the genetic 
analysis o f a complex disease; it can indeed be seen for all other candidate regions 
discussed here.
Not surprisingly, the candidate region on chromosome 21 was also implicated in our 
previous linkage scan, which included both families ANT07 and ANT 14. Unlike the 
present genome scan, our previous study also implicated this region in BPI through 
non-parametric linkage analysis, indicating that the addition o f a further nine 
pedigrees might have introduced a somewhat increased heterogeneity with regards to 
this locus. This is also supported by the difference in a-values in parametric linkage 
analysis between previous and present linkage scan: while in our first study, we 
found an a-value o f 0.51, implying that half o f the families studied were linked to 
chromosome 21q21 (see Table 4.1), as mentioned above, a  is only 0.15 for the
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highest HLOD score identified here. Nevertheless, there continues to be very 
interesting evidence for the presence of a BPI susceptibility locus on chromosome 
21 q21 in our Antioquian pedigrees.
Evidence for linkage o f chromosome 21q21-22 to bipolar disorder has also 
repeatedly been reported in the literature. Detera-Wadleigh and colleagues found a 
LOD score of 1.85 for a region on chromosome 21q22.1 l-q22.12 in a collection of 
extended pedigrees o f European ancestry319, and a linkage study of two BP pedigrees 
from Quebec, one o f them very large, resulted in LOD scores of > 1.0 on 
chromosome 21q21.3-q22.13 (this is the same study that also provided evidence for 
linkage to chromosome 12q)343. A family study from Bulgaria yielded suggestive 
evidence for linkage around marker D21S1252353, and finally, a recent Irish study of 
affected sib pair families detected linkage to chromosome 21q21324. Interestingly, 
except for the Canadian study, the analyses yielding evidence for a locus on 
chromosome 2 1 q had been performed using a narrow definition o f the disease 
phenotype in all o f these studies, including only BPI, or BPI and II as well as 
schizoaffective disorder, but excluding unipolar depression. Where parallel analyses 
on the same data were conducted under a broader phenotype model including 
recurrent unipolar depression, evidence for linkage o f chromosome 2 1 q to the
-JA i A 1 A
phenotype was either not found , or it was weaker than under the narrow model 
This is in line with the results from the present study, where the strongest evidence 
for chromosome 21q was found under the narrow model. For family ANT 14, 
suggestive evidence for linkage was also obtained under the psychosis model, but the 
locus was not supported by the analysis under the broad model, neither for the 
complete study, nor for any individual pedigree. It therefore seems possible that a 
locus on chromosome 21q21-22 acts as a risk factor for severe bipolar disorder. This 
hypothesis is further strengthened by a finding by Lin and colleagues, who reported 
significant evidence for a locus on chromosome 21q22.13 as a susceptibility factor 
for early-onset BP354, a sub-type o f the disorder associated with increased severity of
107clinical symptoms, including higher incidence o f psychosis .
Other authors have reported evidence for the presence o f a susceptibility factor on 
chromosome 21q22.3, telomeric of the region reported here and close to the gene 
encoding the liver phosphofructokinase PFKL355'359, although not all results for that 
region are conclusive360,361. Further work is needed to determine whether there are
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indeed several distinct candidate regions on chromosome 2 1 q, and what their 
respective role is in the aetiology o f BP.
Additional candidate regions
Linkage and haplotype analyses have identified a number of additional regions that 
could be o f importance for genetic susceptibility to mood disorders in general, BP in 
particular, or psychosis. These include regions on chromosomes 2q32-33, 3q26-28, 
4q31, 5ql 1-12, 6pl2-22, 6q24-25, 7pl5-21, 9pl3-21, 10qll-22, l l q l2 ,  and 12q21- 
23. Some o f these loci, such as the regions on chromosomes 2q32-33, 3q26-27, 4q31 
and 1 lql2,  were o f importance in individual pedigrees only. Chromosomes 4q31 and 
3q28 had produced study-wide two-point heterogeneity LOD scores of 1.35 and 
1.61, respectively, in our previous linkage scan o f six families. For chromosome 
3q28, we had additionally found a NPL score o f 1.96 at marker D3S1580. These 
signals are lost in the present genome scan. This probably reflects the fact that the 
study-wide signals found on those chromosomes in the first scan were mainly driven 
by individual families (ANT27 and ANT07, respectively), and that the addition of 
further families might have introduced more heterogeneity with regards to these loci.
Regions that are implicated in individual families only might either contain 
susceptibility variants that are unique to single families, or else susceptibility variants 
that interact with other genetic factors present in these families, leading to the 
clinical phenotype only on the background of the genetic makeup of a specific 
family. A further possibility that always has to be accounted for, especially in the 
context o f the genetic dissection of complex disease, is the occurrence of false 
positive results. Where many families are involved in a linkage study, the probability 
o f obtaining high individual NPL or LOD scores is substantial even in the absence of 
linkage, making a comparison to findings from other studies all the more important.
The majority o f the regions reported above have previously been implicated in the 
genetic susceptibility to BP through linkage, and, in some cases, association analyses 
(reviewed in ref. 207). Exceptions are the regions on chromosomes 5ql 1-12, 6q24-25, 
and 9 pl 3 -2 1 , for which no previous reports o f linkage are available to the best of my 
knowledge. However, a case-control study from Taiwan reported an association 
between BP and the gene encoding the serotonin receptor 1A (HTR1A) on
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chromosome 5ql2.2362, and although other authors have found less conclusive 
results363, it might be of interest to study this gene in the Antioquian population.
The present study has implicated several chromosomal regions in the genetic 
susceptibility to bipolar disorder that were not identified in our initial linkage scan. 
Most notably, regions on chromosomes 12q, 13q and lq  have provided suggestive 
evidence for linkage in the analysis of the joint data set under the narrow model, 
which corresponds to the phenotype model used in our previous scan. These new 
findings most likely reflect the increased power to detect linkage of the expanded 
sample used in this thesis. Moreover, genetic heterogeneity between families remains 
an issue, even within a population isolate, and the addition of new families might 
indeed have introduced novel signals.
On the other hand, our first linkage scan had identified several regions which are not 
supported by the analysis o f the expanded sample. This includes regions on 
chromosome 2q33, 6q22, and 18q23, as well as the region on chromosome 5q33 on 
whose follow-up we had concentrated because o f the agreement with linkage signals 
from the Central Valley o f Costa Rica. The signals for chromosomes 2q33 and 
18q23, identified in parametric and non-parametric analysis, respectively, were only 
o f modest strength, with a HLOD score of 1.33 for chromosome 2q33 and an NPL 
score o f 1.34 for chromosome 18q (see Tables 4.1 and 4.2). These signals could 
either have been o f only minor significance in the original sample, or they might 
even have represented false positive findings. It is surprising that the signal on 
chromosome 6q22, which was relatively strong, with a parametric HLOD score of 
2.01, disappeared in the joint analysis. One reason for this might also lie in an 
increased genetic heterogeneity at this locus. However, because the signal was 
previously so strong, this explanation alone seems unlikely to account for the 
discrepancy between the two studies. An additional factor might have been the re­
analysis o f the marker D6S434, located adjacent to the microsatellite which provided 
the strongest evidence for linkage in our first study, D6S287 (see Table 4.1). In our 
first study, the occurrence o f intermediate alleles had not been taken into account for 
marker D6S434. Analysis o f the corrected genotypes shows evidence against linkage 
at that marker in family ANT04 (LOD score -2.45), formerly the family providing 
strongest support for linkage to chromosome 6q22. Because we performed multipoint
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analysis in the present study, the low LOD score for D6S434 might have pulled 
down the signal for D6S287.
An important observation is that the present study has not confirmed our previous 
findings o f a locus predisposing to severe BP on chromosome 5q31-34184. A likely 
explanation for this discrepancy lies in that in our previous linkage scan, the region 
on chromosome 5q received only moderate support from the analysis of the six 
Antioquian pedigrees alone. The maximum N P L pairs score in the region was 1.92 
for marker D5S410, lower than the most interesting NPL scores reported here. It was 
through the addition o f a further eight Antioquian pedigrees, and most importantly, 
three pedigrees from the Central Valley o f Costa Rica, that a much higher maximum 
N P L pairs  score o f 4.40 was obtained for 5q31-34. Genome-wide analysis of the 
largest o f the Costa Rican pedigrees, followed by fine mapping, had previously 
yielded suggestive evidence for the same region on chromosome 5q178,244, and 
without this pedigree, the evidence for linkage does probably not reach significance. 
This does not invalidate our earlier results for chromosome 5q; however, it suggests 
that it is not a major candidate locus in the population o f Antioquia, and that there are 
other loci that contribute more to the genetic susceptibility to BP in our sample.
Bipolar disorder is a complex disorder, which is characterised by substantial genetic 
heterogeneity. By studying pedigrees from a population isolate, we have 
endeavoured to minimise this heterogeneity. Nevertheless, none of the analyses have 
identified a region for which there is significant evidence of linkage on a genome- 
wide level. This indicates that, even within a population isolate -  and in fact, even 
within sub-isolates such as the Oriente region of Antioquia and the village of 
Aranzazu - ,  the level o f genetic heterogeneity is substantial enough to complicate the 
use o f linkage approaches in the discovery o f genetic susceptibility factors to bipolar 
disorder. This is consistent with findings from other population isolates such as the 
Amish, the Ashkenazim, and the populations o f the Central Valley o f Costa Rica and 
the Canadian province o f Quebec, where linkage approaches have apparently failed 
to yield the successes promised by the increased genetic homogeneity of these 
populations, either because no significant evidence o f linkage was found ’ ' , or 
because follow-up analyses produced conflicting results ’ . In other cases, follow-
up studies have supported initial findings, yet any interesting signals have not led to 
the identification o f a concrete susceptibility locus174,177. Although disappointing, the
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lack o f obvious linkage signals in the study o f bipolar disorder need not be 
interpreted as a failure of linkage approaches to yield interesting and important 
results. As discussed in the introduction to this thesis (see chapter 1.4.3), meta­
analyses o f genome-wide linkage scans have found several genomic regions to be 
consistently implicated in the genetic susceptibility to bipolar disorder204'206. 
Importantly, the regions highlighted in these genome scan meta-analyses did not 
always coincide with those observed to be the most significant in the individual 
studies included. This finding might be interpreted in several ways. First, the most 
significant results o f a genome scan might be of importance in a specific family or 
population only, while less prominent signals could reflect loci o f lesser impact but 
possibly o f greater consistency across studies. An alternative explanation lies in that 
any of the signals in a linkage scan might represent false positives, especially if they 
do not reach genome-wide significance. It is very common for genome-wide linkage 
scans in psychiatric disease to produce suggestive rather than significant evidence for 
linkage, and it might indeed require the comparison and meta-analysis o f such 
linkage scans to decide which of the original signals are real. It has to be stressed, 
however, that this does not invalidate the use o f linkage approaches in the context of 
complex disease; instead, it highlights the need to re-adjust how results from these 
studies should be interpreted. In the light of complex inheritance patterns, most 
individual linkage studies might not have sufficient power to detect susceptibility 
loci for psychiatric disease on their own. Nevertheless, they can -  and do, as the 
recent meta-analyses have shown -  contribute important information to the emerging 
picture o f genetic predisposition to bipolar disorder.
The results obtained in the present study are typical of a linkage study of an 
aetiologically complex and genetically heterogeneous disorder. While no significant 
evidence for linkage has been found at any analysed marker, there are a number of 
chromosomal regions for which suggestive evidence o f linkage has been detected 
under different models, and interesting patterns o f marker genotype-disease 
phenotype co-segregation have been observed in several pedigrees. The results 
reported here are therefore encouraging and will certainly contribute to our growing 
knowledge o f genetic susceptibility to BP. Nevertheless, a few limitations to the 
present study shall also be discussed. First, it is possible that our study lacked power 
to detect loci o f minor impact, or loci showing substantial heterogeneity between and
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within families, such as they are typical of genetically complex disease. Because of 
the complexity o f some o f the pedigrees included in the study, we were only able to 
perform a power analysis for the parametric approach, leaving the (probably lower) 
power o f the present collection of pedigrees for the non-parametric approach 
unexplored. This makes it difficult to judge the false-negative rate of this study. In 
the same manner, some o f the loci that we did identify might have reached genome- 
wide levels o f significance, had our pedigree sample been bigger. On the other hand, 
it was the aim of this study to generate hypotheses for further study in the population 
of Antioquia and elsewhere, and we did identify some promising candidate regions. 
Also, as has been pointed out above, it might not be possible at all to reliably identify 
loci involved in complex disease in a single linkage screen. Our results add 
significance to some o f the findings reported by other groups, and we might also 
have identified some novel loci, especially on chromosome 1 2 , which now await 
replication in additional samples.
Replication, in fact, is required for all findings from the present study: an important 
implication o f the fact that none of our results reached statistical significance on a 
genome-wide level is that some of our findings, or, in the worst case, all o f them, 
could be false positives, which have occurred by chance in the absence o f linkage. 
Although the consistency of our results with those from previous studies is very 
encouraging because it indicates that our findings are not mere products o f chance, it 
is still essential to seek replication of the results from the present study in additional 
samples from Antioquia and other populations.
A further limitation o f the present work lies in the fact that the X-chromosome has 
not been analysed. It was decided to leave this chromosome out because there was no 
indication of sex-linked segregation o f the phenotype in the pedigrees under study. 
Also, non-parametric analysis o f X-chromosome data is not straightforward and 
cannot be performed using SimWalk2. Nevertheless, complex inheritance patterns 
mean that there might be susceptibility genes of minor impact or modifier genes on 
the X-chromosomes without reflecting into a clear sex-linked transmission pattern of 
the disease. Linkage studies have found some evidence for the implication o f X- 
linked loci in BP, and there has been support for genetic association between several
yo 7genes, such as the gene encoding the monoamine oxidase A, MAO A , and BP . It
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might therefore be o f interest to perform linkage analysis on the X-chromosome in 
the Antioquian sample studied here.
4.8. Conclusion and Future Work
Linkage analysis o f a collection of fifteen extended paisa pedigrees segregating 
severe bipolar disorder has yielded suggestive evidence for the implication of a range 
of loci in genetic susceptibility to bipolar disorder in particular, mood disorders in 
general, and the experience of psychosis. The most interesting loci specific to bipolar 
disorder are chromosomes 21q21-22 and 13q33. We have also found loci that might 
predispose to mood disorders in general, including unipolar depression, rather than 
BP in particular, in our sample; the most interesting results are candidate regions on 
chromosomes l p l 3-31, lq25-31 and 12ct-12ql4. Linkage analysis using psychosis 
as the disease phenotype identified candidate regions on chromosomes 2q24-31 and 
16pl2. The fact that many o f these loci had been previously identified as 
susceptibility loci for BP in other samples, often even in several independent studies, 
is very encouraging and fosters the hope that a clearer picture of the genetic 
aetiology o f BP will emerge. On the other hand, we have also identified a novel locus 
on chromosome 1 2 q and, possibly, 1 2 p.
Most o f the candidate regions supported by the present study are several tens o f cM 
long and harbour hundreds o f genes, thereby complicating a follow-up o f this linkage 
study by candidate gene analysis. The only exception is the candidate region on 
chromosome 13q33, which contains no more than nine genes (www.ensembl.org: 
last accessed on 13/06/2008). One o f them is the DAO A gene, which has repeatedly 
been found to be associated to both schizophrenia and bipolar disorder. It will be of 
great interest to follow up this finding by sequencing the DAO A gene in the families 
analysed here, especially in families FAZU01 and ANT07, in which the LOD scores 
for this region were highest. Additionally, an association study o f that gene should be 
performed in the Antioquian population using established genetic variants as well as 
possible variation identified through sequencing in the families, to try and further 
define the role of the DAO A gene in the genetic susceptibility to BP.
In a similar manner, further candidate genes implicated in previously published 
studies and located within the candidate regions found here, such as the HTR1A gene
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on chromosome 5ql2.2, could be sequenced in the pedigrees and/or studied by 
association analysis in the Antioquian population. Association analysis of candidate 
genes can be carried out immediately, using the well-characterised sample of 
sporadic cases that has already been collected in Antioquia and that has also been 
used in the context of this thesis (see chapter 3).
Additionally, in an effort ultimately aimed at finding new candidate genes for BP, 
fine mapping should be undertaken in all o f the promising candidate regions found in 
this study by typing additional markers in those regions, and even more importantly, 
by typing additional individuals from the same pedigrees. For a number of samples 
from the pedigrees analysed here, not enough DNA was available to carry out a 
whole-genome linkage scan. However, enough DNA is left for most o f these samples 
to allow including them in a follow-up study involving few markers. The addition of 
further affected individuals increases the power o f follow-up fine mapping efforts, 
and while some regions might not gain further support, others might show more 
significant evidence for linkage, thereby guiding further attempts to identify suitable 
candidate loci. Fine mapping of the regions on chromosomes lp  and q and 12q is 
already underway.
Because none o f our findings reached statistical significance on a genome-wide 
level, it is essential to confirm the results from the present study through the analysis 
o f additional pedigree, trio or case-control samples from Antioquia, as well as from 
other populations. As a first step, an association analysis of genetic variants in the 
candidate regions with BPI should be performed in the available BP trio sample; 
however, further replication will be required. Moreover, it is of special interest to 
further investigate the role o f specific loci in the causation of the different 
phenotypes studied here. This might involve the collection o f a large sample of 
affecteds and either their parents or matched controls, allowing enough power to 
study BP with and without psychosis separately in an association approach (the latter 
possibly combined with schizophrenia), in order to test the hypothesis that at least 
partly different loci are responsible for the causation of these phenotypes. It would 
naturally also be o f great interest to study further family samples, but it might not be 
realistic to hope for the identification of an additional collection of large and equally 
heavily BPI- and psychosis-loaded pedigrees in the paisa population.
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While it could be argued that our findings should be replicated before attempting to 
fine map specific regions and identify candidate genes, replication requires the 
collection o f additional samples and is therefore a task for the medium to long term. 
Other follow-up work, on the other hand, can be carried out immediately using the 
available pedigree and trio samples: fine mapping and sequencing of previously 
reported candidate genes, as well as testing previously reported genes for association 
in our trio sample will therefore represent the short-term goals to aim for, while long­
term goals lie in the replication o f our findings in additional samples, as well as the 
identification o f susceptibility genes within the candidate regions identified here.
A further approach to be pursued in our collection o f paisa pedigrees segregating BP 
is the analysis o f linkage to endophenotypes o f the disorder. The endophenotype 
approach is based on the concept that, while the behavioural outcome o f psychiatric 
disease is extremely complex, there are simpler phenotypes on a lower physiological 
level that are associated with the disease. Such internal phenotypes, or 
era/ophenotypes, are thought to be closer to the genetic basis of the disease, and 
linkage analysis o f these traits holds the promise of being more straightforward 
because o f a simpler genotype-(endo)phenotype relationship368,369. While 
endophenotypes are only starting to be explored in BP, they have already been 
studied for a long time in schizophrenia. An example is eyetracking dysfunction, 
where affected individuals have difficulties in the smooth visual pursuit o f moving 
objects. As is characteristic for an endophenotype, this trait is not only associated 
with the disorder, it is also significantly more common in unaffected relatives of 
schizophrenia patients than in the general population369.
In collaboration with UCLA and Universidad de Antioquia, we have recently started 
a project aiming at establishing endophenotypes in bipolar disorder and subsequently 
conducting linkage analysis to these traits in bipolar families from Antioquia and the 
Central Valley o f Costa Rica. The families investigated as part o f this new project are 
extended versions o f some o f the pedigrees involved in this study (including ANT04, 
ANT07 and ANT 10), and it shall be of great interest to see whether the results will 
be consistent with the ones obtained here.
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C h a pt e r  F iv e
T r a n sm iss io n  D is t o r t io n  A n a ly s is  O f A  
S c h iz o p h r e n ia  T r io  S a m p le  F ro m  
A n t io q u ia  A t  T h e  NOS1AP Locus
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5. Transmission distortion analysis of a schizophrenia trio 
sample from Antioquia at the N O S1A P  locus
5.1. NOS1AP  as a Candidate Gene for Schizophrenia
Linkage studies o f families with schizophrenia have identified several potential 
susceptibility regions throughout the ge n o m e 172’228>230«331>370-372 One of the most 
promising linkage findings in schizophrenia to date was reported by Brzustowicz and 
colleagues, who carried out a whole genome scan in a collection of 2 2  extended 
Canadian pedigrees segregating schizophrenia and schizoaffective disorder and 
found a maximum parametric multipoint LOD score o f 6.5 for a region on 
chromosome lq21-23331. This finding is supported by several other studies involving 
independent pedigree collections o f Caucasian origin. Shaw and colleagues reported 
a heterogeneity LOD score of 2.4 for marker D1S196 on chromosome lq24 for 70 
families from the U.S.A. and Europe373, and interestingly, the same marker produced 
a HLOD score o f 3.2 in a sample of British and Icelandic schizophrenia pedigrees332. 
Finally, a Taiwanese study o f 45 schizophrenia sib pairs found an estimated 
proportion of IBD sharing o f 57% (p-value 0.03) at marker D1S1679, the same 
marker which showed the most significant evidence of linkage in the Canadian 
study374. The consistency o f linkage findings for chromosome lq21-23 is further 
stressed by the results o f a recent comprehensive meta-analysis including 2 0  
genome-wide linkage scans o f schizophrenia families, which found evidence for the 
presence o f a schizophrenia susceptibility locus in this region228.
Chromosome lq23 harbours several potential susceptibility genes for schizophrenia, 
including the Regulator o f G Protein Signalling 4 (RGS4), the U2AF Homology 
M otif Kinase 1 (UHMK1), and the Nitric Oxide Synthase 1 (neuronal) Adaptor 
Protein (NOS1AP; also called CAPON). Fine mapping o f a 15 cM interval on 
chromosome lq23 in the Canadian sample confirmed the previously obtained LOD 
score o f 6.5 and narrowed the candidate region down to 3 cM (~1 Mb)375. Both 
UHMK1 and RGS4 lie outside this narrow region, and LD analysis o f genetic 
markers across the original linkage peak in the Canadian family sample yielded
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significant evidence o f association between SNPs within the NOS1AP gene and 
schizophrenia (minimum p-value 0.0016)334.
The NOS1AP gene is not only a prime positional candidate gene for schizophrenia; it 
is also an interesting functional candidate due to its role in the glutamatergic 
neurotransmission system. Glutamatergic neurotransmission was first implicated in 
the aetiology o f schizophrenia when it was discovered that subanaesthetic doses of 
dissociative anaesthetics, such as phencyclidine and ketamine, induce negative 
symptoms and cognitive deficits in healthy volunteers that are clinically 
indistinguishable from schizophrenia376. Phencyclidine and ketamine were known to 
act as non-competitive antagonists o f N-methyl-D-aspartate sensitive glutamate 
receptors (NMDARs); the observation that this antagonistic action could lead to 
schizophrenia-like symptoms laid the foundation for the NMDAR hypofunction 
hypothesis o f schizophrenia. This hypothesis postulates that a reduced function of the 
NMDAR on corticolimbic GABAergic neurons is at the root of negative, cognitive 
and, as a downstream effect, positive symptoms, and that NMDAR hypofunction 
also triggers the cortical atrophy that is characteristic of schizophrenia376. The 
NMDAR hypofunction hypothesis has gained further support through 
pharmacological studies, which found that administration o f NMDAR agonists, such 
as glycine and D-serine, to schizophrenic patients led to a significant improvement of 
negative and cognitive symptoms377.
The protein encoded by the NOS1AP gene has been shown to act within the pathway 
of NMDAR mediated neurotransmission. Intracellular NMDAR induced signal 
transmission relies on the interaction of the receptor molecule with the neuronal 
Nitric Oxide Synthase (nNOS) through a mediator protein, PSD95. The NOS1AP 
protein competes with PSD95 for interaction with nNOS and is thought to be 
involved in the regulation o f nNOS activity in the neuron378. Dysregulation of 
NOS1AP availability might lead to a disruption of signalling processes following 
glutamatergic neurotransmission downstream o f the NMDAR, thereby possibly 
eliciting a similar effect to that o f NMDAR hypofunction. In line with a possible role 
for abnormal NOS1AP expression in schizophrenia, Xu and colleagues have recently 
identified a short isoform o f the NOS1AP protein and shown its increased expression 
in the schizophrenic brain in comparison to healthy subjects in a post-mortem brain 
study339.
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In an effort to further characterise the role o f NOS1AP in schizophrenia, several 
studies have evaluated association between markers across the gene region and the 
disorder. A study o f Han Chinese detected significant association between a 
synonymous SNP located in exon 9 of the gene, rs348624, and the disorder (p = 
0.000017)379; however, the results from Canada and China could not be replicated in 
a large British sample380. It is therefore of interest to examine a possible association 
in additional independent samples.
In an evaluation o f candidate genes, our group analysed D1S1679, a microsatellite 
marker 23.5 kb downstream o f the NOS1AP gene, in a trio sample from Antioquia 
and found a significant association o f this marker with schizophrenia (p = 0.019)381. 
To further evaluate this association, I examined the same collection of 102 
Antioquian schizophrenia trios with a dense set of SNPs spread throughout the 
NOS1AP gene and performed single-marker as well as haplotype-based TDT 
analyses. In view o f the psychopathological heterogeneity o f schizophrenia, I also 
used a dimensional approach to evaluate association between clinical features and the 
NOS1AP gene. This dimensional approach was developed together with Dr Jenny 
Garcia from Universidad de Antioquia in Medellin and will be explained in greater 
detail in the following section.
5.2. Clinical Dimensions of Schizophrenia
As discussed earlier, schizophrenia is a clinically heterogeneous disorder. Age of 
onset, inter-episode recovery, and symptom constellations can vary widely between 
patients, and two patients with the same diagnosis of schizophrenia might in fact not 
share a single symptom13,212. It seems therefore likely that the diagnostic category of 
“schizophrenia” encompasses several distinct disease entities with different, yet 
probably related, aetiologies (see chapter 1 ); and the psychopathological 
heterogeneity o f the disorder known to us as schizophrenia is likely to reflect the 
genetic heterogeneity underlying its aetiology. One possible way o f unravelling this 
heterogeneity lies in the use o f clinical dimensions. The concept of clinical 
dimensions is based on the notion that there are symptomatic complexes coexisting 
within the disorder, which vary across affected individuals and which can be 
quantified by using clinical scales measuring the prominence o f each symptom
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complex in affecteds382,383. The rationale for the use of clinical dimensions, rather 
than the diagnosis o f schizophrenia, as a phenotype in gene mapping studies is that 
there should be fewer genes contributing to each dimension than to the disorder as 
such, thereby facilitating the identification of these genes.
There are a number o f examples o f studies using the dimensional approach in the 
literature. The His452Tyr polymorphism in the gene encoding the serotonin receptor 
HTR2A has been found to be associated to affective symptoms of schizophrenia384, 
and negative symptoms o f schizophrenia have been reported to be associated with 
the number o f copies o f a CAG repeat within the hKCa3 potassium channel 
gene385,386, with a specific allele of a microsatellite within the gene encoding the 
brain-derived neurotrophic factor (BDNF)384, and with a haplotype in the 
dystrobrevin binding protein 1 gene (DTNBPl)m . While these results will need to be 
replicated in independent samples, they represent encouraging examples of the 
feasibility o f the dimensional approach in identifying susceptibility genes for 
complex disease. We therefore decided to use this approach in addition to the 
categorical one in assessing association between the NOS1AP gene and 
schizophrenia in the sample from Antioquia.
The clinical dimensions used in this study were obtained from the Scales of 
Assessment o f Positive and Negative Symptoms (SAPS and SANS)388'390 by factor 
analysis. The SANS and SAPS were applied to all schizophrenic patients by an 
experienced psychiatrist. To comply with the minimum sample size recommended 
for factor analysis391,392, the scales were also applied to an additional sample of 150 
schizophrenic patients diagnosed according to the same diagnostic criteria as the 
patients belonging to the trio sample (see chapter 2.1.1) and with similar clinical 
parameters. However, these additional individuals were not available for genotyping. 
On the other hand, the SANS and SAPS could only be applied to 98 out of the 102 
patients available for genotyping, making for a total sample of 248 for factor analysis 
and 98 for the genetic analysis o f the clinical dimensions (see below).
Dimensional scores were obtained by principal component factor analysis performed 
on the individuals items o f the SANS and SAPS. Sampling adequacy was evaluated 
using the Kaiser-Meyer-Olkin measure (KMO)393. The resulting KMO of 0.89 
indicated good variable factorability (i.e., the variables under study have a low partial 
correlation coefficient). Factor analysis was then performed using the programme
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SPSS 13.0 (SPSS Inc.), using the Scree criterion for factor selection394. In order to 
assign items to factors, only the items with a loading of 0.40 or greater were taken 
into account. The factor solution was then rotated (using the VARIMAX procedure) 
and factor scores calculated using regression. All factors had eigenvalues > 1.0, 
indicating that they account for more variance than any single SANS or SAPS item. 
The resulting dimensions and the factor loadings are presented in Table 5.1. The 
dimensions are: (1) affective flattening and alogia; (2) auditory, somatic and visual 
hallucinations, and first rank and paranoid delusions; (3) formal thought disorders; 
(4) avolition and social isolation; (5) bizarre behaviour; and (6) olfactory 
hallucinations and other delusions.
After factor analysis, dimensional scores were calculated for each patient. These 
scores represented the trait, or phenotype, input for the quantitative genetic 
association analysis using the QTDT programme277,395. Trait values should follow a 
normal distribution for analysis with the QTDT programme (Gonsalo Abecasis, 
personal communication); therefore, the dimensional scores were normalised before 
quantitative TDT analysis. To achieve this, all 98 individuals were ranked based on 
their dimensional score. Ranks were converted to percentiles [rank / (N + 1), where 
N is the number o f individuals], and z-scores were obtained using the inverse 
standard normal cumulative distribution. The z-scores were then used as input for the 
quantitative genetic association analysis (see section 5.3.2).
The factor analysis, and the normalisation of the resulting dimensional scores were 
performed by Dr Jenny Garcia at Universidad de Antioquia, Medellin.
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Table 5.1: Clinical dimensions obtained from SANS and SAPS by factor analysis.
1 2
Dimension 
3 4 5 6
Eigenvalue 12.5 7.3 3.7 2.04 1.9 1.5
% of variance 25.1 14.7 7.3 4.1 3.7 3
Items Facial expression 0.80 0.05 0.003 0.37 0.03 0.004
Spontaneous movements 0.83 0.01 -0.04 0.23 0.02 -0.09
Expressive gestures 0.84 0.04 -0.05 0.34 0.01 0.01
Eye contact 0.79 0.04 0.09 0.20 0.17 -0.10
Affective non-responsiveness 0.79 0.04 0.001 0.34 0.09 0.005
Vocal inflections 0.84 -0.009 0.02 0.27 0.07 0.11
Poverty of speech 0.74 -0.09 0.13 0.19 0.35 -0.03
Poverty of content 0.64 -0.10 0.31 0.27 0.24 0.10
Blocking 0.49 0.09 0.33 -0.08 0.25 0.05
Latency of response 0.71 -0.02 0.14 0.07 0.27 -0.13
Grooming and hygiene 0.38 0.07 0.13 0.34 0.42 0.17
Impersistence at work 0.23 -0.01 0.04 0.60 0.20 0.08
Physical anergia 0.37 0.08 0.07 0.64 0.01 -0.04
Recreational interests 0.36 0.16 0.07 0.71 0.073 -0.04
Sexual interest 0.38 0.05 0.02 0.66 0.01 0.05
Intimacy and closeness 0.38 0.12 0.11 0.67 0.15 0.07
Relationship with friends 0.37 0.11 0.08 0.72 0.03 0.03
Social inattentiveness 0.49 0.001 0.34 0.33 0.42 0.02
Inattentiveness during testing 0.30 -0.05 0.26 0.29 0.46 0.03
Auditory hallucinations -0.13 0.72 0.06 0.24 0.16 0.07
Voices commenting -0.20 0.75 0.11 0.16 0.09 -0.03
Voices conversing -0.08 0.75 0.16 0.15 0.08 0.09
Somatic hallucinations 0.03 0.51 0.12 0.18 0.13 0.41
Olfactory hallucinations 0.01 0.29 0.05 0.26 0.06 0.48
Visual hallucinations -0.02 0.50 0.06 0.12 0.19 0.39
Persecutory delusions -0.07 0.75 0.04 0.16 0.17 0.12
Delusions of jealously 0.08 0.05 -0.03 -0.12 0.16 0.55
Delusions of guilt -0.12 0.08 0.02 0.0001 0.12 0.46
Grandiose delusions -0.05 0.08 0.06 0.03 0.05 0.61
Religious delusions 0.002 0.19 0.04 -0.02 -0.09 0.68
Somatic delusions 0.002 0.37 0.17 0.15 0.07 0.52
Delusions of reference -0.07 0.71 -0.04 0.09 0.17 0.11
Delusions of being controlled 0.06 0.77 0.19 0.01 0.06 0.16
Delusions of mind reading 0.14 0.78 0.06 -0.08 -0.004 0.12
Thought broadcasting 0.14 0.75 0.07 -0.13 -0.01 0.07
Thought insertion 0.13 0.78 0.04 -0.03 0.004 0.13
Thought withdrawal 0.15 0.77 0.06 -0.14 -0.06 0.10
Clothing and appearance 0.24 0.21 0.23 -0.12 0.57 0.07
Social and sexual behaviour 0.22 0.25 0.17 0.08 0.59 0.15
Aggressive behaviour 0.09 0.26 0.02 0.13 0.49 0.20
Stereotyped behaviour 0.19 0.11 0.05 0.21 0.54 0.29
Derailment 0.26 0.21 0.74 0.08 0.01 0.22
Tangentiality 0.27 0.16 0.66 0.15 0.06 0.26
Incoherence 0.27 0.04 0.76 -0.01 0.08 0.11
Illogicality 0.25 0.14 0.71 0.02 -0.005 0.19
Circumstantiality -0.19 0.14 0.68 -0.04 0.05 -0.07
Pressure of speech -0.26 0.10 0.60 0.09 0.04 0.04
Distractible speech 0.16 -0.04 0.61 0.16 0.33 -0.06
Clanging -0.06 0.04 0.54 0.07 0.26 -0.15
Inappropriate affect 0.17 0.09 0.48 -0.05 0.51 -0.06
Item loadings after VARIMAX rotation. An item contributes to a dimension if its loading value 
is > 0.4 (indicated by bold type). The dimensions are: 1, affective flattening and alogia; 2, 
auditory, somatic and visual hallucinations, and first rank and paranoid delusions; 3, formal 
thought disorders; 4, a volition and social isolation; 5, bizarre behaviour; 6, olfactory 
hallucinations and other delusions.
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5.3. M aterials and M ethods
The study sample, the diagnostic procedures and the statistical analyses have been 
described in detail in chapter 2. It is therefore the main aim of this section to provide 
details on marker selection and genotyping methods, and to give a brief overview 
over the data analysis.
5.3.1. M arker Selection  an d  G enotyping
24 SNP markers covering 314 kb across the NOS1AP gene region were genotyped in 
this study. A schematic overview of the markers chosen and their location with 
respect to NOS1AP is given in Figure 5.1. The 24 markers included 9 SNPs from the 
original association study of NOS1AP334 (numbers in brackets refer to SNP 
numbering as in Figure 5.1): rsl572495 [#3], rsl538018 [#4], rs945713 [#5], 
rs l4 15263 [#7], rs3924139 [#8], rs4145621 [#11], rs2661818 [#16], rs3751284 
[#17], and rs348624 [#22], and additional SNPs selected from evolutionary 
conserved regions within or close to NOS1AP396: rs 12090585 [#1], rsl 1579080 [#2], 
rs6664602 [#6], rs4592244 [#9], rs4657179 [#10], rs4656362 [#12], rs6680461 
[#13], rs4657181 [#14], rsl0800405 [#15], rsl504430 [#18], rsl7468951 [#19], 
r s l2122048 [#20], rs905720 [#21], rsl 123005 [#23], rsl 1806859 [#24].
Figure 5.1: Location o f all genotyped markers along the NOS1AP  gene region,
10 kb
910
This figure shows all markers genotyped in the present study, including markers rs6664602 (#61 
and rs4656362 [#12] that were later excluded from all analyses (see text). The locations of 
NOS1AP  exons are indicated by black boxes; exon numbers are in italics. Consecutive marker 
numbers from 1 to 24 are included for easier comparison with the LD plot in Figure 5.2. 
Markers significantly associated with schizophrenia in Brzustowicz et al. (2004)334 are labelled 
with an asterisk.
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Genotyping for all but one marker (rs 1415263) was conducted by our collaborators 
on this project at Rutgers University, U.S.A.; the genotyping method used by them 
for this project is based on a ligation detection assay397,398. Clean genotypes were 
sent to our laboratory for data analysis.
Genotyping for marker rs 1415263 was performed in our laboratory using the 
SNaPshot® genotyping kit (Applied Biosystems). The SNaPshot® system is a primer 
extension-based genotyping method that allows the multiplex typing of up to 10 
SNPs. This system was chosen because it enabled us to genotype the SNP rs 1415263 
together with four other SNPs that were used in a different project.
In SNaPshot® genotyping, the genomic DNA containing the SNP is first amplified 
by PCR. In a second step, an extension primer and the four different ddNTPs, each 
labelled with a different fluorescent dye, are added to the cleaned-up PCR product. 
The extension primer comprises a -2 0  bp-sequence matching the sequence of the 
PCR product directly adjacent to the polymorphic site, and a universal tail o f variable 
length, which can be adjusted to distinguish the different products of the multiplex 
assay from each other. In the primer extension reaction, the ddNTP that matches the 
polymorphic site is added to the 3’ end o f the extension primer. After denaturing, the 
product o f the extension reaction is run on a capillary sequencer, where the detection 
of the different fluorescent labels enables genotyping (one peak is detected for 
homozygotes, two peaks o f different colours are detected for heterozygotes). The 
position o f the peak corresponds to the length of the extended SNaPshot® primer.
A 209 bp-fragment containing rs 1415263 was amplified from genomic DNA using a 
standard PCR mix, as shown in Table 2.4. PCR primers were designed by using the 
Primer3 program as described in chapter 2.2.3. Primer sequences were as follows:
forward primer: 5 ,-CAGTGCCTCAGTGCTTTGTT-3 ’
reverse primer: 5 ’ -CT A AAT GGT G AGCCCC A AT G-3 ’
PCR cycling conditions were as listed in Table 2.5, except for the annealing 
temperature, which was 57°C.
After checking the amplification success by agarose gel electrophoresis as described 
in chapter 2.2.4, the PCR product was cleaned in preparation for the SNaPshot® 
reaction. This clean-up step is equivalent to the one used before sequencing (see 
chapter 2.2.6). 2.5pl (2.5U) SAP and 0.1 pi (1U) Exo-I (both USB Corporation) were
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added to lOjil PCR product and topped up with 6H 2O to a total volume of 20pl. The 
mix was then left to incubate for lh  at 37°C, followed by 15min at 72°C for enzyme 
deactivation.
1.6pi o f the clean PCR product were carried forward to the SNaPshot® reaction, 
which was performed following the manufacturer’s instructions. The extension 
primer was designed using the Jellyfish™ vl.5  program (Labvelocity) taking into 
account the following criteria:
• The extension primer must anneal adjacent to the polymorphic site.
• The optimal length o f the extension primer is between 15 and 25bp
(excluding the universal tail).
•  Its GC content should be between 40 and 60%.
• The extension primer should have no more than 4bp self-complementarity.
• If  mismatches are to be incorporated, the 3’ bp (adjacent to the 
polymorphism) must not be a mismatch.
The extension primer used to type SNP rs l415263 had the following sequence:
5’-(GACT)i0TTCCCTATTCCTTTATC-3’
After the SNaPshot® reaction, the samples were sent to the Centre of Comparative 
Genomics, where they were run on an ABI 3730x1® genetic analyser (Applied 
Biosystems). The resulting raw data was sent back to our lab, and genotype analysis 
was performed with the GeneMapper® v3.7 software, using its inbuilt SNaPshot® 
analysis routine. All genotypes were visually checked by two independent 
researchers, including the author o f this thesis (“double scoring”). Upon 
disagreement between the two scorers, a single attempt was made to re-genotype the 




The methods used for the statistical analysis of the data collected as part of this 
project have been presented in detail in chapter 2.3. Briefly, the genotype data were 
checked for Mendelian inconsistencies using PedCheck268. Hardy-Weinberg 
equilibrium was evaluated separately in founders and cases using the Genepop 
program266, and allele frequencies of non-transmitted alleles were estimated using 
TDTPHASE v.2.4275.
The Transmission Disequilibrium Test (TDT)154 for single markers was carried out 
as implemented in the TRANSMIT program, version 2.5.4.155.
Linkage disequilibrium across the NOS1AP gene was evaluated using Haploview 
v3.2276 based on parental genotypes. To compare the LD structure in the Antioquian 
sample to the LD structure in the European population, to which the Antioquian 
population is very close with 80% autosomal European ancestry182, the CEU 
HapMap data for the same region was downloaded from the HapMap project website 
(http://www.hapmap.orgL and the LD plot was also displayed in Haploview. Regions 
with the highest levels o f linkage disequilibrium were used for haplotype-based TDT 
with WHAP v.2.09274 as described in chapter 2.3. Because WHAP only accepts data 
from parent-offspring trios or duos and cannot accommodate other relatives, WHAP 
analyses included only 99 index cases: 38 complete trios and 61 duos. Two tests 
were performed: an omnibus haplotype test (testing the effects across all haplotypes) 
and a specific haplotype test (testing the effect of each haplotype against all others).
Quantitative TDT analysis was carried out on the normalised dimensional scores (z- 
scores; see section 5.2) using the QTDT v.2.5.1 programme277. As mentioned above, 
four o f the index cases had no quantitative data available; thus reducing the sample 




All markers tested were found to be in Hardy-Weinberg equilibrium, with exception 
o f marker rs4656362 [#12] (p = 0.0197) (see Table 5.2). Marker rs6664602 [#6] was 
found not to be polymorphic in the Antioquian population. These two markers were 
therefore excluded from all further analyses.
Table 5.2: Results of the Hardy-Weinberg equilibrium test in 23 SNPs across the N O S1A P  gene 
region in the schizophrenia trio sample from Antioquia.
Locus
Founders (parents) Schizophrenia patients
p-value s.e. p-value s.e.
rsl2090585 0.077 0.0029 0.841 0.0019
rsll579080 0.835 0.002 0.545 0.0043
rsl572495 0.674 0.002 1.000 0
rsl538018 0.847 0.0019 1.000 0
rs945713 1.000 0 0.364 0.0054
rsl415263 0.739 0.0031 0.227 0.0045
rs3924139 1.000 0 0.207 0.0048
rs4592244 1.000 0 0.204 0.0047
rs4657179 0.589 0.003 0.373 0.0033
rs4145621 0.712 0.0036 1.000 0
rs4656362 0.020 0.0015 0.821 0.002
rs6680461 0.443 0.0051 0.546 0.0039
rs4657181 0.850 0.0018 0.223 0.0044
rsl0800405 1.000 0 0.411 0.0045
rs2661818 0.695 0.0033 0.140 0.0042
rs3751284 0.864 0.002 0.288 0.0051
rsl504430 0.334 0.0052 0.263 0.0054
rsl7468951 0.577 0.0039 1.000 0
rsl2122048 0.709 0.0033 1.000 0
rs905720 0.685 0.0031 0.137 0.0031
rs348624 1.000 0 0.367 0.0033
rsll23005 1.000 0 0.783 0.0018
rs l1806859 0.494 0.0039 0.067 0.0025
Global Test3 (44 d.f.) 0.9892 - 0.6754
"Excludes marker rs!415263, which has been tested separately.
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5.4.2. Linkage Disequilibrium Analysis
The pattern of LD between the SNPs genotyped in the Antioquian sample, as 
determined by Haploview, is represented in Figure 5.2. Two regions of strong LD are 
apparent, the first one covering markers rs945713 [#5] to rs2661818 [#16], spanning 
129.1 kb and comprising introns 2 and 3 of NOS1AP (region 1), the second one 
covering markers r s l504430 [#18] to rs348624 [#22] and spanning 5.1 kb mostly 
within intron 8 (region 2). For comparison, the LD structure of the European 
HapMap population (CEU) in the same region is displayed in Figure 5.3. It shows 
great similarity to the pattern seen in the Antioquian sample, with two regions of 
high LD in the same location as observed in Antioquia.
Figure 5.2: LD structure between 22 genotyped SNPs across the NOS1AP  gene in the 
Antioquian trio sample.
8 X ® A
T O *  c
Marker numbers (1 to 24) are as in Figure 5.1. Values in the boxes refer to %  D \  Where no 
number is shown, D ’=1.0. Red and pink boxes indicate a LOD score of > 2.0 (D’ significant); 
blue and white boxes indicate a LOD score of < 2.0 (D’ not significant).
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Only HapMap SNPs also genotyped in this study arc shown. Since not all SNPs included here 
are HapMap SNPs, the set o f SNPs displayed for the European population is smaller than the 
one typed in the Antioquian population. Marker numbers (1 to 24) are as in Figure 5.1. Values 
in the boxes refer to % D \  W here no number is shown, D’=1.0. Red and pink boxes indicate a 
LOD score o f > 2.0 (D ’ significant); blue and white boxes indicate a LOD score of < 2.0 (D’ not 
significant).
5.4.3. Single m a rk e r  a sso c ia tio n  te s ts
The results of the single marker TDT are summarised in Table 5.3. Of the 22 SNPs 
examined, eight showed significant association to schizophrenia (overtransmitted 
alleles are shown in parentheses): rs945713 [#5] (G), rs 1415263 [#7] (T), rs3924139 
[#8] (T), rs4592244 [#9] (A), rs4145621 [#11] (C), rs6680461 [#13] (G), rs4657181 
[#14] (A), and rs3751284 [#17] (T). For all eight markers, both the p-value based on 
the chi-squared approximation and the bootstrap p-value are nominally significant. 
Of these eight markers, seven are in high LD with each other and are located in LD 
region 1, while the remaining marker, rs3751284 [#17], is not in strong LD with any 
other marker (Figure 5.2).
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Tabic 5.3: Single marker TDT (TRANSMIT) for 22 SNPs within the CAPON gene.
SNP #* allele allelefrequency1 O E Var(O-E) X* (ld.f.) p-value
bootstrap
p-valuec
G 0.667 132 132.98
rsl2090585 1 19.558 0.0487 0.825 0.820
A 0.333 68 67.024
G 0.623 110 109.87
rsl 1579080 2 13.812 0.0012 0.972 0.970
T 0.377 64 64.129
G 0.907 180 182.74
rsl572495 3 8.5861 0.8728 0.350 0.397
A 0.093 24 21.263
G 0.650 146 142.31
rsl538018 4 18.396 0.7392 0.390 0.392
C 0.350 60 63.688
G 0.470 120 109.93
rs945713 5 18.947 5.3500 0.021 0.011
A 0.530 82 92.068
C 0.478 87 97.35
rsl415263 7 19.523 5.4866 0.019 0.015
T 0.522 117 106.65
C 0.426 95 105.48
rs3924139 8 18.506 5.9341 0.015 0.007
T 0.574 107 96.521
G 0.426 95 105.48
rs4592244 9 18.506 5.9341 0.015 0.007
A 0.574 107 96.521
G 0.802 164 165.42
rs4657179 10 13.308 0.1518 0.697 0.704
T 0.198 40 38.579
C 0.570 138 126.19
rs4145621 11 18.856 7.3991 0.007 0.004
T 0.430 64 75.812
T 0.740 136 144.44
rs6680461 13 15.679 4.5391 0.033 0.028
G 0.260 68 59.564
A 0.567 143 131.54
rs4657181 14 19.618 6.6972 0.010 0.006
T 0.433 63 74.462
C 0.724 132 139.15
rsl0800405 15 15.149 3.3715 0.066 0.053
G 0.276 66 58.853
C 0.651 128 124.71
rs2661818 16 16.631 0.6498 0.420 0.391
G 0.349 62 65.287
C 0.638 105 114.27
rs3751284 17 20.327 4.2276 0.040 0.019
T 0.362 95 85.73
C 0.681 129 134.41
rs l504430 18 19.001 1.5430 0.214 0.254
T 0.319 75 69.585
A 0.639 139 136.23
rsl7468951 19 18.138 0.4228 0.516 0.538
G 0.361 65 67.769
G 0.633 138 135.1
rsl2122048 20 17.474 0.4817 0.488 0.469
A 0.367 64 66.901
C 0.696 143 139.31
rs905720 21 16.922 0.8057 0.369 0.389
T 0.304 59 62.692
C 0.845 171 171.12
rs348624 22 11.231 0.0013 0.971 0.977
T 0.155 33 32.877
A 0.854 169 173.3
rsll23005 23 11.254 1.6394 0.200 0.283
A 0.718 55 56.138
G 0.282 147 145.86
r s l1806859 24 15.976 0.0810 0.776 0.801
A 0.718 55 56.138
aSNP number as in Figure 5.1. bin untransmittcd chromosomes; Cbascd on 1000 bootstrap
samples; O, observed transmissions; E, expected transmissions; d.f., degree of freedom. 
Nominally significant x 2- and p-values are italicised and bold. Markers belonging to LD regions 
1 (above) and 2 (below) arc shaded.
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5.4.4. Haplotype association
Haplotype analyses were carried out based on the two LD regions shown in Table 5.3 
and Figure 5.2. The results of association tests for LD region 1 (markers rs945713 
[#5] to rs2661818 [#16]) are shown in Table 5.4. The omnibus haplotype test 
resulted in a p-value o f 0.348, indicating no significant overall association of this 
region with schizophrenia. In the specific haplotype test, the p-value for the most 
common haplotype was 0.04 with an odds ratio of 0.54, indicating a possible trend 
towards (negative) association between this particular haplotype and schizophrenia. 
For five of seven markers in LD region 1, the haplotype showing possible negative 
association consisted o f alleles found to be undertransmitted in the single marker 
analyses (rs945713 [#5] -  A; rs3924139 [#8] -  C; rs4145621 [#11] -  T; rs6680461 
[#13] -  T; and rs4657181 [#14] -  T). No significant association was detected 
between LD region 2 (markers r s l504430 [#18] to rs348624 [#22]) and 
schizophrenia (data not shown).
2 4 3
Table 5.4: Results of the transmission disequilibrium test of the haplotype containing the ten 






































































1 A C T A G T T T C G 0.281 reference haplotype 0.54 0.04
2 G T C G T C G A G C 0.131 1.79 0.73 4.37 1.13 0.75
3 G T C G G C G A G C 0.096 2.29 0.85 6.18 1.48 0.38
4 G T c G G c T A C C 0.084 3.37 1.21 9.40 2.24 0.09
5 G T c G G c T T C G 0.059 3.40 1.07 10.82 2.22 0.14
6 A T c G G c G A G C 0.056 1.23 0.36 4.24 0.77 0.65
7 A C T A G c T A C C 0.053 1.67 0.43 6.42 0.99 0.99
8 A C T A G T T A C C 0.048 0.63 0.16 2.40 0.39 0.15
9 G c T A G c T A C C 0.03 1.33 0.25 6.98 0.87 0.86
10 G T C G T c T A C C 0.03 1.12 0.21 5.93 0.72 0.68
11 A T c G G c T A C C 0.028 4.86 1.06 22.24 3.03 0.14
12 G C T A G T T T C G 0.027 1.55 0.25 9.78 0.88 0.88
13 G T T A G c T A C C 0.025 4.19 0.84 20.80 2.63 0.23
14 G T T A T c T A C C 0.015 3.30 0.40 27.33 2.00 0.51
15 A C T A T c G A G C 0.014 0.95 0.06 14.07 0.56 0.66
16 G T C G T c T T C C 0.013 0.92 0.08 10.21 0.59 0.65
17 G C T A G c G A G C 0.011 0.28 0.03 2.77 0.19 0.15
'Upper and lower limit of the 95% confidence interval for the OR of the omnibus test. WHAP 
does not calculate the 95% confidence intervals for the ORs of the haplotype-specific test; 
instead, a p-value is given for each of the tested haplotypes. Nominally significant p-values are 
printed in bold italics. OT, omnibus test; HS, haplotype-specific test; OR, odds ratio.
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5.4.5. QTDT analysis on clinical dimensions
The results o f the QTDT analysis on these clinical dimensions are summarised in 
Table 5.5. Since the QTDT program can only test markers for which 30 or more 
probands are informative, markers rsl 1579080 [#2], r s l572495 [#3], rs4657179 
[#10], rs348624 [#22], and rsl 123005 [#23] could not be included in the analysis. 
Nominally significant associations were obtained for the following marker- 
dimension combinations (the allele associated with increased trait values is given 
after the p-value): dimension 1 (affective flattening and alogia) with marker 
rs3751284 [#17] (p = 0.016; C), dimension 2 (auditory, somatic and visual 
hallucinations, and first rank and paranoid delusions) with marker rs 1415263 [#7] (p 
= 0.034; C), dimension 4 (avolition and social isolation) with markers rs6680461 
[#13] (p = 0.004; G) and rsl0800405 [#15] (p = 0.001; G), and dimension 6 
(olfactory hallucinations and other delusions) with marker rs6680461 [#13] (p =
0.048; C). Three o f the markers showing nominally significant p-values in the 
analysis o f clinical dimensions had also shown nominally significant p-values in the 
categorical analyses (rs3751284 [#17], rsl415263 [#7], and rs6680461 [#13]). For 
markers rs3751284 [#17] and rsl415263 [#7], the alleles associated with increased 
trait values in the quantitative analysis are different from the ones shown to be 
overtransmitted to schizophrenic patients in the categorical analysis (see Table 5.3 
and Table 5.5), whereas for marker rs6680461 [#13], the allele shown to increase the 
trait value corresponds to the overtransmitted allele in the categorical analysis (allele 
G).
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Table 5.5: Results o f the QTDT analysis for 17 SNPs in the NOS1AP gene region.
SNP Informative
trios Dim. 1
Dim. 2 Dim. 3 Dim. 4 Dim. 5 Dim. 6
rsl2090585 1 47 * * * * * *
rsl538018 4 40 * * ♦ * * *
rs945713 5 44 * * * * * *
rsl415263 7 43 * 0.034
(C)
* * * *
rs3924139 8 38 * * * * * *
rs4592244 9 38 * * * * * *
rs4145621 11 39 * * * * * *
rs6680461 13 34 * * * 0.004
(G)
* *
rs4657181 14 45 * * * * * *
rsl0800405 15 31 * • * 0.001
(G)
* *
rs2661818 16 32 « * * * * *
rs3751284 17 50 0.016
(C)
• * * * *
rsl504430 18 42 * * * * * *
rsl7468951 19 44 * * * * ★ *
rsl2122048 20 39 * * * * * *
rs905720 21 43 * * ♦ *
,  0.048 
(C)
r s l1806859 24 31 ♦ * * * * *
Overall Bonferroni significance level: 0.10; overall empirical significance level: 0.08
*SNP number as in Figure 5.1. Dim., dimension. For the explanation of the dimensions, see text 
and Table 5.1. P-values are shown for each marker/dimension combination; the allele that 
increases the trait (dimension) value is shown in parentheses. *p-value > 0.05
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5.5. D iscussion
We have found association of several SNPs in the NOS1AP gene to schizophrenia 
and to clinical dimensions of the disorder in the population of Antioquia, Colombia. 
These findings are in line with previous studies providing compelling evidence for 
the implication o f chromosome lq21-23, and in particular the NOS1AP gene, in 
schizophrenia susceptibility in the Canadian ’ and Chinese Han populations. 
Furthermore, an association between a microsatellite marker 23.5 kb downstream of 
NOSJAP, D1S1679, and schizophrenia has been observed in the population of 
Antioquia381, suggesting that the region might play a role in the aetiology of 
schizophrenia in this population.
NOS JAP is an interesting candidate gene for schizophrenia susceptibility because of 
its involvement in NMDA receptor mediated glutamatergic neurotransmission, which 
is thought to be implicated specifically in the aetiology of schizophrenia232,376. The 
observation o f association of several SNPs in the NOS1AP gene to the schizophrenia 
phenotype and also to specific clinical dimensions of the disorder confirms and 
extends the previous results from Antioquia and further strengthens the link between 
NOS JAP and schizophrenia.
O f the SNPs found to be associated with schizophrenia in our study, two were also 
found to be significant in the study by Brzustowicz and colleagues: rs 1415263 [#7] 
and rs4145621 [#11]334. Moreover, the associated allele was the same in both studies: 
the T allele o f rsl415263 [#7], and the C allele of rs4145621 [#11] (see Table 5.3). 
Interestingly, Xu and colleagues339 found the expression levels of the short NOS JAP 
isoform overexpressed in the schizophrenic brain to be associated with the T allele of 
marker r s l415263 [#7].
Most o f the SNPs found to be associated to schizophrenia in the present study are 
located within LD region 1. The only associated SNP outside LD region 1, 
rs3751284 [#17], is a synonymous change in exon 6 of the gene and has no obvious 
effect on NOS1AP. The markers in LD region 1 showing association are located in 
intron 2 o f NOSJAP. It is possible that these markers are in LD with a further, 
unidentified susceptibility-conferring variant, such as a regulatory element upstream 
of the NOSJAP  gene. This scenario could also explain the identification of a 
protective, rather than a risk-conferring, haplotype -  the common protective
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haplotype 1 might be in LD with the protective allele at the susceptibility locus, 
whereas the risk allele at the same locus might be in LD with not one, but several of 
the remaining, rarer haplotypes, thereby diluting the susceptibility-conferring effect 
in the observed haplotypes. Another possible explanation for our findings is that 
intronic and synonymous exonic SNPs could affect posttranscriptional mRNA 
processes399. In both scenarios, genetic variation could lead to changes in the 
availability o f functional NOS1AP in the neuron and thereby to alterations in 
glutamatergic neurotransmission.
The analysis o f clinical dimensions showed an association between markers 
rs6680461 [#13] and r s l0800405 [#15] with features of avolition and social isolation 
(dimension 4). For both markers, the allele associated with increased symptom 
severity is also overtransmitted to schizophrenic patients in the single marker 
categorical TDT analysis (although the results do not reach statistical significance for 
rsl0800405 [#15]; see Table 5.3 and Table 5.5). These findings are consistent with 
the role o f NOS1AP in the NMDA receptor pathway and the NMDA receptor 
hypofunction theory o f schizophrenia. As discussed above, NMDAR mediated 
neurotransmission is hypothesised to be involved in the aetiology of schizophrenia. 
Interestingly, NMDAR hypofunction -  or generally, hypofunction of glutamatergic 
neurotransmission -  might account for the negative symptoms of schizophrenia, as 
suggested by the induction o f negative symptoms in healthy patients after 
administration o f an NMDAR antagonist, as well as by the improvement of these 
symptoms in schizophrenics during a course of treatment with an NMDAR 
agonist232-376. It is noteworthy that the dimension found to be associated with 
polymorphisms within the NOS1AP gene, dimension 4 (avolition and social 
isolation), captures negative symptoms o f the disorder, in accordance with the role of 
the NOS1AP gene in glutamatergic neurotransmission.
For dimension 1 (affective flattening and alogia), the C allele of marker rs3751284 
[#17] was found to increase trait values. However, in the categorical single marker 
analysis, this allele was found to be undertransmitted to schizophrenic patients. In a 
similar manner, the C allele o f marker rs 1415263 [#7] is associated with increased 
values for dimension 2 (auditory, somatic and visual hallucinations, and first rank 
and paranoid delusions) but was found to be undertransmitted to schizophrenic 
patients. The results o f the different analyses therefore seem somewhat contradictory.
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However, the p-values from the quantitative analyses, although nominally 
significant, are not very small, particularly in view of the many tests carried out in 
this analysis. It is therefore possible that the associations found for dimensions 1 and 
2 are false positives. For marker rs905720 [#21], the direction of association is the 
same in both categorical and quantitative analyses. However, the categorical results 
are not significant, and the uncorrected p-value close to 0.05 in the quantitative 
analysis, suggests that this association might also be a false positive. Further studies 
would be needed to shed light on a possible role of NOS1AP in dimensions 1, 2 and
6.
While there is mounting evidence for a possible link between NOS1AP and schizo­
phrenia400, not all results are consistent. A large case-control study by Puri and 
colleagues failed to replicate the positive findings in a British sample380. Instead, 
these authors have found an association between schizophrenia and the UHMK1 
gene, also located on chromosome lq23, in the British sample and suggest that the 
original linkage signal, as well as the subsequent association results for NOS1AP by 
Brzustowicz and colleagues might be due to UHMKlm . However, the analysis of 
LD patterns in the European HapMap population in the region encompassing 
NOS1AP and UHMK1 revealed no significant LD between the two genes (data not 
shown).
Such discordant results between studies could be accounted for by the presence of 
different susceptibility alleles or loci in the samples under study, especially in a 
heterogeneous disorder such as schizophrenia. The original study by Brzustowicz 
and colleagues was family-based334. Risk factors for a complex disease might vary 
between familiar and sporadic cases (the genetics of breast cancer serve as an 
extreme example), providing a possible explanation for the failure to replicate the 
original findings in the British case-control study. Although the sample used in the 
present study is also based on sporadic cases, it is taken from a well-described 
population isolate (see chapter 1.3). It is an established fact that the genetic history of 
population isolates can lead to the enrichment o f specific risk factors159. It is 
therefore possible that NOS1AP represents a risk factor of specific importance in the 
population o f Antioquia and that cases from this population are enriched for 
NOS1AP susceptibility variants.
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An additional limitation to the comparison of different genetic studies of 
schizophrenia arises from the clinical variability of the disorder and the nosological 
uncertainties it might lead to. We therefore want to stress the importance of the 
results obtained using a dimensional approach, which should be valid independently 
o f such possible nosological uncertainties.
Our results have to be viewed in the context of several limitations. From a conceptual 
point o f view, it should be emphasized that the SANS and SAPS only measure 
positive and negative symptoms, leaving other aspects of the disease, such as 
cognitive and neuropsychological symptoms, unconsidered. However, these scales 
allowed for a hypothesis-driven exploration of a possible link between NOS1AP as 
part o f the NMDA receptor pathway and negative symptoms in schizophrenia, and 
we therefore considered them a good starting point for our analyses.
The main limitation o f our study lies in the moderate sample size. On the one hand, 
this puts a limit to the power o f our statistical analyses; on the other hand, genetic 
effect sizes have been found to be overestimated in small vs. larger studies 402. 
Additionally, because o f high levels of LD observed between the markers under 
study, none o f the analyses presented here have been corrected for multiple testing 
and the interpretation o f our results is based on nominal significance only. All results 
should therefore be interpreted with caution and will need to be replicated in 
independent study samples. However, there are notable consistencies between the 
results o f several o f the analyses within this study, as well as with previously 
published studies. These consistencies corroborate the evidence found in this study 
for an association o f the NOS1AP  gene to schizophrenia and to a negatively loaded 




Future work should aim to investigate whether the association found here, 
particularly the association of NOS1AP with negative symptoms of the disease 
described here, can be replicated in further independent samples. To shed further 
light on a possible role o f NOS1AP in the aetiology of negative symptoms, it would 
be of great interest to study schizophrenia deficit patients. The deficit syndrome of 
schizophrenia is characterised by the enduring presence of negative symptoms, even 
in phases o f clinical remission, and it has been suggested that it might represent a 
separate disease entity to non-deficit schizophrenia214,403 (see also chapter 1.5). If 
NOS1AP is truly relevant to the aetiology of negative symptoms, it should show a 
stronger effect size if  examined in a sample selected for persistence of these 
symptoms. It is also o f great interest that negative symptoms do not only occur in 
disorders o f the schizophreniform spectrum (although this is where they are most 
common); persistent negative symptoms can also be found in mood disorders404"406. 
It would therefore be interesting to focus follow-up studies on a possible the role of 
NOS1AP in the deficit syndrome on deficit patients, both within and outside 
schizophrenia.
While genetic linkage and association studies can provide importance evidence for 
the involvement o f a gene in a certain disorder, the ultimate confirmation must come 
from functional studies, which can help bridge the gap between genotype and 
phenotype and provide a model for the molecular aetiology o f complex disease. It 
would therefore be desirable to conduct further functional studies on NOS1AP and 
schizophrenia. Due to the inherent restraints on functional studies in brain tissue, 
which is only available post mortem, one possibility could be the focus on animal 
studies. On the other hand, adequate animal models will always only be able to 
mirror specific aspects o f human psychiatric disease, and the study of post-mortem 
brain tissue from schizophrenic (or generally, deficit) patients might complement this 
approach.
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6. Summary and Concluding Remarks
This thesis aimed at making a contribution to the elucidation of the genetic basis of 
two severe psychiatric conditions, bipolar disorder and schizophrenia, by studying 
pedigree and trio samples from the population isolate o f Antioquia. Population 
isolates are characterised by a decreased genetic heterogeneity and therefore provide 
an excellent opportunity for the study of genetically complex diseases, for which 
sufficiently homogeneous samples are difficult to collect in an outbred population.
Although the genetic complexity o f psychiatric illness has complicated the search for 
susceptibility loci, in recent years, a picture of genetic predisposition has begun to 
emerge for both schizophrenia and bipolar disorder146,193,207. The results obtained in 
this thesis add to this picture and thereby provide further reason for optimism for the 
future o f psychiatric genetics.
While the candidate gene study o f the CLINT1 gene on chromosome 5q33 has 
provided negative results (chapter 3), the whole-genome linkage scan of bipolar 
disorder, performed to further explore the importance of other candidate regions in 
Antioquia, has been successful in identifying a number of candidate regions for BPI 
in particular, mood disorders in general, and psychosis (chapter 4). While none of the 
linkage signals obtained here reached the formal threshold for genome-wide 
significance, it is very encouraging that many o f the candidate regions we identified 
had been previously implicated in susceptibility to BP in different populations, and 
that our study has therefore provided an independent replication of such prior 
findings. We have also identified a novel locus on chromosome 12q, which now 
awaits replication in additional samples from other populations.
In the light o f genetically complex inheritance, most single genome-wide linkage 
scan might not have sufficient power to reliably detect risk-conferring variants for 
psychiatric illness. An important lesson from the past decade should therefore be that 
we might need to jointly evaluate individual linkage efforts, e.g. by the means of 
meta-analysis, before being able to tease out the real findings from the inevitable 
false positive results. Since meta-analyses will join data sets obtained in a range of 
different populations, this might at first seem contradictory to the emphasis I have 
placed on the importance o f the genetic homogeneity o f population isolates.
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However, we do not expect most loci identified in any population to be exclusive to 
that population (although there might be exceptions to this). We do, however, expect 
that patients from population isolates will be more similar in their genetic makeup, 
thereby increasing the chances of detecting a signal in an initial genome scan, which 
will then contribute to the findings of a meta-analysis. The linkage scan performed as 
part o f this study is a good example of this: the region on chromosome lp, e.g., 
seems to be o f importance in several populations, but we have increased our chances 
of detecting this signal in our patients by choosing them from a relatively 
homogeneous population.
As we have seen, population isolates provide an excellent opportunity for the study 
of complex diseases, including psychiatric disorders. However, as both the genome- 
wide linkage scan and the association study between the NOS1AP gene and 
schizophrenia (chapter 5) show, complementary strategies can be useful in further 
reducing the genetic heterogeneity underlying the aetiology o f mental illness. In the 
genome scan, I have explored different diagnostic models -  BPI; BPI, BPII and 
major depression; and psychosis - ,  all o f which produced evidence for linkage to a 
different range o f candidate regions. In the candidate gene analysis of the NOS1AP 
gene, we have used a dimensional approach to the phenotype of schizophrenia, 
thereby allowing us to dissect the heterogeneous phenotype of DSM-IV 
schizophrenia and to show that the NOS1AP gene might be of special importance in 
the causation o f negative symptoms captured in the dimension of “avolition and 
social isolation”. These are only two examples of phenotypic dissection; another 
important example is the use o f endophenotypes, which allows the identification of 
genes responsible for physiological traits associated with disease. It is of great 
interest to explore such approaches to the dissection of psychiatric phenotypes 
further, and the identification and linkage analysis o f bipolar disorder 
endophenotypes is indeed the next step we are taking in our BP project in Antioquia 
and the Central Valley o f Costa Rica. Generally, it can be anticipated that the 
exploration o f alternative approaches to phenotype definitions will represent one of 
the main focal points o f psychiatric genetics research in the years to come.
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8.2. Data completeness for all markers genotyped as part of the BP 
linkage scan
Table 8.1: Com pleteness o f the d a ta  obtained for chromosome 1 in the genome-wide linkage 
scan of fifteen extended pedigrees segregating severe b ipolar d isorder from  Antioquia.
m arker nam e data  se t 1 data set 2 weighted average1
D1S468 1.00 0.97 0.99
D1S214 0.93 0.92 0.93
D1S450 0.92 0.96 0.94
D1S2667 0.95 1.00 0.97
D1S2697 0.90 0.97 0.93
D1S199 0.97 0.97 0.97
D1S234 0.95 0.99 0.96
D1S255 0.96 1.00 0.98
D1S2797 0.95 0.96 0.95
D1S2890 0.97 0.96 0.96
D1S230 0.93 0.99 0.96
D1S2841 0.93 0.97 0.95
D1S207 0.88 1.00 0.93
D1S2868 0.89 0.95 0.92
D1S206 0.95 0.96 0.95
D1S2726 0.93 1.00 0.96
D1S252 0.86 1.00 0.92
D1S498 0.00 0.97 0.44
D1S484 0.92 0.97 0.95
D1S2878 0.97 0.91 0.94
D1S196 0.98 0.99 0.98
D1S218 0.90 0.95 0.92
D1S238 0.91 0.99 0.95
D1S413 0.90 0.96 0.93
D1S249 0.84 0.91 0.87
D1S425 0.99 0.99 0.99
D1S213 0.99 0.97 0.98
D1S2800 0.95 0.97 0.96
D1S2785 0.90 0.96 0.93
D1S2842 0.95 0.91 0.93
D1S2836 0.00 0.97 0.44
Average chr 1 0.87 0.97 0.92
1 W eighted by the num ber o f individuals in each data  set.
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Table 8.2: Completeness of the data obtained for chromosome 2 in the genome-wide linkage
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m arker nam e data  se t 1 data set 2 weighted average1
D2S319 0.99 0.97 0.98
D2S2211 1.00 0.92 0.96
D2S162 0.98 0.96 0.97
D2S168 1.00 0.99 0.99
D2S305 0.98 0.99 0.98
D2S165 0.91 0.97 0.94
D2S367 0.97 0.92 0.95
D2S2259 0.98 1.00 0.99
D2S391 0.96 1.00 0.98
D2S337 0.99 0.95 0.97
D2S2368 0.98 0.91 0.95
D2S286 1.00 1.00 1.00
D2S2333 0.97 0.97 0.97
D2S2216 0.90 0.97 0.93
D2S160 0.98 0.93 0.96
D2S347 0.98 0.96 0.97
D2S112 0.96 0.95 0.95
D2S151 0.96 0.97 0.96
D2S142 0.97 0.99 0.98
D2S2330 0.99 1.00 0.99
D2S335 0.99 0.99 0.99
D2S364 0.95 0.92 0.93
D2S117 1.00 0.95 0.98
D2S325 0.98 0.97 0.98
D2S2382 0.98 0.96 0.97
D2S126 0.99 0.96 0.98
D2S396 0.81 0.99 0.89
D2S206 1.00 0.97 0.99
D2S338 0.99 0.99 0.99
D2S125 1.00 1.00 1.00
Average chr 2 0.97 0.97 0.97
1 Weighted by the number of individuals in each data set
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Table 8.3: Completeness of the data obtained for chromosome 3 in the genome-wide linkage
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a ta  s e t  1 d a t a  s e t  2 w e ig h te d  a v e r a g e 1
D 3S1297 0 .9 6 0 .9 6 0 .9 6
D 3S1304 0 .9 6 0 .9 9 0 .9 7
D 3S1263 0 .8 1 0 .8 9 0 .8 5
D 3S 2338 0 .9 3 0 .9 7 0 .9 5
D 3S 1266 0 .9 8 0 .9 6 0 .9 7
D 3S1277 0 .9 2 0 .9 3 0 .9 3
D 3S 1289 0 .9 8 0 .9 7 0 .9 8
D 3S1300 0 .9 7 0 .8 9 0 .9 3
D 3S1285 0 .9 7 0 .9 6 0 .9 6
D 3S1566 0 .8 4 0 .9 6 0 .8 9
D 3S3681 0 .8 4 0 .9 7 0 .9 0
D 3S1271 0 .9 9 1 .00 0 .9 9
D 3S1278 0 .9 9 0 .9 6 0 .9 8
D 3S1267 0 .9 9 0 .9 7 0 .9 8
D 3S1292 1 .0 0 0 .9 9 0 .9 9
D 3S1569 0 .9 6 1 .0 0 0 .9 8
D 3S1279 0 .9 6 0 .9 5 0 .9 5
D 3S1614 0 .8 7 1 .0 0 0 .9 3
D 3S 1565 0 .9 7 1 .0 0 0 .9 8
D 3S1262 0 .9 7 0 .9 5 0 .9 6
D 3S 1580 0 .9 3 0 .9 2 0 .9 3
D 3S1601 0 .9 8 0 .9 9 0 .9 8
D 3S1311 0 .9 8 1 .0 0 0 .9 9
A v e ra g e  c h r  3 0 .9 4 0 .9 6 0 .9 5
’Weighted by the number of individuals in each data set.
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Table 8.4: Completeness of the data obtained for chromosome 4 in the genome-wide linkage
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a t a  s e t  1 d a ta  s e t  2 w e ig h te d  a v e r a g e 1
D 4S412 0 .8 8 1 .0 0 0 .9 3
D 4S2935 0 .9 7 1 .0 0 0 .9 8
D 4S403 0 .9 0 0 .9 6 0 .9 3
D 4S419 0 .8 9 0 .9 7 0 .9 3
D 4S391 0 .9 9 1 .00 0 .9 9
D 4S405 0 .9 6 0 .9 9 0 .9 7
D 4S1592 0 .9 7 0 .9 5 0 .9 6
D 4S392 0 .9 8 0 .9 7 0 .9 8
D 4S2964 0 .9 0 1 .0 0 0 .9 5
D 4S1534 0 .9 3 1 .0 0 0 .9 6
D 4S414 0 .8 7 0 .9 9 0 .9 2
D 4S1572 0 .9 7 0 .9 7 0 .9 7
D 4S406 1 .0 0 0 .9 9 0 .9 9
D 4S402 0 .8 8 0 .9 6 0 .9 2
D 4S1575 1 .0 0 1 .0 0 1 .0 0
D 4S424 0 .9 3 0 .9 3 0 .9 3
D 4S413 0 .8 0 0 .8 4 0 .8 2
D 4S1597 0 .8 7 0 .9 6 0 .9 1
D 4S1539 0 .8 6 0 .9 7 0 .9 1
D 4S415 0 .9 3 0 .9 6 0 .9 5
D 4S1535 0 .9 8 0 .9 9 0 .9 8
D 4S426 1 .0 0 0 .9 9 0 .9 9
A v e ra g e  c h r  4 0 .9 3 0 .9 7 0 .9 5
1 Weighted by the number of individuals in each data set
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Table 8.5: Completeness of the data obtained for chromosome 5 in the genome-wide linkage
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a ta  s e t  1 d a ta  s e t  2 w e ig h te d  a v e r a g e 1
D5S1981 0.99 0.97 0.98
D5S406 0.98 0.99 0.98
D5S630 0.96 1.00 0.98
D5S416 0.97 0.97 0.97
D5S419 0.96 1.00 0.98
D5S426 0.99 0.99 0.99
D5S418 0.00 1.00 0.45
D5S407 0.93 0.91 0.92
D5S647 0.99 1.00 0.99
D5S424 0.98 0.99 0.98
D5S641 0.95 0.97 0.96
D5S428 0.95 0.91 0.93
D5S644 0.96 1.00 0.98
D5S433 1.00 1.00 1.00
D5S2027 0.99 1.00 0.99
D5S471 0.99 0.97 0.98
D5S2115 0.91 0.95 0.93
D5S436 0.95 1.00 0.97
D5S410 0.98 0.96 0.97
D5S422 1.00 1.00 1.00
D5S400 1.00 1.00 1.00
D5S408 0.98 0.96 0.97
A v e ra g e  c h r  5 0.93 0.98 0.95
1 Weighted by the number of individuals in each data set.
292
Table 8.6: Completeness of the data obtained for chromosome 6 in the genome-wide linkage
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a ta  s e t  1 d a ta  s e t  2 w e ig h te d  a v e ra g e
D 6S 1574 0 .9 7 1 .00 0 .9 8
D 6S309 0 .9 6 0 .9 7 0 .9 6
D 6S470 0 .9 9 0 .9 3 0 .9 6
D 6S289 0 .9 9 1 .0 0 0 .9 9
D 6S422 0 .9 7 0 .9 9 0 .9 8
D 6S276 0 .9 6 0 .9 6 0 .9 6
D 6S1610 0 .9 5 0 .9 6 0 .9 5
D 6S257 0 .9 9 0 .9 9 0 .9 9
D 6S460 0 .9 8 0 .9 9 0 .9 8
D 6S462 0 .9 6 0 .9 9 0 .9 7
D 6S434 0 .8 7 0 .9 5 0 .9 0
D 6S287 1 .0 0 0 .9 7 0 .9 9
D 6S262 0 .0 0 1 .0 0 0 .4 5
D 6S292 0 .9 6 0 .9 9 0 .9 7
D 6S308 0 .8 7 0 .9 7 0 .9 2
D 6S441 1 .0 0 0 .9 9 0 .9 9
D 6S1581 0 .8 5 0 .9 9 0 .9 1
D 6S264 0 .9 0 0 .9 7 0 .9 3
D 6S446 0 .9 1 0 .9 6 0 .9 3
D 6S281 0 .9 0 0 .9 9 0 .9 4
A v e ra g e  c h r  6 0 .9 0 0 .9 8 0 .9 3
’Weighted by the number of individuals in each data set.
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Table 8.7: Completeness of the data obtained for chromosome 7 in the genome-wide linkage
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a ta  s e t  1 d a t a  s e t  2 w e ig h te d  a v e ra g e 1
D7S531 0.91 0.92 0.92
D7S517 0.99 1.00 0.99
D7S513 0.92 0.97 0.95
D7S507 0.98 0.97 0.98
D7S493 0.95 0.97 0.96
D7S516 0.98 1.00 0.99
D7S484 0.98 0.97 0.98
D7S510 0.95 1.00 0.97
D7S519 0.92 0.97 0.95
D7S502 0.98 0.95 0.96
D7S669 0.95 0.99 0.96
D7S630 0.97 1.00 0.98
D7S657 0.98 1.00 0.99
D7S515 0.98 0.93 0.96
D7S486 0.95 0.88 0.92
D7S530 0.89 0.99 0.93
D7S640 0.91 0.99 0.95
D7S684 1.00 1.00 1.00
D7S661 1.00 1.00 1.00
D7S636 0.92 0.95 0.93
D7S798 1.00 1.00 1.00
D7S2465 0.98 0.97 0.98
A v e ra g e  c h r  7 0 .9 6 0 .9 7 0 .9 6
'Weighted by the number of individuals in each data set.
Table 8.8: Completeness of the data obtained for chromosome 8 in the genome-wide linkage 
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a t a  s e t  1 d a ta  s e t  2 w e ig h te d  a v e ra g e 1
D8S264 0.97 1.00 0.98
D8S277 0.93 0.96 0.95
D8S550 0.97 1.00 0.98
D8S549 0.99 0.93 0.96
D8S258 0.99 0.95 0.97
D8S1771 0.98 0.97 0.98
D8S505 0.96 0.95 0.95
D8S285 0.99 0.97 0.98
D8S260 0.92 1.00 0.96
D8S270 1.00 0.97 0.99
D8S1784 0.77 0.95 0.85
D8S514 0.99 1.00 0.99
D8S284 0.98 0.99 0.98
D8S272 0.99 0.88 0.94
A v e ra g e  c h r  8 0 .9 6 0 .9 7 0 .9 6
’Weighted by the number of individuals in each data set
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Table 8.9: Completeness of the data obtained for chromosome 9 in the genome-wide linkage
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a ta  s e t  1 d a t a  s e t  2 w e ig h te d  a v e r a g e 1
D 9S 288 1 .0 0 0 .9 9 0 .9 9
D 9S 286 0 .9 0 0 .9 6 0 .9 3
D 9S285 1 .0 0 0 .9 7 0 .9 9
D 9S157 0 .9 8 1 .0 0 0 .9 9
D 9S171 0 .9 0 0 .9 9 0 .9 4
D 9S161 1 .0 0 0 .9 5 0 .9 8
D 9S1817 0 .9 9 0 .9 6 0 .9 8
D 9S273 0 .9 0 1 .0 0 0 .9 5
D 9S175 0 .9 9 0 .9 9 0 .9 9
D 9S167 0 .9 6 1 .0 0 0 .9 8
D 9S283 0 .9 6 0 .9 9 0 .9 7
D 9S287 1 .0 0 0 .9 9 0 .9 9
D 9S1690 0 .9 9 0 .9 9 0 .9 9
D 9S 1677 0 .9 7 1 .0 0 0 .9 8
D 9S1776 0 .9 6 0 .9 9 0 .9 7
D 9S1682 0 .9 5 1 .0 0 0 .9 7
D 9S290 0 .9 3 0 .9 9 0 .9 6
D 9S164 0 .9 5 0 .9 9 0 .9 6
D 9S1826 0 .9 1 0 .9 2 0 .9 2
D 9S158 0 .9 0 0 .9 3 0 .9 2
A v e ra g e  c h r  9 0 .9 6 0 .9 8 0 .9 7
W eighted by the number of individuals in each data set.
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Table 8.10: Completeness o f the data obtained for chromosome 10 in the genome-wide linkage
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a ta  s e t  1 d a ta  s e t  2 w e ig h te d  a v e r a g e 1
D10S249 0.99 0.97 0.98
D10S591 0.97 0.99 0.98
DIOS189 0.97 1.00 0.98
D10S547 0.88 0.91 0.89
D10S1653 0.97 1.00 0.98
D10S548 0.99 0.96 0.98
D10S197 0.93 1.00 0.96
D10S208 0.97 1.00 0.98
D10S196 0.97 0.95 0.96
D10S1652 0.97 0.93 0.95
D10S537 0.97 0.95 0.96
D10S1686 0.98 0.97 0.98
D10S185 0.98 1.00 0.99
D10S192 0.97 1.00 0.98
D10S597 0.99 0.95 0.97
D10S1693 0.97 0.97 0.97
D10S587 0.98 0.95 0.96
D10S217 1.00 0.96 0.98
D10S1651 1.00 0.99 0.99
D10S212 1.00 1.00 1.00
A v e ra g e  c h r  1 0 0 .9 7 0 .9 7 0 .9 7
W eighted by the number of individuals n each data set.
Table 8.11: Completeness of the data obtained for chromosome 11 in the genome-wide linkage 
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a ta  s e t  1 d a ta  s e t  2 w e ig h te d  a v e r a g e 1
D11S4046 0.92 0.99 0.95
D11S1338 0.85 0.97 0.90
D11S902 1.00 0.99 0.99
D11S904 0.93 1.00 0.96
D11S935 0.93 0.95 0.94
D11S905 0.00 0.97 0.44
D11S4191 0.93 0.99 0.96
D11S987 1.00 0.99 0.99
D11S1314 1.00 1.00 1.00
D11S937 0.92 0.99 0.95
D11S901 1.00 1.00 1.00
D11S4175 0.89 0.96 0.92
D11S898 0.96 0.99 0.97
D11S908 0.90 0.99 0.94
D11S925 0.87 0.96 0.91
D11S4151 0.99 0.97 0.98
D11S1320 0.97 0.93 0.95
D11S968 0.93 0.97 0.95
A v e ra g e  c h r  11 0 .8 9 0 .9 8 0 .9 3
W eighted by the number of individuals in each data set.
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Table 8.12: Completeness o f the data obtained for chromosome 12 in the genome-wide linkage
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a ta  s e t  1 d a ta  s e t  2 w e ig h te d  a v e r a g e 1
D12S352 0.95 0.99 0.96
D12S99 0.98 0.91 0.95
D12S336 0.95 0.95 0.95
D12S364 0.95 0.97 0.96
D12S310 0.91 0.92 0.92
D12S1617 0.98 0.97 0.98
D12S345 0.91 0.91 0.91
D12S85 0.90 0.96 0.93
D12S368 0.90 0.96 0.93
D12S83 0.90 0.93 0.92
D12S326 0.93 0.96 0.95
D12S351 0.99 0.92 0.96
D12S346 0.99 0.99 0.99
D12S78 1.00 0.92 0.96
D12S79 0.84 0.99 0.90
D12S86 0.93 0.99 0.96
D12S324 0.92 0.92 0.92
D12S1659 1.00 0.99 0.99
D12S1723 1.00 0.91 0.96
A v e ra g e  c h r  12 0 .9 4 0 .9 5 0 .9 5
W eighted by the number of individuals in each data set.
Table 8.13: Completeness of the data obtained for chromosome 13 in the genome-wide linkage 
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a ta  s e t  1 d a ta  s e t  2 w e ig h te d  a v e r a g e 1
D13S175 1.00 0.99 0.99
D13S217 0.96 0.88 0.92
D13S171 0.97 0.95 0.96
D13S218 0.98 0.99 0.98
D13S263 0.96 1.00 0.98
D13S153 0.85 0.97 0.90
D13S156 0.97 0.96 0.96
D13S170 0.93 0.99 0.96
D13S265 0.95 0.97 0.96
D13S159 0.00 0.93 0.42
D13S158 0.96 0.95 0.95
D13S173 0.95 0.96 0.95
D13S1265 0.91 0.89 0.90
D13S285 0.97 1.00 0.98
A v e ra g e  c h r  13 0 .8 8 0 .9 6 0 .9 2
W eighted by the number of individuals in each data set
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Table 8.14: Completeness o f the data obtained for chromosome 14 in the genome-wide linkage
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
marker name data set 1 data set 2 weighted average1
D14S261 0.96 0.96 0.96
D14S283 1.00 0.95 0.98
D14S275 0.98 0.97 0.98
D14S70 0.95 0.92 0.93
D14S288 0.91 1.00 0.95
D14S276 0.92 1.00 0.96
D14S63 0.97 0.97 0.97
D14S258 1.00 0.97 0.99
D14S74 0.91 1.00 0.95
D14S68 0.93 0.89 0.92
D14S280 0.98 0.92 0.95
D14S65 0.90 0.97 0.93
D14S985 0.93 0.91 0.92
D14S292 1.00 0.93 0.97
Average chr 14 0.95 0.96 0.95
W eighted by the number of individuals In each data set.
Table 8.15: Completeness of the data obtained for chromosome 15 in the genome-wide linkage 
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
marker name data set 1 data set 2 weighted average1
D15S128 1.00 1.00 1.00
D15S1002 0.97 0.89 0.93
D15S165 0.97 0.93 0.95
D15S1007 0.93 0.95 0.94
D15S1012 0.99 1.00 0.99
D15S994 0.00 0.97 0.44
D15S978 1.00 1.00 1.00
D15S117 0.98 0.95 0.96
D15S153 0.95 0.99 0.96
D15S131 0.95 0.99 0.96
D15S205 0.91 0.97 0.94
D15S127 0.95 0.97 0.96
D15S130 0.99 0.95 0.97
D15S120 1.00 0.99 0.99
Average chr 15 0.90 0.97 0.93
‘Weighted by the number of individuals in each data set.
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Table 8.16: Completeness o f the data obtained for chromosome 16 in the genome-wide linkage
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a ta  s e t  1 d a ta  s e t  2 w e ig h te d  a v e r a g e 1
D16S423 0.89 0.91 0.90
D16S404 0.92 0.93 0.93
D16S3075 0.96 0.92 0.94
D16S3103 0.96 0.97 0.96
D16S3046 1.00 1.00 1.00
D16S3068 0.95 1.00 0.97
D16S3136 0.97 0.96 0.96
D16S415 0.95 0.97 0.96
D16S503 0.97 0.92 0.95
D16S515 0.89 0.92 0.90
D16S516 0.96 0.83 0.90
D16S3091 0.92 0.97 0.95
D16S520 0.95 0.97 0.96
A v e ra g e  c h r  1 6 0 .9 4 0 .9 4 0 .9 4
!Weighted by the number of individuals in each data set
Table 8.17: Completeness of the data obtained for chromosome 17 in the genome-wide linkage 
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a t a  s e t  1 d a ta  s e t  2 w e ig h te d  a v e r a g e 1
D17S849 0.82 0.92 0.87
D17S831 0.96 0.97 0.96
D17S938 0.98 0.99 0.98
D17S1852 0.99 0.97 0.98
D17S799 0.99 0.93 0.96
D17S921 0.98 0.97 0.98
D17S1857 1.00 0.95 0.98
D17S798 0.00 0.92 0.42
D17S1868 0.90 0.93 0.92
D17S787 1.00 0.96 0.98
D17S944 0.98 0.97 0.98
D17S949 0.91 0.95 0.93
D17S785 1.00 0.99 0.99
D17S784 0.91 0.96 0.93
D17S928 0.99 0.97 0.98
A v e ra g e  c h r  17 0 .8 9 0 .9 6 0 .9 2
W eighted by the number of individuals in each data set.
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Table 8.18: Completeness of the data obtained for chromosome 18 in the genome-wide linkage
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a t a  s e t  1 d a ta  s e t  2 w e ig h te d  a v e r a g e 1
D 18S59 0 .9 5 0 .9 6 0 .9 5
D 18S63 1 .0 0 0 .9 9 0 .9 9
D 18S452 0 .9 2 0 .9 5 0 .9 3
D 18S 464 0 .9 6 0 .9 9 0 .9 7
D 18S53 0 .9 9 0 .9 9 0 .9 9
D 18S478 0 .9 0 0 .9 7 0 .9 3
D 18S 1102 0 .9 8 0 .8 8 0 .9 3
D 18S474 1 .0 0 0 .9 9 0 .9 9
D 18S64 0 .9 6 0 .9 7 0 .9 6
D 18S68 0 .9 7 0 .8 8 0 .9 3
D 18S61 0 .9 8 0 .9 5 0 .9 6
D 18S 1161 0 .9 5 0 .9 6 0 .9 5
D 18S462 0 .9 8 0 .9 5 0 .9 6
D 18S70 0 .7 8 0 .9 6 0 .8 6
A v e ra g e  c h r  18 0.95 0.96 0.95
Weighted by the number of individuals in each data set.
Table 8.19: Completeness of the data obtained for chromosome 19 in the genome-wide linkage 
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a t a  s e t  1 d a ta  s e t  2 w e ig h te d  a v e r a g e 1
D 19S209 0 .9 6 0 .9 6 0 .9 6
D 19S216 1 .0 0 0 .9 9 0 .9 9
D 19S 884 0 .9 7 0 .9 9 0 .9 8
D 19S221 0 .0 0 0 .8 7 0 .3 9
D 19S 226 0 .9 9 0 .9 9 0 .9 9
D 19S 414 0 .9 5 0 .9 9 0 .9 6
D 19S 220 0 .9 6 1 .0 0 0 .9 8
D 19S 420 1 .0 0 0 .9 9 0 .9 9
D 19S902 0 .9 8 0 .9 3 0 .9 6
D 19S571 0 .8 0 0 .9 2 0 .8 6
D 19S 418 0 .8 7 0 .9 7 0 .9 2
D 19S 210 0 .9 9 0 .8 8 0 .9 4
A v e ra g e  c h r  19 0.87 0.96 0.91
1 Weighted by the number of individuals in each data set.
3 0 0
Table 8.20: Completeness o f the data obtained for chromosome 20 in the genome-wide linkage
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a t a  s e t  1 d a t a  s e t  2 w e ig h te d  a v e r a g e 1
D20S117 0.93 1.00 0.96
D20S889 0.96 0.99 0.97
D20S115 0.98 0.99 0.98
D20S186 0.96 0.97 0.96
D20S112 0.90 0.91 0.90
D20S195 0.99 0.97 0.98
D20S107 0.97 0.92 0.95
D20S119 1.00 0.96 0.98
D20S178 0.86 0.95 0.90
D20S196 0.97 0.97 0.97
D20S100 0.98 0.92 0.95
D20S171 0.85 0.95 0.89
D20S173 0.99 0.95 0.97
A v e ra g e  c h r  20 0.95 0.96 0.95
'Weighted by the number of individuals in each data set.
Table 8.21: Completeness of the data obtained for chromosome 21 in the genome-wide linkage 
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a t a  s e t  1 d a ta  s e t  2 w e ig h te d  a v e r a g e 1
D21S1256 0.84 0.89 0.86
D21S1914 0.98 0.93 0.96
D21S263 0.00 0.95 0.43
D21S1252 0.90 0.99 0.94
D21S266 0.90 0.97 0.93
A v e ra g e  c h r  21 0.72 0.95 0.82
W eighted by the number of individuals in each data set.
Table 8.22: Completeness of the data obtained for chromosome 22 in the genome-wide linkage 
scan of fifteen extended pedigrees segregating severe bipolar disorder from Antioquia.
m a r k e r  n a m e d a t a  s e t  1 d a t a  s e t  2 w e ig h te d  a v e r a g e 1
D22S420 1.00 0.97 0.99
D22S539 0.91 0.97 0.94
D22S315 0.87 0.96 0.91
D22S280 0.95 0.97 0.96
D22S283 0.96 0.97 0.96
D22S423 0.99 0.96 0.98
D22S274 0.89 0.96 0.92
A v e ra g e  c h r  2 2 0.94 0.97 0.95
i  n each data set.
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8.3. Published Papers and Manuscripts
In this section o f the appendix, I have attached all papers on which I have 
collaborated during the time o f my Ph.D. studies in Professor Ruiz-Linares’ 
laboratory.
302
